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Abstract 
Most invasive pathogens produce polysaccharide capsules, which play an essential 
role in conferring protection against host immune defense. In the case of 
Staphylococcus aureus, most clinical isolates are encapsulated, and inhibition of 
capsule biosynthesis may offer a valuable strategy for novel anti-infective treatment. 
Despite their importance for pathogenicity, the biochemistry underlying the assembly 
of staphylococcal capsular polysaccharides is not fully understood. Three nucleotide-
activated sugar precursors, synthesized in the cytoplasm of the cell, are required for 
S. aureus capsule production. In this thesis, the UDP-N-acetyl-D-glucosamine 
4,6-dehydratases CapD and CapE of S. aureus serotype 5, which catalyze the first 
steps in the synthesis of the soluble capsule precursors UDP-N-acetyl-D-fucosamine 
(UDP-D-FucNAc) and UDP-N-acetyl-L-fucosamine (UDP-L-FucNAc), respectively, 
were purified and characterized. CapD is an integral membrane protein and was 
obtained for the first time in a purified, active form. Using a new, robust and sensitive 
capillary electrophoresis-based method for detection of the soluble capsule 
precursors, kinetic studies for CapD and CapE were performed, and a compound 
library was screened in search for enzyme inhibitors. Several active compounds were 
identified and characterized, including suramin (IC50 at CapE 1.82 µM) and ampicillin 
(IC50 at CapD of 40.1 µM). Moreover, the cell wall precursors UDP-N-acetylmuramyl-
pentapeptide and lipid II appear to function as inhibitors of CapD enzymatic activity, 
suggesting an integrated mechanism of regulation for cell envelope biosynthesis 
pathways in S. aureus. A further aim of the present study was the elucidation of the 
pathway underlying UDP-D-FucNAc biosynthesis in S. aureus. Using the purified 
recombinant enzymes CapD and CapN, enzymatic in vitro synthesis of the soluble 
capsule precursor UDP-D-FucNAc was achieved for the first time. Furthermore, the 
role of the tyrosine kinase complex CapAB in the regulation of capsular 
polysaccharide production was investigated. The capsule biosynthetic enzyme CapE 
was identified as regulatory target of the CapAB kinase complex, and it was shown 
that tyrosine phosphorylation enhances CapE catalytic activity in vitro. Besides 
substantial progress in the understanding of capsule biosynthesis and the underlying 
regulation, the established in vitro systems provide the molecular basis for screening 
for potential anti-virulence agents. 
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Abbreviations and symbols 
aa amino acid(s) 
ABC ATP binding cassette 
ADP adenosine 5′-diphosphate 
aqua a.i. aqua ad iniectabilia 
ATCC American Type Culture Collection  
ATP adenosine 5′-triphosphate 
Bis-Tris 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol 
BY-kinase bacterial tyrosine kinase 
°C degree Celsius 
C18 alkyl chain(s) of 18 carbon atoms 
CapDtr truncated soluble CapD mutant protein 
CAPS 3-(cyclohexylamino)-1-propanesulfonic acid 
CE capillary electrophoresis 
Ci Curie 
CP capsular polysaccharide 
CP5/CP8 Staphylococcus aureus serotype 5/8 capsular polysaccharide 
C55P(P) undecaprenyl-(pyro)phosphate 
Da Dalton 
DDM n-dodecyl-β-D-maltoside 
DE3 λ prophage carrying bacteriophage T7 RNA polymerase 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxynucleoside triphosphates 
dTDP deoxythymidine 5′-diphosphate 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid  
e.g. from Latin exempli gratia, meaning “for example” 
EPS exopolysaccharide 
et al. from Latin et alii, meaning “and others” 
E-value expectation value  
(D/L-)FucNAc N-acetyl-D/L-fucosamine 
g gram 
(D-)GlcNAc N-acetyl-D-glucosamine 
h hour 
HA hyaluronic acid 
His6 hexahistidine 
HIV human immunodeficiency virus 
HPLC high pressure liquid chromatography 
Hz hertz 
IC50 half maximal inhibitory concentration 
i.e. from Latin id est, meaning “that is to say” 
IPTG isopropyl-β-D-thiogalactopyranoside  
K antigen capsular antigen 
kb kilobase 
Km Michaelis-Menten constant 
KPi potassium phosphate buffer 
x 
 
 
l litre 
LB lysogeny broth 
LDS lithium dodecyl sulfate 
lipid II undecaprenyl-pyrophosphoryl-N-acetylmuramyl-(pentapeptide)-N-
acetylglucosamine 
lipid Icap undecaprenyl-pyrophosphoryl-N-acetyl-D-fucosamine 
lipid IIcap undecaprenyl-pyrophosphoryl-D-FucNAc-N-acetyl-L-fucosamine 
lipid IIIcap undecaprenyl-pyrophosphoryl-D-FucNAc-L-FucNAc-N-acetyl-D-
mannosaminuronic acid 
lipid A glycolipid component of lipopolysaccharide 
LPS lipopolysaccharide 
λmax wavelength of the most intense UV/VIS absorption 
M mol/litre 
m metre 
[M−H]− deprotonated molecular ion 
MALDI-TOF MS matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry 
(D-)ManNAc N-acetyl-D-mannosamine 
(D-)ManNAcA N-acetyl-D-mannosaminuronic acid 
MeOPN O-methyl phosphoramidate 
min minute 
MOPS 3-(N-morpholino)propanesulfonic acid 
Mr relative molecular mass 
MRSA methicillin-resistant Staphylococcus aureus 
MS mass spectrometry 
(D-)MurNac N-acetyl-D-muramic acid 
m/z mass-to-charge ratio  
NAD(P)+ β-nicotinamide adenine dinucleotide (2′-phosphate), oxidized form 
NAD(P)H β-nicotinamide adenine dinucleotide (2′-phosphate), reduced form 
nanoLC-MS/MS nanoscale liquid chromatography coupled to tandem mass 
spectrometry 
NaPi sodium phosphate buffer 
NCBI National Center for Biotechnology Information (United States) 
NCTC National Collection of Type Cultures (Public Health England) 
Ni-NTA nickel-nitrilotriacetic acid  
NMR nuclear magnetic resonance 
O antigen highly variable glycan polymer component of lipopolysaccharide  
OD600 optical density at a wavelength of 600 nm 
PAP 3′-phosphoadenosine 5′-phosphate 
PCR polymerase chain reaction 
pET plasmid expression by T7-RNA-polymerase 
PG peptidoglycan 
pH from Latin pondus hydrogenii; hydrogen ion concentration  
PHP histidinol phosphate phosphoesterase 
polybrene hexadimethrine bromide 
ppm parts per million 
psi pounds per square inch 
PSSMID identifier for a position specific scoring matrix  
p calculated probability 
xi 
 
 
(r)RNA (ribosomal) ribonucleic acid 
rpm rounds per minute  
RT room temperature 
s second 
SDR short-chain dehydrogenase/reductase 
SDS(-PAGE) sodium dodecyl sulfate (polyacrylamide gel electrophoresis) 
Sugp 2-acetamido-2,6-dideoxy-D-xylo-4-hexulose 
SWISS-PROT Swiss protein database 
T4/T7 bacteriophage T4/T7 
TLR Toll-like receptor 
Tris tris(hydroxymethyl)-aminomethan 
Triton X-100 polyethylene glycol tert-octylphenyl ether 
UDP uridine 5′-diphosphate 
UV (light) ultraviolet light 
V volt 
VIS visible light 
Vmax maximum velocity 
v/v volume per volume 
W watt 
WTA wall teichoic acid 
w/v weight per volume 
2YT broth double-strength yeast extract-tryptone broth 
Decimal multiples and submultiples of units are formed using metric prefixes. 
Abbreviations for amino acids and nucleotide bases follow the recommendations of 
the IUPAC-IUB (International Union of Pure and Applied Chemistry & International 
Union of Biochemistry; www.chem.qmul.ac.uk/iupac/). 
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1 Introduction 
1.1 Structural diversity of bacterial capsular polysaccharides  
Polysaccharide capsules are ubiquitous structures found on the cell surface of a 
broad range of bacterial species. Capsular structures often constitute the outermost 
layer of the bacterial cell and may as such mediate interactions between the 
microorganism and its immediate environment; they fulfill various biological functions 
and were identified as important factors in the virulence of numerous Gram-positive 
(e.g. Streptococcus pneumoniae, Staphylococcus aureus) and Gram-negative (e.g. 
Neisseria meningitidis, Haemophilus influenzae, Escherichia coli) pathogens.1–5 
Bacterial capsular polysaccharides (CPs) are structurally diverse molecules 
composed of monosaccharide subunits connected via glycosidic bonds; they can 
either be homo- or heteropolymers, the latter normally being made up of repeating 
units comprising two to six sugar residues.6 The wide variation in structure is caused 
not only by the diversity of monosaccharide compositions, but also by the diversity of 
linkages between the sugars subunits, which may be joined in a number of 
configurations. Further structural complexity arises from the introduction of branches 
into the polysaccharide chain, variation of the modal chain length, or from 
modification with non-sugar moieties such as O-acetyl groups or amino acid residues 
(for more details, readers may refer to www.glycome-db.org).  
Capsule polymers are highly flexible, extend radially from the cell wall, and are rarely 
cross-linked to one another by strong bonding forces.7 It is assumed that the stability 
of capsular structures is largely due to electrostatic, divalent cation-dependent 
interactions within the often highly acidic (i.e. rich in carboxyl groups) polymer.7 CPs 
of Gram-positive organisms can be covalently linked to different cell envelope 
components, with attachment to the peptide moiety of peptidoglycan (PG) for Bacillus 
anthracis, attachment to N-acetylglucosamine (GlcNAc) of PG for Streptococcus 
agalactiae, and covalent attachment to the PG GlcNAc moiety or to the membrane 
for S. pneumoniae.8–10 Experimental evidence suggests, that the CPs of Gram-
negative bacteria may be anchored to the cell surface by covalent linkages between 
their reducing ends and either lipid A (in the case of E. coli KLPS, see 1.5) or 
phospholipid molecules.11–14 However, other mechanisms (e.g. electrostatic 
interactions) might also contribute to CP retention in Gram-negative organisms.15 The 
tight association with the cellular surface has been used as a criterion to differentiate 
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CPs from exopolysaccharides (EPSs), which are secreted by bacteria to form a slime 
layer or a biofilm matrix. This broad distinction is only approximate, since CPs may 
also be released into the growth medium.16 Furthermore, certain EPS molecules 
seem to be tightly associated with the bacterial cell surface in the absence of any 
detectable cell envelope anchoring.17  
 
TABLE 1  
Capsular serotypes of selected pathogenic bacteria 
Species Number of capsular 
serotypes 
Serotypes associated with invasive 
disease
a
 
Bacillus anthracis 1 (polyglutamic acid)  
Escherichia coli 80 K1, K5 
Haemophilus influenzae 6 (a–f) b 
Klebsiella pneumoniae 77 K1, K2 
Neisseria meningitidis 12 A, B, C 
Pseudomonas aeruginosa 1 (alginate)  
Salmonella enterica  1 (Vi antigen)  
Staphylococcus aureus  4 (1, 2, 5, 8) 5, 8 
Streptococcus pneumoniae 93 children: 4, 6B, 9V, 14, 18C, 19F, 23F  
adults: 1, 3, 4, 6, 7, 8, 9, 12, 14, 18, 23 
Streptococcus pyogenes 1 (hyaluronan)  
Note. Adapted from Cartee, R.T. & Yother, J. (2006) Capsules. In C.A. Nickerson & M.J. Schurr 
(editors), Molecular Paradigms of Infectious Disease: A Bacterial Perspective (pages 138–174).  
a
indicated for species that have more than one serotype 
A large number of different capsule types have been identified in human pathogens 
by serotyping, but only some of the corresponding CP primary structures have been 
elucidated biochemically. Various capsule types can be found in one bacterial 
species (TABLE 1). For example, more than 80 antigenically distinct CP types, also 
referred to as K antigens (K is short for the German word Kapsel), have been 
identified in E. coli, so far.18 In contrast, only one capsular serotype has been 
described for Salmonella.19 Except in rare circumstances, a given bacterial cell 
contains the genes for, and expresses only, one type of CP.10 Serotyping of bacterial 
clones is of great importance in epidemiology as it often represents the simplest tool 
to monitor the spread of a pathogen in an affected community.20 In addition, the 
capacity to cause certain human diseases may be limited to a few capsular serotypes 
of a bacterial species. For instance, E. coli strains expressing the K1 antigen are the 
major cause of Gram-negative bacillary meningitis in neonates.21  
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1.2 Functions of bacterial capsules 
Bacterial polysaccharide capsules are involved in various functions and processes 
relevant to pathogenicity, including prevention of desiccation, adherence, and 
resistance to non-specific and specific host immune defense.22 Bacterial capsules 
form a highly hydrated gel-like polymer that may protect the cell from the harmful 
effects of desiccation.23 Mucoid (i.e. encapsulated) strains of E. coli exhibit 
significantly prolonged survival under conditions of dehydration, compared to 
isogenic non-mucoid mutants.24 The enhanced survival of capsule-bearing bacteria, 
also observed in other species, may be particularly relevant for host-to-host 
transmission.24,25 These findings may furthermore explain the positive correlation 
between high osmolarity and CP production seen with many species.26,27 
The influence of CP expression on bacterial adherence and biofilm formation seems 
to depend on the polysaccharide type and the organism. In Staphylococcus 
epidermidis, the ability to establish a biofilm and to colonize abiotic surfaces (e.g. 
catheters and other medical devices) was found to be strongly correlated with the 
ability to cause infections in a clinical setting.28 The capsular polysaccharide/adhesin 
of S. epidermidis was demonstrated to mediate initial cell–surface interactions crucial 
for biofilm development by this organism.29 In contrast, a negative influence on 
biofilm formation was observed for several S. pneumoniae CP types.30 Furthermore, 
downregulation of pneumococcal capsule expression was shown to enhance host 
cell invasion during establishment of the asymptomatic carrier state, although the 
capsule must be restored for survival after invasion.31,32 The reduced capsule 
thickness leads to exposure of adhesins otherwise shielded by the CP molecules, 
which promote adhesion to host cells and subsequent pathogen uptake.31,33 The 
significance of a properly modulated CP biosynthesis has also been demonstrated in 
case of N. meningitidis infections; the “phase-off” state of capsule production 
enhances host tissue invasion, whereas the “phase-on” state is essential for survival 
in systemic infections.34,35 
Most bacteria causing invasive disease produce CPs, which serve as essential 
immune evasion factors enabling bacterial persistence in the blood-stream of infected 
hosts, or abscess formation.4,36–39 Bacterial capsules play an important role in 
protecting microbes against complement attack. 
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FIGURE 1. Bacterial capsular polysaccharides contribute to complement resistance. Antiphagocytic 
capsules inhibit activation/deposition of complement, or block access of phagocytic receptors to 
deposited complement components. Antilytic capsules prevent lysis of Gram-negative bacteria by the 
complement C5b–9 membrane attack complex.
40
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The complement is a complex system of circulating and cell-surface-bound proteins, 
which serve as substrates, enzymes, or modulators of a hierarchical series of 
extracellular proteolytic cascades (FIGURE 1). This system contributes to microbial 
clearance either by direct killing through formation of a lytic membrane attack 
complex (only Gram-negative bacteria), or by opsonization of microbes enabling 
phagocytic uptake (for reviews, see references 41,42). The complement system 
represents a functional bridge between innate and adaptive immune responses, and 
can be activated by antigen-antibody complexes (classical pathway), certain 
carbohydrates (lectin pathway), or by various surfaces that are not decorated with 
natural inhibitors (alternative pathway). All three pathways culminate in the cleavage 
of C3 and in the generation of the principal complement opsonins C3b and iC3b 
(degradation fragment of C3b). Opsonization of foreign surfaces by C3b enables 
phagocytosis and leads to the assembly of C5 convertases, which cleave C5 to form 
C5a and C5b. The C5b fragment associates with components C6, C7, C8, and 
multiple C9 molecules. On membrane surfaces where the formation of polymeric C9 
is not inhibited, such as on the membranes of serum-sensitive Gram-negative 
bacteria, membrane attack complexes are formed, and the collapse of membrane 
potential leads to cell death.  
Polysaccharide capsules may contribute to complement resistance by a variety of 
mechanisms (FIGURE 1). Most bacterial CPs are poor activators of the alternative 
complement pathway.43 The expression of such polysaccharides may serve to 
provide a permeability barrier to complement components physically masking 
underlying surface structures, that would otherwise act as potent activators of the 
alternative pathway (e.g. cell wall polymers or LPS).1 Similarly, encapsulation may 
inhibit the recognition of surface antigens by specific IgG antibodies and the cell 
surface-binding of mannose-binding lectin, thereby preventing activation of the 
classical pathway and the lectin pathway, respectively.44–46 For instance, 
encapsulated strains of S. aureus are not agglutinated by antibodies direct against 
PG and WTA, which play an important role in the phagocytic clearance of non-
encapsulated S. aureus.44 However, even if the complement system is activated and 
opsonins (C3b, iC3b) are formed, they may become embedded deep in the capsular 
network and be inaccessible to the respective cell surface receptors on 
polymorphonuclear leukocytes.47–49 The accessibility may be restored in the 
presence of anticapsular antibodies, which direct the deposition of C3 fragments to 
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the capsule itself.48,50 For example, acapsular mutants of S. aureus are efficiently 
opsonized for phagocytosis by non-immune serum, whereas phagocytosis of 
encapsulated strains requires the presence of both, specific anti-CP antibodies and 
complement.4,44 In Gram-negative organisms, capsule formation is furthermore 
thought to confer protection against direct killing, by preventing correct insertion of 
the cytolytic membrane attack complex (C5b–9) into the outer membrane. Ward & 
Inzana demonstrated that the Actinobacillus pleuropneumoniae CP confers 
protection against complement-mediated lysis by limiting the deposition of C9 on the 
bacterial cell surface, although it does not hinder the early steps of complement 
activation.51  
Besides being major complement resistance factors, bacterial capsules may also 
contribute to immune evasion by impairing Toll-like receptor (TLR)-mediated 
pathogen recognition. The TLRs are germ-line encoded pattern recognition receptors 
that sense conserved microbial structures, so called pathogen-associated molecular 
patterns (for a review, see reference 52). TLR signaling plays an essential role in the 
host defense to microbial infections, not only by enhancing innate immune 
responses, but also by providing a link to the adaptive immune system. Activation of 
TLRs on phagocytes (e.g. macrophages, dendritic cells) stimulates the production of 
microbicidal substances (e.g. reactive oxygen species, nitric oxid, antimicrobial 
peptides) and induces the expression of proinflammatory cytokines, chemokines, and 
co-stimulatory molecules, which subsequently control the activation of antigen-
specific adaptive immune responses. Some polysaccharide capsules may 
downregulate the host immune response by shielding of the bacterial surface, and 
thus preventing TLR-mediated recognition of pathogen-associated molecular 
patterns.46 Certain CPs, however, seem to interfere with TLR-mediated immune 
responses in a more specific way. It has been suggested that the type C CP of 
N. menigitidis inhibits LPS-induced activation of TLR4 by direct binding to the 
accessory molecule CD14.53 The unusual O-methyl phosphoramidate (MeOPN) 
modification, found on about 70% of C. jejuni CPs,54 has been shown to modulate the 
host cytokine response by interfering with TLR signaling. The MeOPN modifications 
on the Campylobacter jejuni NCTC 11168 CP were demonstrated to reduce the 
TLR4-mediated release of the proinflammatory cytokines IL-6 (interleukin-6), IL-10 
(interleukin-10) and TNF (tumor necrosis factor) from mouse dendritic cells.55 
MeOPN-mediated downregulation of TLR activation and cytokine production has also 
Introduction 
 
7 
been observed with the structurally distinct C. jejuni 81-176 CP, suggesting an active 
and specific role for the MeOPN moieties in interfering with TLR signaling.56 
In contrast to the majority of CPs, which are capable of eliciting an antibody 
response, certain CPs are poorly immunogenic due to similarities to host-associated 
carbohydrate structures; expression of such CPs does therefore confer some 
measure of protection against the host’s specific immune response.25 For example, 
the polysialic acid capsule of N. meningitidis serogroup B and E. coli K1 strains is 
antigenically similar to structures expressed on human foetal neuronal cells, and 
consequently poorly immunogenic.57,58 Another example of such a molecular mimicry 
is the E. coli K5 antigen strongly resembling human desulpho-heparin.59 
1.3 Bacterial capsular polysaccharides as vaccine agents 
Bacterial capsular polysaccharides have the capacity to elicit type-specific antibody 
responses that confer protection against invasive disease by enabling 
opsonophagocytic killing of encapsulated bacteria. Thus, they are attractive 
candidates for vaccine development (for a review, see Weintraub6). Moreover, CPs 
are generally non-toxic and have none of the deleterious adverse effects associated 
with whole-cell vaccines.6 Today, several vaccines based on CPs are successfully 
used in the prevention of infectious diseases (TABLE 2), such as H. influenzae 
serotype B meningitis in children. To overcome the poor immunogenicity of 
polysaccharide vaccines in infants, conjugate vaccines consisting of polysaccharides 
linked to highly immunogenic protein carriers (e.g. diphtheria or tetanus toxoids) have 
been developed.60,61 Such protein-polysaccharide conjugates act as T cell-dependent 
antigens.62 The differences between polysaccharide vaccines and conjugate 
vaccines are most marked for infants and immunocompromised persons, with 
conjugate vaccines inducing much stronger immune responses.63,64 The design of 
peptides (i.e. T cell-dependent antigens) that mimic polysaccharide antigens may 
represent a further strategy to overcome T cell independency.65  
Many vaccine development projects have faced the problem of antigenic variability, 
which arises from the wide structural heterogeneity among the polysaccharides within 
and between species (see section 1.1), and the fact that anti-polysaccharide 
antibodies are usually serotype/serogroup specific. This problem has been 
approached by multivalent vaccine formulations, which raise immunity individually 
targeted against the clinically most important capsule types. For example, the 
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polysaccharide vaccine Pneumovax® 23 (see TABLE 2) contains purified CPs from 
the 23 most prevalent S. pneumoniae serotypes, which are accountable for 
approximately 90% of all pneumococcal infections (www.who.int). 
 
TABLE 2 
Licensed vaccines based on bacterial capsular polysaccharides  
Indication Trade Name(s)
®
 Vaccine type 
Haemophilus influenzae  
serotype b  ActHIB, Hiberix 1-valent conjugate vaccine
a
 
Neisseria meningitidis 
serogroup C Meningitec, Menjugate 1-valent conjugate vaccine
b
 
 NeisVac-C 1-valent conjugate vaccine
a
 
serogroups A, C Meningokokken-
Impfstoff A+C Mérieux 
2-valent polysaccharide vaccine 
serogroups A, C, W-135, Y Mencevax
 
ACWY 4-valent polysaccharide vaccine 
 Menveo 4-valent conjugate vaccine
b
 
 Nimenrix 4-valent conjugate vaccine
a
 
Salmonella enterica 
serovar Typhi Typhim Vi, Typherix 1-valent polysaccharide vaccine 
Streptococcus pneumoniae 
serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 
19F, 23F 
Synflorix 10-valent conjugate vaccine
c
 
Synflorix serotypes + 3, 6A, 19A Prevenar 13 13-valent conjugate vaccine
b
 
Prevenar-13 serotypes + 2, 8, 9N, 10A, 
11A, 12F, 15B, 17F, 20, 22F, 33F 
Pneumovax 23 
 
23-valent polysaccharide vaccine 
Note. The complete list of vaccines licensed for immunization and distribution in Germany is available 
at the Paul-Ehrlich-Institute website (www.pei.de).  
a
tetanus toxoid as carrier protein 
b
non-toxic mutant of diphtheria toxin (CRM197) as carrier protein 
c
H. influenzae protein D + diphtheria toxoid + tetanus toxoid as carrier proteins 
In some cases, the mimicry of host-associated carbohydrate structures by bacterial 
polysaccharides represents a key obstacle to vaccine development. Perhaps the best 
example of this is the meningococcal serogroup B CP, which is structurally identical 
to the polysialic acid chains found on an important nervous system developmental 
protein—the neural cell adhesion molecule (N-CAM).57,58 The search for an effective 
vaccine against serogroup B meningococcus, which is the most important cause of 
endemic meningitis in industrialized countries, has been complicated by the inability 
of its CP to induce a significant antibody response, even when conjugated to a carrier 
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protein.66 Furthermore, the use of this polysaccharide in a vaccine has the potential 
risk of inducing autoantibodies.58,67 In such cases, other surface-exposed molecules 
seem to be the more promising candidate antigens for vaccine development.68 Only 
recently, Bexsero® (Novartis Vaccines and Diagnostics) was licensed for the 
prevention of serogroup B meningococcal disease, a vaccine that contains three 
recombinant proteins and outer membrane-vesicles derived from a N. meningitidis 
group B strain as immunogenic components.69 In the case of other clinically 
important pathogens, the search for an effective vaccine is still ongoing. For instance, 
Pfizer’s SA4Ag, a multiantigen vaccine for prevention of S. aureus disease, which 
contains CPs from the two most prevalent serotypes, as well as two protein antigens, 
is currently in Phase II development (http://clinicaltrials.gov/show/NCT01364571).70  
1.4 Biochemistry and genetics of bacterial capsular polysaccharide 
production 
Despite the remarkable diversity in bacterial oligo- and polysaccharide structures 
(see section 1.1), conserved themes are evident in the biosynthesis-export pathways. 
Central to the understanding of these processes has been the elucidation of LPS 
O antigen biosynthesis in Gram-negative bacteria, and the identification of three 
general assembly–export strategies, termed “Wzy-dependent”, “synthase-
dependent”, and “ATP-binding cassette (ABC) transporter-dependent”;71 the bacterial 
systems for capsule synthesis can be grouped into the same categories (FIGURE 2; 
reviewed in references 10,14). The Wzy-dependent pathway of capsule biosynthesis is 
widespread among both, Gram-negative and Gram-positive bacteria. The respective 
polymers usually have complex repeating units comprising different sugars and, 
often, side chains.72,73 The CPs of essentially all Gram-positive organisms, including 
those of staphylococci and most streptococci, as well as the group 1 and group 4 
capsules of Gram-negative bacteria, are produced via the Wzy-dependent 
pathway.72,74–77 Wzy-dependent CP synthesis mechanistically resembles PG 
biosynthesis and involves the formation of lipid-linked intermediates. Basic repeating 
units are built on the isoprenoid lipid carrier undecaprenyl-phosphate (C55P), by 
sequential glycosyltransferase reactions occurring at the inner face of the 
cytoplasmic membrane.75 
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Once the basic repeating unit is assembled, the polyprenol-linked intermediates are 
exported across the membrane by a process involving a Wzx “flippase”.79 The lipid-
linked repeat units are polymerized at the outer surface of the cell membrane by a 
Wzy polymerase, through growth at the reducing end.80  
In contrast, CP molecules synthesized via ABC transporter-dependent pathways are 
fully polymerized in the cytoplasm, whereby growth of the polysaccharide chain at the 
non-reducing end is catalyzed either by a single glycosyltransferase, or by the 
concerted action of several glycosyltransferases.81–83 The completed polymer is 
exported across the membrane via a pathway-defining transporter of the ABC-2 
family.84 So far, ABC transporter-dependent capsule synthesis has only been 
described in Gram-negative bacteria. The E. coli K1 and K5 capsules, as well as CP 
molecules from a number of other pathogens, including C. jejuni, N. meningitidis and 
H. influenzae, are synthesized by this mechanism.85–89 ABC transporter-dependent 
polymers tend to be unbranched, simple structures.14 However, this trend does not 
apply for all species. For example, C. jejuni NCTC 11168 produces complex, 
branched CP molecules that are exported by an ABC transporter.86,90 Initiation of CP 
biosynthesis in ABC transporter-dependent systems remains poorly understood. 
Neither the acceptor used for chain extension, nor the enzymes responsible for 
initiation, have been identified. CPs assembled via ABC transporter-dependent 
pathways bear terminal phospholipid moieties at their reducing ends, which likely 
serve as outer membrane anchors.11–14 In E. coli and N. meningitidis, the 
predominant lipid is a lysophosphatidylglycerol moiety that is attached to the repeat-
unit domain of the CP via multiple residues of 3-deoxy-D-manno-oct-2-ulosonic acid 
(Kdo).14 The precise point in the biosynthetic pathway at which the phospholipids are 
added is unknown, though it has been suggested that they might represent the 
endogenous acceptors for ABC transporter-dependent polymer assembly.14,91 
However, the glycan chain might also be built on a different acceptor molecule (e.g. 
C55P) and transferred to the phospholipid anchor prior to export.
73 
Only a few capsules composed of relatively simple polysaccharides are produced via 
the synthase-dependent pathway, such as the S. pneumoniae type 3 capsule, and 
the Streptococcus pyogenes and Pasteurella multocida hyaluronic acid (HA) 
capsules.92–94 These CPs comprise either a monosaccharide or a heterodisaccharide 
repeat unit, and require only a single glycosyltransferase—the synthase—for initiation 
and polymerization.10,95 Bifunctional synthases, which catalyze the addition of two 
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different sugars and/or the formation of different glycosidic bonds, represent an 
exception to the usual “one enzyme, one sugar linkage” dogma of glycobiology.96 
Such dual-action glycosyltransferases are involved in the synthesis of some 
important biopolymers, including bacterial cellulose, alginate, hyaluronan, and 
chondroitin.97–100 In the case of the S. pneumoniae serotype 3 synthase, the ability to 
transfer two different monosaccharides seems to involve a single carbohydrate-
binding site that recognizes two different UDP-sugars.101 In contrast, the P. multocida 
HA synthase comprises two independent glycosyltransferase sites, as revealed by 
mutation analysis.93 Most bacterial polysaccharide synthases are integral membrane 
proteins that share a similar topology with four transmembrane domains and a large 
cytoplasmic loop that harbours the glycosyltransferase activity.102–105 The nature of 
the acceptor on which the polymer is built is often ambiguous, as well as the process 
by which the polymer is exported. It has been demonstrated that S. pneumoniae 
utilizes phosphatidylglycerol as lipid acceptor for the synthesis of type 3 CP, whereas 
HA assembly in Streptococcus equisimilis does not seem to involve lipid-linked 
intermediates.106,107 Several synthases are proposed to be sufficient for both, 
polymerization and export.94,108 To date, the only synthase for which polysaccharide 
export activity has been definitely proven is the HA synthase from S. equisimilis.107 
However, the exact mechanism through which synthases mediate extrusion of 
nascent polymers remains elusive. In other synthase-dependent systems, additional 
components may be required for CP transport across the cytoplasmic membrane. For 
example, an ABC transporter has been implicated in HA export in P. multocida.109  
The capsule biosynthetic genes, which encode enzymes involved in the production of 
activated nucleotide sugar precursors and the respective glycosyltransferases, 
generally form a cluster on the bacterial chromosome (often named cps/kps/cap for 
“capsule” or eps/exo for “exopolysaccharide”).110 These clusters furthermore 
comprise genes required for CP polymerization and export, and genes with 
regulatory functions (as described in the following text and in section 1.5). Within 
mechanistic types (Wzy-dependent, synthase-dependent, ABC transporter-
dependent), the genetic loci for CP production demonstrate similar 
organization;10,95,111 genes encoding for pathway-defining proteins (i.e. Wzx 
“flippases”, Wzy polymerases, transmembrane and nucleotide-binding domains of 
ABC-2 transporters) can be predicted by their putative membrane topologies, or by 
the presence of conserved sequence motifs.84,112,113 In Gram-negative bacteria, the 
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export apparatus used in the synthase-dependent pathway is clearly distinct from the 
OPX (outer membrane polysaccharide export) and PCP (polysaccharide 
co-polymerase) proteins required for the secretion of Wzy- and ABC transporter-
dependent polymers.114,115 It comprises a tetratricopeptide repeat (TPR)-containing 
scaffold protein, which is thought to protect the polymer from degradation once it 
reaches the periplasm, and a β-barrel protein, that forms a pore in the outer 
membrane.116,117 Due to their predictability by sequence analysis programs, these 
protein families serve as identifiable hallmarks of synthase-dependent systems in 
Gram-negative bacteria.95 Most of the enzymes necessary for CP synthesis are 
encoded in the polysaccharide-specific loci. However, the lipid acceptors and many 
of the nucleotide-diphospho-sugar precursors are common to other biosynthetic 
pathways (e.g. PG, WTA and LPS biosynthesis) and are obtained from cellular pools 
without the need for unique enzymes.10,118  
1.5 Regulation of bacterial capsule expression 
The fact, that the biosyntheses of CP and PG share a common pool of limited 
precursors, makes a well-orchestrated temporal and spatial regulation of these 
processes essential for the viability of the cell.119–124 This hypothesis is supported by 
the frequent observation that growth and division reduce CP production, while growth 
conditions which reduce the demand for new cell wall synthesis tend to enhance CP 
production.125–127 Furthermore, it has long been appreciated that CP expression must 
be modulated in order to ensure a balance between the protective functions of the 
capsule and the surface exposure of molecules required for substrate-binding and/or 
colonization.128 For instance, bacteria that colonize the nasopharynx may reduce CP 
production to expose adhesins, which are important for interactions with the host 
epithelium, but would increase capsule production when in the bloodstream to ensure 
protection against opsonophagocytosis (see section 1.2).  
Temperature provides a key signal for transcriptional regulation of capsule genes in 
many organisms, and this may serve to limit capsule production to the environments 
in which it will confer a selective advantage.128 In E. coli, the expression of group 2 
capsule genes is driven by two thermoregulated promoters, with maximal CP 
production occurring at or near 37°C, while capsule expression is negligible at 
temperatures below 20°C.129,130 Osmolarity is another environmental factor 
influencing CP expression. For example, the expression of the Vi (capsular) antigen 
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in Salmonella enterica typhi is known to be inhibited by high concentrations of NaCl 
(> 300 mM), such as those found in the human gut.131,132 This inhibition enables the 
release of invasion-promoting Sip proteins, which, whilst the bacterium is expressing 
a capsule, are not secreted, but stockpiled in the cell.131 A positive correlation 
between CP expression and osmolarity is seen with many other species, indicating a 
potential function of the capsule in the prevention of desiccation (see section 1.2).26,27 
Further physicochemical parameters were identified as signals for modulation of 
bacterial CP expression, such as Mg2+ and iron levels, pH, and oxygen 
availability.125,133–136 The CrgA transcriptional regulator of N. meningitidis represents 
an example how more specific, host-cell derived stimuli may be integrated in the 
regulation of capsule expression. This regulator, which acts as repressor of capsule 
gene expression, is induced upon intimate contact with epithelial cells, thus reducing 
meningococcal capsule production.137  
Given the substantial energy investment that CP biosynthesis and export represent to 
bacteria, and that the formation of a capsule is not appropriate for all circumstances 
(see above), it is not astonishing that capsule expression is tightly regulated and 
controlled at multiple levels.138 Besides regulation through phase-variation or 
transcription factors, bacterial CP expression is controlled on the post-translational 
level enabling short-term modulation.34,139–143 The post-translational control is exerted 
by tyrosine kinase phosphoregulatory systems, which are associated with Wzy- and 
synthase-dependent polymerization systems of both, Gram-positive and Gram-
negative bacteria.115 
Most protein tyrosine kinases found in bacteria, including those involved in the 
regulation of CP and EPS production, belong to the family of bacterial tyrosine 
(BY-)kinases.144 BY-kinases are structurally and functionally unrelated to their 
eukaryotic counterparts.145–147 At first they were believed to be exclusively 
autophosphorylating enzymes functioning as “co-polymerases” in the biosynthesis of 
CP and EPS.115 However, in recent times, members of the BY-kinase family were 
shown to phosphorylate endogenous protein substrates, such as biosynthetic 
enzymes involved in polysaccharide production, but also RNA polymerase sigma 
factors and single-stranded DNA binding proteins.148–150 Therefore, BY-kinases can 
be considered as promiscuous enzymes involved in diverse biological processes 
including stress response, DNA metabolism, and cell-cycle control.148,149,151,152 
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FIGURE 3. Defining structural features of bacterial tyrosine kinases (adapted from Grangeasse et al.
144
). All bacterial tyrosine (BY-)kinases share several 
common features: an external sensory loop is linked to an intracellular catalytic domain, either directly (Proteobacteria) or via specific protein-protein 
interactions (Firmicutes). The catalytic domain contains the Walker-like motifs A, Aʹ and B (green) and a C-terminal tyrosine cluster comprising up to 7 
(auto)phosphorylatable tyrosine residues (red). Amino acid sequence alignments are provided for BY-kinases from the following species: Escherichia coli Wzc, 
GenBank accession number CDU38087.1, and Etk, P38134.2; Acinetobacter johnsonii Ptk, CAA75431.1; Sinorhizobium meliloti ExoP, AAA16042.1; 
Streptococcus pneumoniae CpsD, ADQ39181.1; Staphylococcus aureus CapB1, BAF66368.1, and CapB2, BAF68834.1; Bacillus subtilis YwqD, CAB15642.1. 
aa, amino acids; TM, transmembrane domain. 
16                                                                                                                                            Introduction 
 
The proteins of the BY-kinase family are characterized by a number of common 
structural features (FIGURE 3). They possess an external “sensor” domain that is 
thought to modulate tyrosine kinase activity upon yet unidentified stimuli, and an 
internal catalytic domain. The catalytic domain encompasses three Walker-like motifs 
(named A, Aʹ and B) and a C-terminal tyrosine cluster comprising up to seven 
tyrosine residues, which can be autophosphorylated at the expense of ATP.145,149,153–
157 This autophosphorylation seems to influence the oligomerization state of the BY-
kinase.147 Moreover, the load of tyrosine phosphorylation is supposed to affect the 
ability of the BY-kinase to interact with other components of the capsule assembly 
and translocation machinery.156,158 
The BY-kinases of Proteobacteria are encoded in the capsule loci as a single 
polypeptide; they are composed of an N-terminal membrane-spanning activation 
domain and a C-terminal cytoplasmic tyrosine kinase domain.144 In Firmicutes, the 
two domains are located on separate, interacting proteins, which are usually encoded 
by adjacent genes in the capsule loci.144 Based on studies in S. aureus and 
S. pneumoniae, the cytoplasmic kinase protein alone is not sufficient for 
phosphotransfer, but has to interact with the C-terminus of the transmembrane 
adaptor to undergo autophosphorylation.159–161 In contrast, Bacillus subtilis YwqD 
alone shows tyrosine autokinase activity in vitro.149 Nevertheless, this activity is 
enhanced in the presence of the cognate transmembrane adaptor YwqC.149 
The dynamic regulation of cellular processes by protein phosphorylation is achieved 
through a fine balance of opposing kinase and phosphatase activities. In 
Proteobacteria, the phophatases involved in the regulation of CP production belong 
to the family of low-molecular-weight phosphatases (LMW-PTPs), whereas in 
Firmicutes, they belong to the DNA polymerase and histidinol phosphate 
phosphoesterase (PHP) family.162–164 The phosphatases are encoded within the 
capsule loci, by genes located either immediately upstream (both types) or 
downstream (only PHPs) of those encoding the cognate kinases.162–164 These 
enzymes efficiently dephosphorylate BY-kinases and, at least in some cases, the 
respective BY-kinase protein targets.162–164  
The autophosphorylation state of BY-kinases, regulated by the corresponding 
phosphatases, influences the amount, the length and other properties of the 
polysaccharide produced.156,160,165,166 In E. coli K30, the capsule building blocks can 
undergo one of two fates. High-level polymerization can occur to generate 
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high-molecular-weight CP or, alternatively, one to a few repeat units can be ligated 
onto a lipid A-core and expressed on the cell surface as so-called KLPS.
167 
Autophosphorylation of the WzcCP BY-kinase, as well as its dephosphorylation by the 
cognate phosphatase Wzb, are both required for assembly of a high-molecular-
weight capsule, though not for low-level polymerization or assembly of KLPS.
156,166 
Similarly, the phosphorylation state of the Sinorhizobium meliloti BY-kinase ExoP 
influences the ratio of low- to high-molecular weight succinoglycan.165 Current 
hypotheses suggest that BY-kinases may, depending on their phosphorylation and 
oligomerization state, interact with the export and polymerization machinery to control 
the level of CP production and/or CP chain length.147,168,169 However, their exact 
mode of function remains enigmatic. Recently, it has been demonstrated that the 
modulatory effects of BY-kinases are at least partially due to the phosphorylation of 
biosynthetic enzymes.149,161,175,176 For instance, the E.coli BY-kinase WzcCA was 
shown to phosphorylate the enzyme UDP-glucose dehydrogenase, thereby 
increasing its catalytic activity in vitro, and probably the formation of precursors for 
polysaccharide production in vivo.175 In addition to modulating enzyme activities, 
BY-kinase-mediated phosphorylation seems to affect protein targeting.151 
1.6 Capsule biosynthesis in Staphylococcus aureus 
Staphylococcus aureus is an important opportunistic pathogen that may colonize 
moist skin areas, skin glands, and mucous membranes without causing symptoms of 
infection.177 The anterior nares (30% of individuals), perineum (15%) and axillae 
(2–7%) represent the main habitats for S. aureus on healthy humans; other body 
sites may be colonized as well, such as the vagina, pharynx, rectum, and the
toe-web spaces.178–181 The Gram-positive, coccus-shaped bacterium is capable of 
causing a broad spectrum of human diseases, such as skin and soft tissue infections, 
endovascular infections, pneumonia, septic arthritis, endocarditis, osteomyelitis, 
foreign-body infections, and sepsis.182 Its pathogenic nature led to the first 
description of the Gram-positive bacterium over 130 years ago by the Scottish 
surgeon Sir Alexander Ogston, who identified the organism in human pus and coined 
the name Staphylococcus (derived from the Greek words staphyle and kokkos, 
meaning “bunch of grapes” and “berry”, respectively).183 Since then, it has become 
clear that S. aureus is highly versatile, and adept at acquiring and developing 
resistance against virtually all antibiotics.184 The excessive use of antibiotics has 
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favored the evolution of highly virulent, drug-resistant S. aureus strains, thus leading 
to a rise in the occurrence and severity of infections over the last 20 years.185,186 
Methicillin-resistant S. aureus (MRSA) strains, which are resistant to all available 
penicillins and most other β-lactam antibiotics (with exception of the advanced-
generation cephalosporines ceftaroline and ceftobiprole), were first identified in 1961 
and soon became endemic in hospitals and health-care facilities worldwide.186–188 For 
the following decades, MRSA infections were largely confined to the nosocomial 
setting, and did predominantly affect patients with health care-associated risk factors, 
such as hospitalization or residence in a long-term care facility, presence of 
indwelling medical devices, ulcers or surgical wounds, or chronic dialysis 
treatment.186,189–193 Since the mid-1990s, however, there has been a rise in the 
number of MRSA infections occurring in a non-hospital environment in otherwise 
healthy individuals.186 This increase in disease burden has been attributed to
so-called “community-associated MRSA” strains, which show enhanced virulence 
potential, and are capable of causing invasive disease in immunocompetent hosts.186 
Hospital- and community-associated multidrug-resistant MRSA strains, which display 
resistance to β-lactam antibiotics combined with resistance to other classes of 
antibiotics, do currently challenge our ability to treat bacterial infections, and evoke 
fears of an upcoming “post-antibiotic era”.194–197 Within the health care setting alone, 
MRSA infections are estimated to affect more than 150,000 patients annually in the 
European Union, causing more than 5000 attributable deaths, and extra in-hospital 
costs of € 380 million.198 In the US, MRSA is the second leading cause of death by 
infectious disease, with more than 11,000 MRSA-related deaths in 2011 
(www.cdc.gov/drugresistance/threat-report-2013/). 
The pathogenic properties of S. aureus are due to an armament of virulence factors, 
ranging from secreted toxins to immune evasion molecules.199 The expression of a 
polysaccharide capsule, which confers protection against opsonophagocytosis, 
contributes substantially to the ability to cause invasive disease (see section 1.2 
“Functions of bacterial capsules”); the majority (~80%) of S. aureus strains recovered 
from patients are encapsulated.200,201 Serotype 5 and 8 capsular polysaccharide 
types (CP5 and CP8) are dominant among clinical isolates.200,202 They share similar 
trisaccharide repeating units, which are identical in monosaccharide composition and 
sequence, only differing in the glycosidic linkages between the sugars and the sites 
of O-acetylation.203–205  
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Although polysaccharide structures of CP5 ((→4)-β-D-ManNAcA-(1→4)-3-O-acetyl-α-
L-FucNAc-(1→3)-β-D-FucNAc-(1→)n) and CP8 ((→3)-4-O-acetyl-β-D-ManNAcA-
(1→3)-α-L-FucNAc-(1→3)-α-D-FucNAc-(1→)n) were elucidated decades ago, only 
little is known about the biochemistry underlying the assembly of these clinically 
important polymers. 
The serotype 5 and 8 capsule gene clusters are allelic and comprise a ~17.5 kb 
region on the staphylococcal chromosome composed of 16 genes transcribed in one 
orientation (cap5(8)A through cap5(8)P).77,206 Since CP5 and CP8 are built from the 
same three sugar residues, it is not surprising that 12 of the 16 genes are nearly 
identical (> 97% sequence identity). The genes responsible for serotype specificity 
(cap5HIJK and cap8HIJK) are located in the central regions of the loci, and show 
little sequence similarity between the two gene clusters. The type-specific regions 
comprise genes that encode putative Wzx “flippases” (cap5J, cap8I) and Wzy 
polymerases (cap5K, cap8K) (see section 1.4). Furthermore, these regions contain 
genes encoding putative glycosyltransferases (cap5I, cap8H) and 
O-acetyltransferases (cap5H, cap8J).  
Database homology searches with amino acid sequences of cap5 operon gene 
products allowed for the prediction of individual enzymatic functions and the proposal 
of a pathway for capsule biosynthesis in S. aureus.77 Within this Wzy-dependent 
pathway, synthesis of soluble capsule precursors occurs via three distinct reaction 
cascades, through which the universal substrate UDP-N-acetyl-D-glucosamine (UDP-
D-GlcNAc) is converted into the three different nucleotide-coupled sugars UDP-N-
acetyl-D-fucosamine (UDP-D-FucNAc), UDP-N-acetyl-L-fucosamine (UDP-L-FucNAc) 
and UDP-N-acetyl-D-mannosaminuronic acid (UDP-D-ManNAcA) (FIGURE 4). The 
synthesis of the first soluble precursor UDP-D-FucNAc is allegedly catalyzed in a two-
step process by the enzymes CapD and CapN, although experimental evidence is 
lacking so far. The integral membrane protein CapD is proposed to be a 
4,6-dehydratase, that generates the intermediate UDP-2-acetamido-2,6-dideoxy-D-
xylo-4-hexulose (UDP-Sugp) by eliminating a water molecule from UDP-D-GlucNAc. 
This intermediate is further converted to UDP-D-FucNAc by the action of the 
membrane-associated reductase CapN. Subsequently, CapM is supposed to transfer 
the N-acetyl-D-fucosamine moiety of UDP-D-FucNAc to the membrane-anchored lipid 
carrier bactoprenol (C55P), yielding lipid Icap. 
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FIGURE 4. Model for the Wzy-dependent capsule biosynthesis pathway in Staphylococcus aureus serotype 5. Synthesis of soluble capsule precursors occurs in 
the cytoplasm via three reaction cascades, through which the universal substrate UDP-N-acetyl-D-glucosamine is converted into the three different nucleotide-
coupled sugars UDP-N-acetyl-D-fucosamine, UDP-N-acetyl-L-fucosamine and UDP-N-acetyl-D-mannosaminuronic acid. Trisaccharide repeating units are 
assembled on the lipid carrier undecaprenyl-phosphate (C55P), and further modified by O-acetylation, before they are exported to the outer surface of the cell 
membrane where polymerization takes place. The polymerized CP5 is attached to the peptidoglycan; the carrier lipid C55P is released and recycled. Post-
translational control of capsule biosynthesis is exerted by the bacterial tyrosine kinase complex CapAB. Upon activation by the transmembrane adaptor CapA, 
the cytoplasmic kinase CapB undergoes autophosphorylation and may phosphorylate target proteins (e.g. biosynthetic enzymes), thus modulating their activity. 
The phosphorylation state of CapB is regulated by the cognate phosphatase CapC. 
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The second reaction cascade generating the soluble precursor UDP-L-FucNAc 
involves the enzymes CapE, CapF and CapG, the enzymatic functions of which have 
already been elucidated biochemically.207 The UDP-2-acetamido-2,6-dideoxy-L-
talose 2-epimerase CapG finally produces the nucleotide-activated sugar 
UDP-L-FucNAc, which is assumed to be attached to lipid Icap by the transferase 
CapL, leading to the formation of the second capsule lipid intermediate, lipid IIcap. The 
third nucleotide-activated monosaccharide required for CP5 production is generated 
by the enzymes CapP and CapO, which have already been characterized 
biochemically.38,208 CapP is a 2-epimerase that converts UDP-D-GlcNAc into
UDP-D-ManNAc. This enzymatic product is further modified into UDP-D-ManNAcA by 
the enzymatic action of the dehydrogenase CapO. The transmembrane protein CapI 
has been proposed to transfer the D-ManNAcA moiety to lipid IIcap, thereby 
generating the final capsule lipid precursor lipid IIIcap. The C55P-coupled trisaccharide 
is most likely further modified by the putative acetyltransferase CapH,209 which 
catalyzes the O-acetylation of L-FucNAc residues at position C3. This modification is 
characteristic for staphylococcal CPs and has been implicated in virulence.209 The 
complete, modified precursor is then translocated to the outer surface of the cell 
membrane, where polymerization takes place. These processes are proposed to 
involve the putative Wzx “flippase” CapK and the putative Wzy polymerase CapJ. 
The polymerized CP5 is attached to the MurNAc moiety of PG by a yet unknown 
mechanism,210 assumed to release the carrier lipid C55P, which may enter a new 
synthesis cycle. 
In S. aureus, CP production is maximal during the post-exponential phase of cell 
growth, whereas only little CP is produced in the logarithmic growth 
phase;125,134,211,212 the underlying regulation is not only achieved by transcriptional 
control,143,213–215 but has moreover been linked to tyrosine phosphorylation 
(FIGURE 4).175,176,236 Two triplets of adjacent genes encoding for a transmembrane 
adaptor, a cytoplasmic BY-kinase, and a PHP family phosphatase, were identified in 
the genome of S. aureus serotype 5: the capA1/capB1/capC1 triplet located at the 
5ʹ-end of the cap operon, and the highly similar capA2/capB2/capC2 triplet, which is 
located elsewhere on the bacterial chromosome, and probably arose from gene 
duplication.161,206 In vitro kinase activity could be demonstrated for CapB2, but not for 
CapB1, with CapA1 being the more potent activator protein.161,217 The nature of the 
stimulus that triggers cellular CapAB-signaling and the exact mode of signal 
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transduction are still elusive. Nevertheless, an enzyme participating in CP5 
biosynthesis could be identified as endogenous substrate of the CapAB BY-kinase. 
Soulat et al. demonstrated that the CapA1B2 complex phosphorylates the 
dehydrogenase CapO, and that this modification is required for catalytic activity in 
vitro.216,218 
1.7 Short-chain dehydrogenases/reductases 
Short-chain dehydrogenases/reductases (SDRs) constitute a large, evolutionary old 
family of NAD(P)(H)-dependent oxidoreductases, sharing sequence motifs and 
displaying similar mechanisms.219,220 Members of the SDR superfamily are found in 
nearly all organisms, from bacteria to man.221 They are involved in the metabolism of 
cofactors, carbohydrates, lipids and amino acids, and participate in redox sensing.220 
SDRs are a functionally diverse collection of proteins, and catalyze a wide range of 
chemical reactions, including oxidation, reduction, epimerization, dehydration and 
decarboxylation.220 Sequence identity between different SDR enzymes is generally 
low (typically 15–30% residue identity), and homology-based function prediction is 
especially difficult.219,222 The only unifying criterion for SDRs is the occurrence of a 
structurally conserved Rossmann fold dinucleotide-binding motif, consisting of a 
six-stranded β-sheet flanked by α-helices.219,223 This structural motif is characterized 
by the presence of a glycine-rich sequence pattern, which stabilizes the central 
β-sheet and mediates the interaction with the pyrophosphate moiety of the nucleotide 
cofactor.224,225 Most SDRs display a simple one-domain architecture comprising an 
N-terminal NADP(H)-binding fold, a largely conserved N[ST]YK active site tetrad, and 
a highly variable C-terminal region, that harbors the substrate binding site.226–228 Two 
main types of SDR enzymes can be distinguished: “classical” SDRs have a core 
structure with a chain length of about 250 amino acid residues, while “extended” 
SDRs have an additional C-terminal region of about 100 amino acids, that shows 
only little sequence conservation.219,220 In addition, transmembrane domains or signal 
peptides may be attached to these core structures.226,229 
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1.8 Objectives of this work 
Infections with multiresistant bacteria represent a serious threat to human health. 
Moreover, such infectious diseases create a substantial financial burden having 
detrimental effects on global health care systems.230 Since established antibiotics are 
becoming increasingly inefficient, there is an urgent need to explore new treatment 
strategies to counteract drug-resistant pathogens.231,232 Capsule biosynthesis is not 
essential for bacterial cell viability per se. However, inhibitors targeting this process 
may have the potential for use as anti-virulence agents (see Discussion, section 5.1). 
To explore constituents of the capsule biosynthetic pathway as drug targets, we need 
a profound understanding of the underlying molecular processes. 
The present study is designed to contribute to the elucidation of capsule biosynthesis 
in the important opportunistic pathogen S. aureus. In serotype 5 and 8 strains, which 
account for most clinical isolates, three nucleotide-activated sugars synthesized in 
the cytoplasm, which constitute the major building units of the CP polymer, are 
required for CP production (see section 1.6).77 The enzymatic reactions involved in 
the syntheses of the soluble capsule precursors UDP-L-FucNAc and 
UDP-D-ManNAcA have already been studied in vitro.38,207,208 In contrast, in vitro 
characterization of the biosynthesis of the soluble capsule precursor UDP-D-FucNAc 
has long been hampered by the fact that CapD, the enzyme catalyzing the initial step 
of the biosynthetic reaction cascade, is a protein with multiple transmembrane 
domains.  
In this thesis, reconstitution of the biosynthetic reactions underlying UDP-D-FucNac 
production shall be achieved using purified recombinant enzymes. For this purpose, 
the full-length membrane protein CapD and the cytoplasmic enzyme CapN of the 
serotype 5 strain S. aureus Newman will be overexpressed as recombinant 
hexahistidine fusion proteins, purified via immobilized metal-ion affinity 
chromatography, and characterized at the molecular level. Capillary electrophoresis 
(CE) and mass spectrometry (MS) are the methods of choice for analyzing the 
interconversion of nucleotide-activated dideoxy sugars, and these techniques will be 
utilized to monitor enzymatic activities. An enzymatic platform for production of the 
rare amino sugar UDP-D-FucNAc may not only enable future reconstitution of the 
complete S. aureus capsule biosynthesis pathway, but may also help in 
reconstructing FucNAc-containing glycan structures from other medically important 
bacteria (e.g. O glycans from P. aeruginosa).  
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Biosynthesis of S. aureus capsular polysaccharide consumes essential precursors, 
i.e. the universal lipid carrier C55P and the diphospho-nucleotide sugar 
UDP-N-acetylglucosamine, also required for the syntheses of the major cell wall 
components peptidoglycan and wall teichoic acid.120,122,124 Since the cellular 
undecaprenol pool is limited, precursor fate and prioritization for the different 
biosynthesis pathways need to be tightly controlled in time and space to ensure 
bacterial viability.119,121,123  
The present study aims to provide evidence that enzymatic checkpoints within the 
CP biosynthetic pathway are controlled by the tyrosine kinase complex CapAB to 
regulate consumption of shared precursors. Preliminary experiments identified the 
biosynthetic enzyme CapE as potential regulatory target of the CapAB complex.233 
Thus, the influence of CapAB-mediated phosphorylation on CapE catalytic activity 
shall be analyzed in vitro using a CE-based detection method for quantification of the 
CapE enzymatic product UDP-2-acetamido-2,6-dideoxy-β-L-arabino-hexulose.207,234  
Besides substantial progress in the understanding of capsule biosynthesis and the 
underlying regulation, the in vitro systems established in this study shall provide the 
molecular basis to screen for inhibitors of capsule biosynthesis as potential anti-
virulence agents. Moreover, they may enable in vitro synthesis of lipid-linked capsule 
intermediates as molecular tools for target-based screening (compare Müller & Ulm 
et al.235). 
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2 Materials and methods 
2.1 Materials 
2.1.1 Reagents and chemicals 
All chemicals and reagents utilized in this study were of analytical grade or better; the 
respective suppliers are given in TABLE 3. Compounds used for inhibitor screening 
can be found in SUPPLEMENTARY TABLE 1. 
 
TABLE 3 
Chemicals and reagents used in this study 
Manufacturer/Supplier  Chemical/Reagent 
B. Braun, Melsungen aqua ad iniectabilia  
Becton Dickinson, Heidelberg Difco
TM
 2YT broth 
Bio-Rad Laboratories, München (Bradford) protein assay dye reagent concentrate 
Carl Roth, Karlsruhe ethidium bromide, glycerol, kanamycin, saccharose, SDS, yeast 
extract 
Clontech Laboratories, Heidelberg Talon
®
 metal affinity resin 
Eurofins MWG Operon, Ebersberg oligonucleotides 
Glycon Biochemicals, Luckenwalde n-dodecyl-β-D-maltoside (DDM) 
Hartmann Analytic, Braunschweig γ-labeled [
33
P]-ATP 
J.T. Baker; Distributor: VWR 
International, Langenfeld 
chloroform, ethanol, methanol, water (HPLC grade) 
Life Technologies, Darmstadt Invitrogen™ NuPAGE
®
 Novex
®
 4–12% Bis-Tris gels with 
reducing agent, LDS sample buffer and MOPS SDS running 
buffer 
Merck, Darmstadt agar-agar, bromophenol blue, calcium chloride, EDTA, glacial 
acetic acid, orthophosphoric acid, peptone, potassium 
phosphate monobasic/dibasic, sodium chloride, sodium 
phosphate monobasic/dibasic, tryptic soy broth 
MP Biomedicals, Eschwege tryptone 
New England BioLabs, Frankfurt 
am Main 
dNTPs, Phusion
®
 High-Fidelity DNA polymerase with HF buffer, 
Type II restriction endonucleases 
Qiagen, Hilden DNeasy
®
 blood & tissue kit, MinElute
®
 PCR purification kit, Ni-
NTA agarose, QIAprep
®
 spin miniprep kit, QIAquick
®
 gel 
extraction kit 
Roche, Mannheim T4 DNA ligase with ligation buffer  
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TABLE 3 (continued)  
Sigma-Aldrich, Taufkirchen ATP, ammonium bicarbonate, 6-aza-2-thiothymine, bovine 
serum albumin, CAPS, diammonium hydrogen citrate, DMSO, 
DTT, deoxyribonuclease I, formic acid, imidazole, 
iodoacetamide, lysostaphin, lysozyme, magnesium chloride, 
NAD(P)
+
, NAD(P)H, PAP, polybrene, ribonuclease A, sodium 
acetate, triethylammonium acetate buffer (1 M, pH 7), Triton X-
100, Tris base/hydrochloride, trypsin (sequencing grade), UDP, 
UDP-D-GlcNAc 
Thermo Fisher Scientific, Schwerte Fermentas™: GeneRuler™ 1 kb DNA ladder, IPTG, 
PageBlue™ protein staining solution, PageRuler™ Plus 
prestained protein ladder, TopVision
TM
 LE GQ agarose; Oxoid 
blood agar base number 2, Pierce
®
 Zeba™ desalt spin columns 
(5 ml, 7 kDa molecular weight cut-off)  
VWR International, Langenfeld HiPerSolv Chromanorm
® 
acetonitrile 
Note. Suppliers are located in Germany. Abbreviated names of chemicals are explained in 
“Abbreviations and symbols”. 
 
2.1.2 Plasmids and oligonucleotides 
The Novagen® pET (plasmid expression by T7-RNA-polymerase) system is based on 
the T7 expression system established by Studier et al. and was developed for cloning 
and expression of recombinant proteins in E. coli.236 Target genes are cloned in pET 
plasmids under control of a strong bacteriophage T7 promoter; high-level expression 
of recombinant proteins is induced by providing a source of T7 RNA polymerase in 
the host cell. 
Recombinant plasmids enabling overexpression and purification of hexahistidine 
fusion proteins for in vitro reconstitution of capsule biosynthesis reactions were 
constructed on the basis of the pET vectors 24a(+) and 28a(+) (TABLE 4). The 
oligonucleotide primers utilized for plasmid construction are listed in TABLE 5. The 
identity of recombinant plasmids was confirmed by sequencing (Sequiserve, 
Vaterstetten, Germany).  
 
 
 
 
 
 
 
Materials and methods 
 
27 
TABLE 4  
Plasmids used in this study 
Plasmid  Characteristics/Use Reference/Source  
pET24a(+) Escherichia coli vector, expression of C-terminal His6 
fusion proteins, Km
R
, T7 promoter 
Novagen
®  
by Merck 
pET28a(+) E. coli vector, expression of N-terminal His6 fusion 
proteins, Km
R
, T7 promoter 
Novagen
® 
 
pET24a-capD Staphylococcus aureus Newman capD in pET24a Prof J.C. Lee
a
 
pET28a-capDtr truncated capD in pET28a, encodes soluble CapD 
derivative (amino acids 249–611) 
this thesis 
pET24a-capE 
(pKBK50d) 
S. aureus Newman capE in pET24a reference 
207
 
pET24a-capN S. aureus Newman capN in pET24a Prof J.C. Lee
a
 
pET28a-capA1 S. aureus Newman capA1 in pET28a reference 
233
 
pET28a-capB2 S. aureus Newman capB2 in pET28a reference 
233
 
pET28a-pglF truncated Campylobacter jejuni pglF in pET28a, encodes 
soluble PglF derivative (amino acids 130–590) 
this thesis, according 
to reference 
237
 
Note. His6, hexahistidine; Km
R
, kanamycin-resistance marker. 
a
Brigham & Women's Hospital/Harvard Medical School, Boston, USA 
TABLE 5 
Sequences of oligonucleotide primers used for plasmid construction 
Primer name Sequence (5′-3′)
a
 Restriction site 
capD for 
capD rev 
TATACATATGGCTAGCTTATCTGTGAAATTG 
TTTGTCTCGAGATAATTATCTCCCTTTTTGC 
NheI 
XhoI 
capDtr for 
capDtr rev 
GCGCGGCTAGCATGTCTGGTGAGTTAGAAGTG 
GCGCGCTCGAGTCATCGAACATAATTATCTCCC 
NheI 
XhoI 
capE for 
capE rev 
GGAGGCTAGCATGTTCGATGACAAAATT 
CTCTCGAGTCTCATTGAAGCTTTATAAT 
NheI 
XhoI 
capN for 
capN rev 
GTGCAGCTAGCATGAGAAAAAATATT 
AATAGATCTCGAGTGCCTTATCTTTG 
NheI 
XhoI 
capA1 for 
capA1 rev 
GCGCGGCTAGCATGGAAAGTACATTAGAATTAAC 
GCGCGCTCGAGTTAATTAAATTTTTGAATTGAACCC 
NheI 
XhoI 
capB2 for 
capB2 rev 
GCGCGGCTAGCATGACGAATACACGAAGAAGTA 
GCGCGCTCGAGTCATTCATCAGTCCCATAATATG 
NheI 
XhoI 
pglF for 
pglF rev 
GCGCGCATATGCTTGTGGATTTTAAACCTTC 
GCGCGCTCGAGTTATACACCTTCTTTATTGTGTT 
NdeI 
XhoI 
a
Underlining indicates the restriction enzyme recognition site engineered into the primer.
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2.1.3 Bacterial strains and culture media  
Bacterial strains used in this thesis are shown below in TABLE 6; the different growth 
media utilized for their maintenance are given in TABLE 7.  
 
TABLE 6 
Bacterial strains used in this study 
Bacterial strain Characteristics/Use Reference/Source 
Campylobacter jejuni 
clinical isolate DNA template for PCR amplification of pglF IMMIP 
Escherichia coli 
BL21 (DE3) general purpose expression host, λ prophage DE3 
carries T7 RNA polymerase gene under control of an 
IPTG-inducible promotor (lacUV5)  
Novagen
®
 by 
Merck 
C43 (DE3)  derivative of E. coli BL21 (DE3), optimized for 
expression of membrane proteins 
reference 
238
 
DH5α non-expression host, general purpose cloning, plasmid 
propagation and storage  
reference 
239
 
Staphylococcus aureus 
Newman methicillin-sensitive, capsular serotype 5, DNA template 
for PCR amplification of capsule biosynthesis genes  
reference 
240
 
Note. IMMIP, Institute of Medical Microbiology, Immunology and Parasitology, University of Bonn, 
Germany. 
TABLE 7 
Culture media used in this study 
Culture medium Composition 
Blood agar 40 g/l Oxoid
TM
 blood agar base number 2, 7% (v/v) sterile 
defibrinated sheep blood
a
 
Lysogeny broth (LB) 10 g/l tryptone, 10 g/l NaCl, 5 g/l yeast extract;  
+ 15 g/l agar-agar for LB agar plates  
Tryptic soy broth (Merck) 17 g/l peptone from casein, 3 g/l peptone from soymeal, 5 g/l 
NaCl, 2.5 g/l K2HPO4, 2.5 g/l glucose monohydrate 
Double-strength yeast extract-
tryptone broth (Difco
TM
 2YT) 
16 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl 
Note. All media were prepared in deionized distilled water. 
a
added after autoclaving and cooling down to 50°C 
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2.1.4 Sterilization procedures 
Growth media, solutions, plastic vials and pipette tips were sterilized by autoclaving 
at 121°C for 20 min. (Varioklav® 500E; H+P Labortechnik, Oberschleißheim, 
Germany). Heat-labile substances, such as antibiotics, were sterilized by filtration 
using Acrodisc® syringe filters (sterile, pore size 0.2 µM; Pall, Dreieich, Germany) 
The sterilization of glassware was carried out in an oven (model SLM 700; Memmert, 
Schwabach, Germany) at 200°C for 4 h.  
2.2 Growth, maintenance and preservation of bacterial strains 
Bacterial strains used in this thesis are listed in TABLE 6; the different growth media 
utilized for their maintenance are denoted in TABLE 7. Glycerol cultures were 
prepared for long-term storage of bacterial strains. For this purpose, aliquots of 
overnight cultures were mixed 1:1 (v/v) with sterile glycerol and stored in cryovials at 
−70°C. For recovery from glycerol stocks, bacterial strains were streaked out onto 
appropriate agar plates. S. aureus Newman was cultivated on blood agar plates, 
which were incubated at 37°C for 24 to 48 h. E. coli strains were streaked onto 
lysogeny broth (LB) agar plates and grown overnight at 37°C. Transformed E. coli 
DH5α strains used for long-term storage of recombinant plasmids were cultivated on 
LB agar containing 25 µg/ml kanamycin. The agar plates with the recovered bacterial 
strains were stored at 4°C for up to three weeks. 
Prolonged storage of transformed E. coli expression strains, at 4°C as well as at 
−70°C, may lead to plasmid instability and/or plasmid loss, resulting in drastically 
reduced recombinant protein productivity. Therefore, the E. coli strains BL21 (DE3) 
and C43 (DE3), utilized as expression hosts in this study, were transformed with the 
appropriate plasmids immediately before use. The transformed cells were streaked 
onto LB agar plates containing 25 µg/ml kanamycin and grown overnight at 37°C. 
These working cultures were stored at 4°C for two weeks maximum. 
If not indicated otherwise, liquid cultures were grown aerobically at 37°C in a shaking 
water bath (model 1083; Gesellschaft für Labortechnik, Burgwedel, Germany), using 
a 1% (v/v) inoculum from an overnight starter culture. S. aureus Newman was 
cultivated in tryptic soy broth. E. coli strains were grown in LB or in double-strength 
yeast extract-tryptone (2YT) broth (Becton Dickinson); the media were supplemented 
with 25 µg/ml kanamycin, if appropriate. 
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2.3 Methods in molecular genetics 
2.3.1 Isolation of genomic DNA from S. aureus 
For preparation of genomic DNA, 4 ml of a S. aureus Newman overnight culture were 
harvested by centrifugation (13,000 rpm, 2 min, RT; MiniSpin® microcentrifuge, rotor 
F-45-12-11; Eppendorf, Hamburg, Germany), and cells were resuspended in 180 µl 
ATL buffer (from DNeasy® blood & tissue kit; Qiagen). The suspension was 
supplemented with lysozyme (100 mg/ml) and lysostaphin (5 mg/ml), and incubated 
at 37°C for 1 h to enable cell wall degradation and complete lysis of the 
staphylococcal cells. Subsequently, extraction of genomic DNA from the lysate was 
carried out using the DNeasy® blood & tissue kit as described in the manufacturer’s 
instructions. Genomic DNA was eluted from the spin columns with 2 x 100 µl aqua ad 
iniectabilia (aqua a.i.) and stored at −20°C until further use. The concentration of the 
purified genomic DNA was determined photometrically by measuring the absorbance 
at 260 nm in a UV/VIS spectrophotometer (NanoPhotometer®; Implen, München, 
Germany); purity was assessed by the ratio of absorbance at 260 nm and 280 nm. 
Quality and quantity of the genomic DNA were also analyzed by agarose gel 
electrophoresis. 
2.3.2 Preparation of plasmid DNA 
Bacterial overnight cultures were prepared by picking a single E. coli colony from an 
LB agar plate and inoculating 16 ml of LB, to which 25 µg/ml kanamycin were added 
for selection. The next day, cells were harvested by centrifugation (13,000 rpm, 
2 min, RT; MiniSpin® microcentrifuge, rotor F-45-12-11; Eppendorf, Hamburg, 
Germany), and plasmid DNA was isolated from the cells using the QIAprep® spin 
miniprep kit (Qiagen) according to the manufacturer’s instructions. Plasmid DNA was 
eluted from the spin columns with 50 µl aqua a.i. and stored at −20°C until further 
use. Quality and quantity of the purified plasmid DNA were analyzed by agarose gel 
electrophoresis and by measurement of absorbance (see 2.3.1). 
2.3.3 Polymerase Chain Reaction (PCR)  
PCR amplification of DNA fragments was performed on the iCycler™ thermal cycler 
(Bio-Rad Laboratories, München, Germany), using Phusion® High-Fidelity DNA 
polymerase (New England Biolabs) following the manufacturer’s instructions, and 
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according to standard PCR procedures.241 Oligonucleotide primers (TABLE 5) were 
obtained from Eurofins MWG Operon; dNTPs were purchased from New England 
Biolabs.  
Amplification of pglF was performed using genomic DNA from a clinical isolate of 
C. jejuni as template. For this purpose, several colonies were picked from a blood 
agar plate and resuspended in aqua a.i. The cells were lysed by heating (10 min, 
100°C), and cell debris was removed by centrifugation (13,000 rpm, 5 min, RT; 
MiniSpin® microcentrifuge, rotor F-45-12-11; Eppendorf, Hamburg, Germany). The 
genomic DNA in the supernatant was used as PCR template without further 
purification. Purified genomic DNA from S. aureus Newman (see 2.3.1) was utilized 
as template for the amplification of capDtr. 
Size and purity of PCR amplificates were controlled by agarose gel electrophoresis. 
To enable restriction enzyme digestion, DNA fragments were purified from PCR 
mixtures using the MinElute® PCR purification kit (Qiagen) according to the 
manufacturer’s instructions. PCR products were eluted from the silica columns with 
20 µl aqua a.i. and stored at −20°C. Quality and quantity of the purified PCR 
amplificates were determined by absorbance measurements (see 2.3.1).  
2.3.4 Agarose gel electrophoresis  
DNA fragments were analyzed by standard agarose gel electrophoresis,241 on a 
horizontal electrophoresis apparatus (Renner Laborbedarf, Dannstadt, Germany). 
TopVision™ agarose (Fermentas™) and TAE buffer (Tris-acetate EDTA buffer; 
40 mM Tris, 20 mM glacial acetic acid, 1 mM EDTA, pH 8) were used to prepare 
1% (w/v) agarose gels, which were supplemented with 0.5 µg/ml ethidium bromide to 
enable detection of DNA fragments. DNA-containing samples were mixed with 
10% (v/v) loading dye (25% (w/v) saccharose, 0.1% (w/v) SDS, 0.05% (w/v) 
bromophenol blue, 5 mM sodium acetate) before they were applied onto the agarose 
gel. The GeneRuler™ 1 kb DNA ladder (Fermentas™) was utilized as length 
standard. The electrophoresis was performed in TAE buffer, at constant 100 V, for 
30 min to 3 h. DNA fragment patterns were visualized under UV light and 
documented using the Molecular Imager® Gel Doc™ XR+ system (Bio-Rad 
Laboratories, München, Germany).  
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2.3.5 Cleavage of DNA by restriction endonucleases 
Type II restriction endonucleases were purchased from New England Biolabs; 
restriction of purified plasmid DNA and PCR fragments was performed according to 
the manufacturer’s instructions. PCR fragments were purified from restriction 
digestion mixtures using the MinElute® PCR purification kit; linearized plasmids were 
isolated by agarose gel electrophoresis, and purified from agarose gel slices using 
the QIAquick® gel extraction kit (both kits were obtained from Qiagen). Restricted 
DNA fragments were eluted from the silica columns with 20 µl aqua a.i. and stored at 
−20°C until further use. Quality and quantity of restricted DNA fragments were 
analyzed by absorbance measurements (see 2.3.1). 
2.3.6 Ligation of DNA fragments 
T4 DNA ligase obtained from Roche was utilized to enable molecular cloning. 
Ligation reactions were performed following the manufacturer’s instructions and 
according to standard cloning procedures.241 The mixture with the ligation products 
was either directly utilized for transformation of chemocompetent E. coli cells, or 
stored at −20°C until further use. 
2.3.7 Preparation of CaCl2-competent E. coli cells 
For preparation of chemocompetent cells, E. coli strains were grown in 500 ml LB at 
37°C. At an OD600 of 0.5, cultures were harvested by centrifugation (7,000 rpm, 
12 min, 4°C; Sorvall® Evolution™ RC centrifuge, rotor SLC-6000; Thermo Fisher 
Scientific, Schwerte, Germany). Subsequently, the cells were resuspended in 10 ml 
ice-cold 0.1 M CaCl2, incubated on ice for 20 min, and again harvested by 
centrifugation (see above). The cell pellet was resuspended in 2 ml ice-cold 0.1 M 
CaCl2 supplemented with 15% (v/v) glycerol, and the suspension was incubated on 
ice for 1 h. Afterwards, aliquots of 50 µl were prepared, which were stored at −70°C 
until further use. 
2.3.8 Transformation of CaCl2-competent E. coli cells 
50-µl aliquots of chemocompetent E. coli cells were thawn on ice and mixed either 
with 3 µl plasmid DNA, or with up to 20 µl ligation mixture. After 30 min on ice, the 
cells were heat-shocked for 90 s at 42°C, and incubated on ice again for about 3 min. 
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The cells were pipetted into 1 ml pre-warmed LB, and recovered at 37°C for 1 h in a 
shaking water bath to enable expression of the resistance marker. Finally, aliquots of 
the suspension were streaked onto LB agar plates containing 25 µg/ml kanamycin, 
which were incubated at 37°C until the next day. 
2.4 Protein and biochemical methods 
2.4.1 Overexpression and purification of hexahistidine fusion proteins 
E. coli strain BL21 (DE3) was used as host for recombinant expression of 
cytoplasmic enzymes (CapB2-His6, CapE-His6, PglF-His6) and of an integral 
membrane protein (CapA1-His6) involved in capsule biosynthesis. Furthermore, 
E. coli BL21 was utilized for the expression of a soluble CapD mutant protein 
(CapDtr-His6). Cells were grown at 37°C in 2 l LB (or 0.5 l LB for overexpression of 
PglF-His6) containing 25 µg/ml kanamycin. At an OD600 of 0.6, IPTG was added to 
induce expression of the recombinant protein, either at a concentration of 0.5 mM (for 
overexpression of CapE-His6 and PglF-His6) or at 1 mM (for CapA-His6, CapB-His6 
and CapDtr-His6). Expression times and temperatures were optimized for the 
individual constructs. Cultures for overexpression of PglF-His6 and CapE-His6 were 
induced at 37°C for 4 h; overexpression of CapA1-His6, CapB2-His6 and CapDtr-His6 
was performed at 30°C for 4 h. After induction, cells were harvested (8,000 rpm,
10 min, 4°C; Sorvall® Evolution™ RC centrifuge, rotor SLC-6000; Thermo Fisher 
Scientific, Schwerte, Germany) and resuspended in lysis buffer (50 mM NaPi, 
300 mM NaCl, pH 7.5), which was supplemented with 1% (v/v) Triton X-100 (Sigma-
Aldrich) for purification of the integral membrane protein CapA1-His6. Lysozyme
(250 µg/ml), deoxyribonuclease I (50 µg/ml) and ribonuclease A (10 µg/ml) were 
added. The suspension was incubated on ice for 30 min and sonicated (50 W, 
30 kHz, 10 x 20 s, with cooling periods of 1 min between each burst of sonication; 
Sonifier UP50H; Hielscher Ultrasonics, Teltow, Germany). Cell debris was removed 
by centrifugation (14,000 rpm, 30 min, 4°C; Sigma 2K15 centrifuge, rotor 12148;
B. Braun, Melsungen, Germany). The supernatant was incubated with 1 ml Ni-NTA-
agarose slurry (50% (w/v); Qiagen) for 2 h at 4°C under gentle stirring. The mixture 
was then loaded onto a column support (5 ml polypropylene cartridge; Qiagen, 
Hilden, Germany). After washing with lysis buffer, weakly bound material was 
removed with 10 and 20 mM imidazole. His6-tagged recombinant proteins were 
eluted with lysis buffer containing 300 mM imidazole. Three fractions were collected 
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each, and stored in 30% (v/v) glycerol at −20°C. Preparations of CapE-His6 and 
PglF-His6 were dialysed against 10 mM KPi, pH 7.5 before storage (see 2.4.4). Purity 
of elution fractions was controlled by SDS-PAGE; protein concentration was 
measured by Bradford’s method.242  
Recombinant proteins CapD-His6 and CapN-His6 were expressed in host strain 
E. coli C43 (DE3). Cells transformed with the respective plasmids were grown at 
30°C in 2 l 2YT broth (Becton Dickinson) supplemented with 25 µg/ml kanamycin. At 
an OD600 of 0.6, inducer IPTG was added at a concentration of 0.5 mM. Cultures 
were incubated at 25°C for 18 h to allow expression of the recombinant proteins. The 
membrane-associated protein CapN-His6 was purified as described above, using 
lysis buffer supplemented with 1% (v/v) Triton X-100. Preparations of CapN-His6 
were supplemented with 50% (v/v) glycerol (final concentration) and stored at −20°C 
until use. A different protocol was applied to facilitate purification of CapD-His6, an 
enzyme comprising four membrane-spanning domains. Cells containing recombinant 
CapD-His6 were harvested (8,000 rpm, 10 min, 4°C; Sorvall
® Evolution™ RC 
centrifuge, rotor SLC-6000) and resuspended in lysis buffer (50 mM NaPi, 300 mM 
NaCl, 20% (v/v) glycerol, pH 7.5). The suspension was sonicated on ice (see above) 
and centrifuged (13,000 rpm, 30 min, 4°C; Sorvall® Evolution™ RC centrifuge, rotor 
SS-34). The pellet was resuspended in lysis buffer supplemented with 49 mM 
n-dodecyl β-D-maltoside (DDM; Glycon Biochemicals). For solubilization of 
membrane-embedded proteins, the mixture was incubated on ice for 30 min with 
gentle shaking. Insoluble components were removed by centrifugation (14,000 rpm, 
30 min, 4°C; Sigma 2K15 centrifuge, rotor 12148), and the cleared supernatant was 
mixed with 1 ml Talon® metal affinity resin (50% (w/v) slurry; Clontech Laboratories). 
The suspension was incubated for 1 h at 4°C under gentle stirring, before it was filled 
into a support cartridge (see above). The resulting column was washed with lysis 
buffer containing 1 mM DDM. A second wash was performed with lysis buffer 
containing 1 mM DDM and 15 mM imidazole. To elute recombinant proteins, lysis 
buffer supplemented with 1 mM DDM and 200 mM imidazole was applied to the 
column. Three fractions were collected, and analyzed regarding purity and protein 
content as described above. CapD-His6 turned out to be inactivated by freezing, even 
in the presence of high glycerol concentrations. For this reason, recombinant 
CapD-His6 was prepared freshly for all assays. 
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2.4.2 Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein-containing elution fractions were analyzed by discontinuous SDS 
polyacrylamide gel electrophoresis using pre-cast NuPAGE® Novex® 4–12% Bis-Tris 
mini gels (Invitrogen™). In contrast to the widely used gel system according to 
Laemmli, the NuPAGE® Bis-Tris system operates at a neutral pH value enabling 
stability of proteins and gel matrix during electrophoresis, and better band 
resolution.243,244 Sample preparation for SDS-PAGE analysis was performed 
according to the manufacturer’s instructions, with the exception that samples 
containing membrane proteins were heated to 55°C for 3 min after addition of LDS 
sample buffer. If indicated, NuPAGE® reducing agent was omitted from the samples. 
PageRuler™ Plus prestained protein ladder (Fermentas™) was employed as 
molecular weight standard; NuPAGE® MOPS SDS running buffer was used as 
running buffer. The electrophoresis was carried out at constant 200 V for 50 min in 
an XCell SureLock® electrophoresis cell (Invitrogen™ by Life Technologies, 
Darmstadt, Germany). Subsequently, gels were washed with distilled water, stained 
to the desired intensity with PageBlue™ protein staining solution (Fermentas™), and 
again incubated in distilled water, until the background was completely destained. 
The Molecular Imager® Gel Doc™ XR+ imaging system (Bio-Rad Laboratories, 
München, Germany) was used for documentation. 
2.4.3 Determination of protein concentrations according to Bradford 
Sample protein concentrations were determined by Bradford’s method using the Bio-
Rad protein assay dye reagent following the manufacturer’s protocol for microplate 
assays242. In brief, 10-µl aliquots of protein samples were pipetted into the wells of a 
flat-bottom polypropylene microplate (Anicrin; Distributor: VWR International, 
Langenfeld, Germany) and mixed with 200 µl appropriately diluted Bradford reagent. 
After 10 min of incubation at room temperature, the absorption at a wavelength of 
595 nm was measured in a microplate reader (Infinite® M200 NanoQuant equipped 
with Magellan™ 6 software; Tecan, Crailsheim, Germany). All samples were 
analyzed in duplicates. A bovine serum albumin standard curve (0–500 µg/ml) was 
prepared analogously. 
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2.4.4 In vitro synthesis of soluble capsule precursors  
For functional reconstitution, capsule biosynthetic enzymes were expressed as 
hexahistidine fusion proteins and purified via Ni-NTA affinity chromatography.245 
Preparations of CapE-His6 and PglF-His6 were dialysed against 10 mM KPi, pH 7.5, 
using Zeba™ desalt spin columns (5 ml, 7 kDa molecular weight cut-off; Pierce™) 
according to the manufacturer’s instructions. Dialysates were supplemented with 
30% (v/v) glycerol and stored at −20°C until further use. Elution fractions containing 
CapD-His6 and CapN-His6 were used for enzyme assays without prior buffer 
exchange. CapN-His6 was stored in 50% (v/v) glycerol at −20°C; CapD-His6 was 
prepared freshly for all assays. 
Syntheses of soluble capsule precursors UDP-2-acetamido-2,6-dideoxy-D-xylo-4-
hexulose (UDP-Sugp) and UDP-2-acetamido-2,6-dideoxy-L-arabino-4-hexulose, 
catalyzed by CapD and CapE, respectively, were carried out in a total volume of 
50 µl, containing UDP-D-GlcNAc (concentrations of UDP-D-GlcNAc varied according 
to assay type) in 10 mM KPi, 10 mM MgCl2, pH 7.5. CapD assays additionally 
contained 0.8% (v/v) Triton X-100 and, if not stated otherwise, 2 mM NADP+ as 
cofactor. Reactions were initiated by the addition of 3 µg CapD-His6, or of 8.5 µg 
CapE-His6, and incubated at 30°C for 30 min to 12 h.  
The synthesis of the precursor UDP-Sugp was also performed with a recombinant 
truncated version of the enzyme PglF from C. jejuni, as described by Schoenhofen et 
al.237 In brief, 5 µg PglF-His6 and 3 mM UDP-GlcNAc were incubated in 50 µl 10 mM 
KPi, pH 7.5 at 30°C for 16 h.  
The PglF-His6 enzymatic product was used as substrate for reconstitution of CapN 
catalytic activity. For this purpose, PglF reactions were carried out overnight and 
quenched by heating (5 min, 90°C). CapN-catalyzed synthesis of UDP-D-FucNAc 
was carried out in a total volume of 40 µl. CapN-His6 (12 µg) was incubated in the 
presence of ~3 mM UDP-Sugp, 0.8% (v/v) Triton X-100 and 10 mM KPi, pH 7.5, for 
2 h at 30°C. Alternatively, synthesis of UDP-D-FucNAc was performed in a one-pot-
assay containing 3.5 µg PglF, 12 µg CapN, 3 mM UDP-D-GlcNAc, 0.8% (v/v) Triton 
X-100 and 10 mM KPi, in a total volume of 60 µl. Cofactors NADH or NADPH were 
added at a concentration of 1.875 mM, if indicated.  
All enzymatic reactions were quenched by heating (5 min, 90°C) to enable reliable 
quantifications. For capillary electrophoresis (CE) analysis, samples were prepared 
as described above. Synthesis of larger quantities of soluble capsule precursors for 
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mass spectrometric analysis was achieved by a 10-fold upscale of the synthesis 
reaction.  
2.4.5 Determination of kinetic parameters for CapD and CapE 
To determine the linear range of the enzymatic reactions, formation of CapD and 
CapE enzymatic products was monitored over time (six time points, 10 min to 6 h) at 
30°C with a substrate (UDP-D-GlcNAc) concentration of 1 mM. For determination of 
the kinetic parameters Km (Michaelis-Menten constant) and Vmax (maximum 
velocity),246 eight different substrate concentrations were chosen. For CapD assays, 
the cofactor NADP+ was added at a concentration of 2 mM. Each analysis was 
repeated three times in independent experiments.  
2.4.6 Investigation of CapD and CapE inhibitors 
A library of selected compounds (73 compounds for CapD; 46 compounds for CapE; 
SUPPLEMENTARY TABLE 1) was initially screened at high concentrations of 
100 µM (for highly water-soluble compounds), or at 10 µM. Subsequently, full 
concentration–inhibition curves were determined for the most potent inhibitors, and 
IC50 values (concentration required for 50% inhibition in vitro) were calculated. The 
substrate (UDP-D-GlcNAc) concentration for CapD and CapE inhibition testing was  
1 mM, and substrate conversion was strictly controlled to be below 10%. For CapD 
assays, the cofactor NADP+ was added at a concentration of 600 µM. The IC50 
values of inhibitors were obtained by testing a suitable range of inhibitor 
concentrations (eight data points spanning three orders of magnitude). The 
incubation time was chosen to be within the linear range (steady-state phase; 30 min 
to 1 h). Negative control reactions were performed in the presence of heat-
inactivated (10 min, 100°C) enzymes. For further details, see below, in the CE 
quantification section. Each analysis was repeated three times in independent 
experiments. For the determination of the inhibition mechanism, eight different 
substrate concentrations and three different inhibitor concentrations were used, and 
each analysis was carried out with duplicate measurements. 
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2.4.7 Capillary electrophoresis analysis of soluble capsule precursors 
Capillary electrophoresis (CE) analyses described in this thesis were performed on a 
P/ACE™ MDQ capillary electrophoresis apparatus (Beckman Coulter, Krefeld, 
Germany) equipped with a diode array detector. The electrophoretic separations 
were carried out using uncoated fused-silica capillaries of 60 cm total length (50 cm 
effective length) × 75.5 µm (inner diameter) × 363.7 µm (outer diameter) obtained 
from Polymicro Technologies (Kehl, Germany). Data collection and corrected peak 
area analysis were performed with 32 Karat™ software (Beckman Coulter). Further 
data analysis was carried out using the software GraphPad Prism 4 (GraphPad 
Software Inc., La Jolla, United States). The capillary temperature was kept constant 
at 15°C. The following conditions were applied: λmax 260 nm, separation voltage 
−15 kV, running buffer 68 mM CAPS, 0.002% polybrene, pH 12.4 (adjusted with 
NaOH), electrokinetic injection (−1 kV, 20 s). The capillary was washed with 0.2 M 
NaOH for 2 min (20 psi) and with running buffer for 3 min (20 psi) before each 
injection. Analytical samples were diluted 1:40 in autoclaved ultrapure water to give a 
volume of 50 µl, and 50 µl of 3′-phosphoadenosine 5′-phosphate (PAP) dissolved in 
sterile ultrapure water were added as an internal standard (final concentration 
6.45 µM). An aliquot of the test mixture (90 µl) was pipetted into the sample vial and 
subsequently measured by CE.  
CE analysis of CapN enzymatic reactions was performed as described by Kneidinger 
et al.207  
2.4.8 CE-based quantification of CapD and CapE reaction products 
The CapD and CapE reaction products are UDP-Sugp and UDP-2-acetamido-2,6-
dideoxy-L-arabino-4-hexulose, respectively. Since both compounds are not 
commercially available, CE calibration was performed with enzymatic products.  
Recombinant CapE and PglF are both capable of catalyzing 100% conversion of the 
substrate UDP-D-GlcNAc. However, the final product concentrations in the reaction 
mixtures are lower than the initial substrate concentrations, due to simultaneous 
hydrolysis of substrate and products yielding UDP. To determine the actual product 
concentration in the samples, we quantified the degradation product UDP, 
substracted the respective values from the initial substrate amount and considered 
the difference to represent the amount of UDP-Sugp and UDP-2-acetamido-2,6-
dideoxy-L-arabino-4-hexulose, respectively. 
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The amount of UDP was determined as follows: UDP was diluted with water to 
different concentrations; then 50-µl aliquots of the different UDP dilutions were mixed 
with 50 µl of the internal standard PAP (final concentration 3.125 µM), which was 
prepared in biological matrix (PglF reaction mixture diluted 1:40 (v/v) with water). 
Since UDP is also formed during in vitro PglF assays, UDP calibration was 
performed using biological matrix as a blank value. 
 
TABLE 8 
Quantification of CapD and CapE reaction products: method validation 
Parameters CapD product UDP-2-acetamido-
2,6-dideoxy-α-D-xylo-hexulose 
CapE product UDP-2-acetamido-
2,6-dideoxy-β-L-arabino-hexulose 
Regression equation
a
  y = 7.533x − 0.35 y = 7.873x − 0.767 
R
2
 0.9927 0.9801 
LOD (µM) 0.71 0.81 
LOQ (µM) 2.15 2.45 
Calibration range (µM) 0.22–7.09 0.33–5.34 
 
 Concentration 
(µM) 
Accuracy  
(% recovery)
a
 
Accuracy 
acceptable range
b
 
Precision 
(RSD %)
a
 
Precision 
acceptable range
b
 
CapD product 0.44 100.9 80–120% 14.4 20% 
0.89 100.4 80–120% 2.3 20% 
3.55 101.0 80–120% 5.4 20% 
7.09 99.9 80–120% 7.0 20% 
CapE product 0.67 100.9 80–120% 4.4 20% 
1.34 93.6 80–120% 7.0 20% 
2.67 101.5 80–120% 11 20% 
5.35 99.9 80–120% 11 20% 
Note. Performed by Wenjin Li (Pharmaceutical Chemistry I, University of Bonn), according to ICH and 
FDA guidelines.
247,248
 LOD, limit of detection; LOQ, limit of quantification; R
2
, coefficient of 
determination; RSD, relative standard deviation. 
a
triplicate samples with duplicate measurements 
b
according to ICH guidelines 
The CE-based detection method for monitoring of UDP-D-GlcNAc 4,6-dehydratase 
activity was validated according to the guidelines published by the International 
Conference on Harmonisation (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, and by the US Food and Drug Administration 
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(FDA), demonstrating its suitability for the analysis of enzyme kinetics and for 
inhibitor testing.247,248 A summary of the parameters of method validation is provided 
in TABLE 8. 
The linearity of the quantitative determination and the limits of detection and 
quantification of the enzymatic products UDP-Sugp and UDP-2-acetamido-2,6-
dideoxy-L-arabino-4-hexulose were determined by processing six-point calibration 
curves (triplicate samples with duplicate measurements) in the presence of 3.125 µM 
PAP as internal standard. The precision and accuracy values were determined at the 
following concentrations: 0.44, 0.89, 3.55 and 7.09 µM for UDP-Sugp; 0.67, 1.34, 
2.67 and 5.35 µM for UDP-2-acetamido-2,6-dideoxy-L-arabino-4-hexulose (triplicate 
samples with duplicate measurements; 3.125 µM PAP as internal standard). 
Accuracy was determined by calculating the ratios of the predicted concentrations 
and the spiked values, and relative standard deviations were calculated. 
2.4.9 MALDI-TOF mass spectrometric analysis of soluble capsule precursors 
Synthesis of larger quantities of soluble capsule precursors for mass spectrometric 
analysis was achieved by a 10-fold upscale of the synthesis reaction. Reaction 
mixtures were quenched by acidification to pH ~2.5 (addition of 3–5 µl 20% (v/v) 
H3PO4). Precipitated material was removed by centrifugation (13,000 rpm, 10 min, 
RT; MiniSpin® microcentrifuge, rotor F-45-12-11; Eppendorf, Hamburg, Germany). 
UDP-coupled monosaccharides were purified from salts, detergents and cofactors by 
ion-pair reversed-phase high pressure liquid chromatography using a Gilson HPLC 
system equipped with Trilution LC software (Gilson, Limburg an der Lahn, Germany). 
Sample separation was performed under isocratic conditions (20 mM 
triethylammonium acetate, pH 7, 1 ml/min) on a Hypersil™ octadecyl silane (C18) 
column (particle size 5 µm, 250 mm x 4.6 mm; Schambeck SFD, Bad Honnef, 
Germany), with detection set at 260 nm. Fractions containing UDP-D-GlcNAc and its 
derivatives were lyophilized to dryness (Beta freeze dryer; Martin Christ 
Gefriertrocknungsanlagen, Osterode am Harz, Germany), resuspended in 
methanol–chloroform (1:1, v/v) and subjected to matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).  
MALDI-TOF MS analyses were performed as follows: Samples were spotted onto a 
ground steel MALDI-TOF target plate and allowed to dry at room temperature. 
Subsequently, each sample was overlaid with 1 µl of matrix (saturated solution of 
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6-aza-2-thiothymine in 50% (v/v) ethanol, 20 mM diammonium hydrogen citrate) and 
air dried at again. Spectra were recorded in the reflector negative mode at a laser 
frequency of 9 Hz within a mass range from 300 to 3000 Da on a Biflex™ III mass 
spectrometer (Bruker Daltonik, Bremen, Germany). Data analysis was performed 
using flexAnalysis™ software (Bruker Daltonik). 
2.4.10 In vitro kinase assays 
In vitro phosphorylation of different purified proteins (compare reference 161) was 
carried out at 30°C in a total volume of 15 µl containing 2 µg of the recombinant 
target protein, 0,5 µg of CapA1-His6 and CapB2-His6, 1 mM DTT, 1 mM EDTA, and 
4 μCi [γ-33P]-ATP (~300 nM; Hartmann Analytic) in 25 mM Tris-HCl, 10 mM MgCl2, 
pH 7.0. After 30 min of incubation, reactions were stopped by addition of NuPAGE® 
LDS sample buffer and analyzed by SDS-PAGE (see 2.4.2). SDS-PAGE separation 
of phosphorylated proteins was performed using electrophoresis buffer without 
NuPAGE® reducing agent. Radioactive protein bands were visualized using a storage 
phosphor screen in a Storm imaging system (GE Healthcare, München, Germany). 
2.4.11 Identification of phosphorylation sites by nanoLC-MS/MS 
Nanoscale liquid chromatography coupled to tandem mass spectrometry (nanoLC-
MS/MS) was utilized to identify phosphorylation sites on capsule biosynthetic 
enzymes. For this purpose, recombinant His6-tagged proteins were phosphorylated in 
vitro and separated by SDS-PAGE as described above, with omission of radiolabeled 
ATP from the reaction mixture.  
NanoLC-MS/MS and data analysis were performed as follows: For peptide 
preparation, protein bands were excised from the Coomassie-stained polyacrylamide 
gels and subjected to tryptic in gel digestion.249,250 In brief, proteins were reduced 
with 20 mM DTT, slices were washed with 50 mM ammonium bicarbonate, and 
proteins were alkylated with 40 mM iodoacetamide. The slices were washed again 
and dehydrated with acetonitrile. Slices were dried in a vacuum concentrator and 
incubated with 400 ng sequencing grade trypsin (Sigma-Aldrich) at 37°C overnight. 
The peptide extract was dried in a vacuum concentrator and stored at −20°C. Dried 
peptides were dissolved in 10 µl 0.1% (v/v) formic acid (solvent A) and aliquots (1 µl) 
were injected onto a C18 trap column (20 mm x 100 µm; NanoSeparations, 
Nieuwkoop, Netherlands). Bound peptides were eluted onto a C18 analytical column 
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(200 mm x 75 µm; NanoSeparations). Peptides were separated in a linear gradient 
from 0% to 55% solvent B (80% (v/v) acetonitrile, 0.1% (v/v) formic acid) within 
40 min at a flow rate of 400 nl/min. The nanoHPLC was coupled online to an LTQ 
Orbitrap Velos™ mass spectrometer (Thermo Fisher Scientific, Schwerte, Germany). 
Peptide ions between 395 and 1800 m/z were scanned in the orbitrap detector with a 
resolution of 30,000 (maximum fill time 400 ms, automatic gain control target at 106). 
The 25 most intense precursor ions (threshold intensity 5000) were subjected to 
collision-induced dissociation, and fragments were analyzed in the linear ion trap. 
Fragmented peptide ions were excluded from repeat analysis for 15 s. 
Raw data processing and analysis of database searches were performed with 
Proteome Discoverer software version 1.40.288 (Thermo Fisher Scientific, Schwerte, 
Germany). Peptide identification was done with an in-house Mascot server version 
2.3 (Matrix Science, London, United Kingdom). MS2 data was searched against 
Staphylococcus aureus strain N315 NCBInr (release 20130323) and E. coli 
sequences from SWISS-PROT (release 2013_03). Precursor ion m/z tolerance was 
8 ppm, fragment ion tolerance was 0.6 Da, b- and y-ion series were included. 
Semitryptic peptides with up to one missed cleavage were searched. The following 
dynamic modifications were set: Alkylation of Cys by iodoacetamide or acrylamide, 
phosphorylation (Tyr), and oxidation (Met). The PhosphoRS3.0 node was used for 
scoring of the phosphosite assignment.251 Mascot results from searches against 
SWISS-PROT were sent to the percolator algorithm version 2.04 as implemented in 
Proteome Discoverer 1.4.252  
2.4.12 In vitro modulation of CapD and CapE catalytic activity by the CapA1B2 
kinase complex 
The influence of CapAB-mediated tyrosine phosphorylation on CapD and CapE 
catalytic activity was examined in vitro using purified recombinant proteins. Assays 
were performed in a total volume of 100 µl containing the respective target protein 
(17 µg CapE-His6 or 3 µg CapD-His6) and 8.5 µg of purified CapA1-His6 and CapB2-
His6. CapAB-mediated modulation of CapE catalytic activity was tested in the 
presence of 3 mM UDP-D-GlcNAc and 1 mM ATP in 10 mM KPi, 10 mM MgCl2, pH 
7.5 supplemented with 1 mM DTT. Assays for investigation of in vitro modulation of 
CapD enzymatic activity additionally contained 0.8% (v/v) Triton X-100 and 2 mM 
NADP+. Samples were incubated for 10 min to 16 h at 30°C. Reactions were 
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quenched by heating (5 min, 90°C), then subjected to CE analysis. Control reactions 
were performed with heat-inactivated (10 min, 100°C) proteins CapA-His6 and 
CapB-His6. 
2.5 In silico methods  
2.5.1 Similarity searches and sequence analysis  
Protein and gene sequences were retrieved from databases of the National Center 
for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov). Homology searches 
against SWISS-PROT and the NCBI non-redundant protein database were 
performed on the NCBI BLAST server253 (www.ncbi.nlm.nih.gov/blast) using BLASTp 
with a BLOSUM62 weight matrix254 and default parameters. Similarity searches with 
nucleotide sequences were performed using BLASTx (with default settings) against 
the NCBI non-redundant nucleotide database. The BLASTp algorithm as 
implemented in the BLAST-2-sequences option255 was employed to determine 
percent identity and percent similarity of protein sequences. Global pairwise 
sequence alignments were performed with the Needleman-Wunsch alignment tool256 
available at the NCBI BLAST server. If not stated otherwise, multiple sequence 
alignments were carried out using NCBI’s COBALT aligner257 (www.st-
va.ncbi.nlm.nih.gov/tools/cobalt/re_cobalt.cgi) with default settings. 
Amino acid sequences were analyzed with bioinformatics tools to predict 
transmembrane helices and potential phosphorylation sites: TMHMM 
(www.cbs.dtu.dk/services/TMHMM-2.0/), a hidden Markov model-based program,258 
was utilized to predict transmembrane helices; potential phosphorylation sites were 
predicted using the neural-network-based program NetPhos2.0259 (available at 
www.cbs.dtu.dk/services/NetPhos/).  
2.5.2 Identification of Sugp 4-keto reductases and phylogenetic tree 
reconstruction 
Potential orthologs for Staphylococus aureus CapN were retrieved from the 
OrtholugeDB database260 (www.pathogenomics.sfu.ca/ortholugedb/). Bacterial 
sequences with a length of 260–340 aa and a putative nucleotide-binding motif at the 
N-terminus were considered as potential orthologs. Furthermore, BLASTp searches 
(see 2.5.1) were performed against the NCBI non-redundant protein database using 
the amino acid sequences of the (proposed) Sugp 4-keto reductases CapN of 
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Staphylococcus aureus (GenBank accession number BAF66380.1), WbpK 
(AAC45865.1) and WbpV (AAF23991.1) of Pseudomonas aeruginosa, WreQ of 
Rhizobium etli (AAQ93037.1), and WbcT of Francisella tularensis (CAG46095.1) as 
query sequences. The query sequences, as well as selected BLASTp hits with 
E-values < 1e-25, identity ˃ 35%, and query length coverage ˃ 75%, were included in 
the analysis. After removal of duplicates, an initial data set of 402 sequences was 
obtained. Multiple sequence alignments were performed with ClustalW2261 using the 
Gonnet substitution matrix262 and default parameters (gap opening penalty, 10; gap 
extension penalty, 0.2; gap distance penalty, 5) at the European Bioinformatics 
Institute website (www.ebi.ac.uk). When identical or nearly identical sequences were 
detected, only a single representative sequence was selected and the other 
sequences were discarded (with a few exceptions). The sequences were re-aligned, 
and a distance-based tree was generated from the alignment using the neighbor-
joining option implemented in ClustalW2 (default settings; without exclusion of gaps). 
Based on the clustering results, a set of 184 sequences was chosen for further 
analysis (SUPPLEMENTARY TABLE 2). As revealed by homology searches, the 
data set did not only contain potential Sugp 4-keto reductases, but also proteins from 
dTDP-4-dehydrorhamnose reductase263,264 and C55PP-GlcNAc epimerase
265 protein 
families.  
For further differentiation, a phylogenetic analysis was performed on the Phylogeny.fr 
platform (http://phylogeny.lirmm.fr) as follows: Sequences were aligned with 
MUSCLE266 (version 3.7) configured for highest accuracy (default settings). The 
phylogenetic tree was reconstructed using the maximum likelihood method 
implemented in the PhyML program267 (version 3.0). The default substitution model 
was selected assuming an estimated proportion of invariant sites and 4 gamma-
distributed rate categories to account for rate heterogeneity across sites. The gamma 
shape parameter was estimated directly from the data. Reliability for internal 
branches was assessed by an approximate likelihood-ratio test (Shimodaira–
Hasegawa-like).267 TreeDyn268 (version 198.3) was utilized for tree visualization. In 
this phylogenetic reconstruction, the homologs from dTDP-4-dehydrorhamnose 
reductase and C55PP-GlcNAc epimerase protein families clustered according to their 
(proposed) functions with high statistical support (˃ 0.99). The sequences contained 
in the respective clades were excluded from the analysis, as well as the sequences 
of Nitrosococcus oceani, Methylomonas methanica, Aromateolum aromaticum and 
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Desulfomicrobium baculatum forming a separate clade apart from the alleged 
proteobacterial UDP-Sugp reductase sequences (see SUPPLEMENTARY TABLE 2).  
Since the proposed UDP-Sugp reductases CapN, WbjF, WbpK, WbpV and WreQ 
(see above) had been found to align well with the multi-domain models cd05232269 
(PSSMID 187543; “UDP-glucose 4 epimerase, subgroup 4”) and COG0451270 
(PSSMID 223528; “WcaG”), a batch CD-Search269 (online tool available at 
www.ncbi.nlm.nih.gov/Structure/bwrpsb/bwrpsb.cgi) against the NCBI conserved 
domain database (version 3.12) was performed with the remaining 132 sequences. 
For most of these protein sequences, cd05232 and COG0451 were the top-ranking 
domain models. However, three sequences of Rhizobiales (NCBI accession numbers 
YP_001627391.1, YP_002732468.1, YP_001371115.1) were assigned to domain 
model pfam01370271 (“epimerase”) instead. They were thus removed from the data 
set, together with six further sequences found in the same clade in the maximum 
likelihood tree, which also produced relatively low alignment scores with cd05232 
and COG0451 (compare SUPPLEMENTARY TABLE 2).  
Phylogenetic analysis was again performed with the reduced data set. Two archaeal 
sequences (potential CapN orthologs retrieved from OrtholugeDB; GenBank 
accession numbers ADG90620.1, AGT34472.1) were included as outgroup for tree 
rooting. Alignments were obtained with MUSCLE, as well as with ClustalW, and 
phylogenetic trees were constructed from both of the sequence alignments, using 
either PhyML (see above) or the neighbor-joining method implemented in BioNJ272 
(all analyses were performed at the Phylogeny.fr website). On the basis of these 
analyses, several “rogue sequences”273 were identified and removed, thus improving 
the overall support. A set of 119 proteins was chosen for reconstruction of the final 
maximum likelihood tree of the Sugp 4-keto reductase family. The phylogenetic 
reconstruction was performed using MUSCLE and PhyML as described above. The 
statistical significance of the phylogenetic tree obtained was assessed by bootstrap 
analysis274 with 100 replicates.  
2.5.3 Genomic context analysis of Sugp 4-keto reductases 
The genomic neighborhood of the 119 potential UDP-Sugp keto reductases identified 
in the phylogenetic analysis (see 2.5.2) was surveyed for genes encoding large 
membrane-bound UDP-GlcNAc 4,6-dehydratases and WbpL- or CapM-type 
glycosyltransferases. To facilitate the analysis, genomic context networks were 
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obtained by searching the STRING database275 (http://string-db.org) with the amino 
acid sequences of the proposed reductases CapN, WbpK, WbpV, WreQ, and WbcT 
(for accession numbers, see 2.5.2). Furthermore, gene annotation tables were 
retrieved from the NCBI gene and nucleotide databases, along with the respective 
gene product sequences. If no ortholog of capD and/or capM/wbpL was found in the 
neighborhood of a reductase gene, tBLASTn searches of the respective genome or 
nucleotide sequence were performed. The BLASTp algorithm as implemented in the 
BLAST-2-sequences option255 was employed to assess the similarity between gene 
product sequences and reference proteins (S. aureus Newman CapD and CapM, 
P. aeruginosa WbpL; GenBank accession numbers BAF66370.1, BAF66379.1, and 
AAF23990.1, respectively). Proteins fulfilling the following criteria were accepted as 
orthologs: CapD, 540–718 aa length, E-value ≤ 2e-104, ≥ 61% query coverage, 
domain model COG1086;270 CapM, 164–240 aa (the CapM homolog from 
Methylococcus capsulatus is 464 aa long; AAU90617.1), E-value ≤ 6e-32, 
≥ 59% query coverage; WbpL, 319–380 aa, E-value ≤ 1e-19, ≥ 75% query coverage, 
domain model cd06854.269  
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3 Results 
3.1 UDP-N-acetylglucosamine 4,6-dehydratases 
 
FIGURE 5. Proposed divergent pathways for the biosynthesis of 2-acetamido-2,6-dideoxy-hexoses 
from the common precursor substrate UDP-D-GlcNAc (chemical structures were retrieved from 
www.metacyc.org). Biochemical evidence for the last reaction step in UDP-D-FucNAc synthesis (red 
arrow) has been lacking so far. In the present study, functional reconstitution of the complete 
biosynthetic pathway was achieved for the first time using recombinant purified enzymes from 
Staphylococcus aureus serotype 5 (red frames). Names of enzymes that have not been characterized 
at the biochemical level are shaded grey. Biosynthetic enzymes are from the following species: 
Pseudomonas aeruginosa, WbjB/C/D/F & WbpK/M/V; S. aureus, CapD/E/F/G/N; Francisella 
tularensis, WbtA/C; Rhizobium etli, LpsB2 & WreQ; Vibrio cholerae, WbvB/D/R. D(L)-FucNAc, N-
acetyl-D(L)-fucosamine (2-acetamido-2,6-dideoxy-D(L)-galactose); D-GlcNAc, N-acetyl-D-glucosamine 
(2-acetamido-2-deoxy-D-glucose); L-PneNAc, N-acetyl-L-pneumosamine (2-acetamido-2,6-dideoxy-L-
talose); D(L)-QuiNAc, N-acetyl-D(L)-quinovosamine (2-acetamido-2,6-dideoxy-D(L)-glucose); L-
RhaNAc, N-acetyl-L-rhamnosamine (2-acetamido-2,6-dideoxy-L-mannose); Sugp, 2-acetamido-2,6-
dideoxy-D-xylo-4-hexulose.
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Various rare deoxysugars recognized as important functional components of 
bacterial cell surface glycans are synthesized from the activated sugar nucleotide 
precursor UDP-D-GlcNAc. Many of the respective biosynthetic pathways are initiated 
by the activity of UDP-GlcNAc 4,6-dehydratases.276,277 These enzymes are members 
of the extended SDR superfamily (see Introduction, section 1.7) and catalyze 4,6-
dehydratation of UDP-D-GlcNAc to form a 4-keto-6-deoxy intermediate (FIGURE 
5).278,279 
 
FIGURE 6. Topological model of CapD (A) showing transmembrane domains (black) as predicted with 
TMHMM 2.0. (B) Schematic representation of CapD and CapE showing six conserved motifs identified 
using MEME motif discovery software as described by Creuzenet et al.
280
 Motifs 1–6 of S. aureus 
Newman CapD (GenBank accession number BAF66370.1) encompass amino acids 289–308 (motif 
6), 367–416 (motif 1), 449–477 (motif 2), 478–519 (motif 3), 535–563 (motif 4), and 417–439 (motif 5). 
The NTMK active site residues are marked by stars.  
The S. aureus serotype 5 capsule biosynthetic enzymes CapD (GenBank accession 
number BAF66370.1) and CapE (BAF66371.1) belong to the extended SDR family 
and possess the typical TGXXGXXG nucleotide-binding signature.220 CapD and 
CapE are homologous to a wide range of enzymes involved in the production of 
surface-exposed polysaccharides in bacterial pathogens. Several of these enzymes 
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were demonstrated to function as UDP-GlcNAc 4,6-dehydratases, including FlaA1 
from Helicobacter pylori, PglF from C. jejuni, and WbpM from P. aeruginosa.237,280–282  
Many of the homologs of CapD and CapE are large membrane proteins (~600 aa) 
with four N-terminal transmembrane helices, and a cytoplasmic C-terminal half 
containing five to six conserved sequence motifs arranged in the same pattern. As 
revealed by prediction of transmembrane topology and multiple sequence 
alignments, this is also true for CapD (FIGURE 6).280 However, several much shorter 
homologs (~350 aa), including CapE, do only correspond to the soluble C-terminal 
half of CapD.280 Besides size and cellular localization, the two protein subfamilies 
seem to differ in function. All soluble enzymes that have been characterized 
biochemically are UDP-GlcNAc 5-inverting 4,6-dehydratases, whereas all 
transmembrane proteins investigated so far function as 5-retaining 4,6-dehydratases 
(i.e. the configuration at C5 remains unaltered during the enzymatic 
reaction).207,234,237,280–287 
3.2 Comparative genomic and phylogenetic analysis of Sugp 4-keto 
reductases 
The biosyntheses of the nucleotide-activated sugars UDP-N-acetyl-D-quinovosamine 
(UDP-D-QuiNAc) and UDP-N-acetyl-D-fucosamine (UDP-D-FucNAc) have been 
proposed to start from UDP-D-GlcNAc involving two steps (see FIGURE 5).276 The 
first step is the generation of the 4-keto-6-deoxy intermediate UDP-2-acetamido-2,6-
dideoxy-D-xylo-4-hexulose (UDP-Sugp) by 4,6-dehydratation of UDP-D-GlcNAc. In a 
second step, the 4-keto group of this intermediate can be reduced either to an axial 
or to an equatorial hydroxyl moiety by different stereospecific 4-keto reductases, 
generating UDP-D-QuiNAc or its C4-epimer UDP-D-FucNAc, respectively. Only 
recently, the synthesis of UDP-D-QuiNAc has been reconstituted in vitro using 
purified recombinant enzymes from P. aeruginosa and Rhizobium etli.288 In contrast, 
biochemical evidence confirming the proposed route for UDP-D-FucNAc biosynthesis 
is still lacking.  
The stereospecific 4-keto reductases which catalyze production of UDP-D-QuiNAc 
and UDP-D-FucNAc belong to the same protein family (compare reference 289). 
Members of this protein family are common among bacteria, but routinely 
misannotated as UDP-glucose 4-epimerases in the NCBI and SWISS-PROT 
databases. Starting from an in silico analysis of S. aureus CapN, an extensive survey 
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of the protein family was undertaken, to facilitate allocation of gene function in 
polysaccharide gene clusters. Correct annotation of such reductase genes may not 
only help to prevent confusion and misinterpretation, but also allow for prediction of 
structural features of bacterial polysaccharides. 
 
TABLE 9  
Sequence similarities of selected bacterial proteins to Staphylococcus aureus Newman CapN 
Bacterial strain Protein GenBank 
accession number 
Sequence similarity to CapN Reference 
Identity Overlap
a
 
Escherichia coli      
O157:H7 Gnu KFF50896.1 26% 267/331 
290
 
Francisella tularensis      
SCHU S4 WbtC CAG46095.1 37% 261/263 
291
 
Pseudomonas aeruginosa 
PAO1 (O5) WbpK AAC45865.1 26% 280/320 
287
 
IATS O6 WbpV AAF23991.1 28% 284/320 
287
 
PA103 (O11) WbjF AAB39483.1 33% 209/314 
292
 
Rhizobium etli      
CFN42 WreQ AAQ93037.1 27% 280/309 
288
 
Staphylococcus aureus  
Newman (serotype 5) CapF BAF66372.1 25% 146/369 
264
 
MW2 (serotype 8) Cap8N BAB94002.1 98% 295/295 
206
 
M (serotype 1) Cap1N AAL26668.1 42% 262/287 
293
 
Streptococcus iniae 
SF1 (serotype I) CpsG AGM98615.1 39% 259/286 
294
 
Vibrio cholerae      
O139 WbfT AAC46247.1 29% 285/328 
295
 
Note. Sequence similarities to CapN (GenBank accession number BAF66380.1) were determined 
using the NCBI BLAST-2-sequences option. 
a
length of overlap with CapN/total number of amino acids 
 
The S. aureus serotype 5 capsule biosynthetic enzyme CapN (GenBank accession 
number BAF66380.1) displays sequence patterns characteristic of the extended SDR 
family, such as a canonical NTYK active site tetrad, and a TGXXGXXG nucleotide-
binding signature found near the N-terminus of the protein.220 CapN was postulated 
to function as 4-keto reductase catalyzing the formation of UDP-D-FucNAc by 
stereospecific reduction of the proposed CapD reaction product UDP-Sugp.77 
Corroborating this assignment, genes encoding proteins with high sequence identity 
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to serotype 5 CapN were identified in the capsule loci of S. aureus serotype 1 and 8 
strains, which produce D-FucNAc-containing CPs (TABLE 9).204,206,293,296,297 
The BLASTp algorithm was used to search the NCBI non-redundant protein 
database for genes encoding CapN homologs. Astonishingly, most homologs 
identified in Firmicutes species (100 best hits), such as CpsG from Streptococcus 
iniae (see TABLE 9), have a G to S substitution in their nucleotide-binding motif 
(consensus sequence TGXXSYIG; see SUPPLEMENTARY FIGURE 1). None of 
these proteins have been characterized so far, but serological differences between 
S. iniae strains have been attributed to mutations in the cpsG gene, indicating that 
the gene product possesses enzymatic activity.294 The TGXXSYIG motif is also found 
in some homologous proteins from Gram-negative species, for example in WbtC 
from Francisella tularensis. As deduced from knockout mutant studies, WbtC likely 
catalyzes the reduction of the 4-keto group of UDP-Sugp to yield UDP-D-QuiNAc, 
suggesting that this protein is capable to bind NAD(P)H.291 Notably, a second 
sequence consistent with a cofactor-binding motif was detected in WbtC, as well as 
in many other CapN homologs (SUPPLEMENTARY FIGURE 1).  
Genetic evidence suggests, that the enzymes WbpK and WbjF, involved in O antigen 
biosynthesis in Pseudomonas aeruginosa O5 and O11 strains, respectively, mediate 
the same reaction as CapN.287,292,298 However, CapN shares only moderate identity 
(~30%) at the amino acid level with the two putative reductases (TABLE 9). Similar 
results were obtained upon comparison with the protein WreQ from R. etli, and with 
its homolog WbpV from P. aeruginosa, enzymes which convert UDP-Sugp to UDP-D-
QuiNAc (TABLE 9).287,288,292 Moreover, CapN shares only 25% sequence identity 
(over a length of ~150 aa) with the 4-keto reductase domain of S. aureus Newman 
CapF, which is not surprising, since the two enzymes are assumed to reduce 
stereochemically distinct substrates and exhibit different overall folds.77,207,264 A 
BLASTp search against the well-annotated SWISS-PROT database identified the 
putative UDP-glucose 4-epimerase WbfT from Vibrio cholerae O139 and the C55PP-
GlcNAc 4-epimerase Gnu from E. coli O157:H7 as closest homologs of CapN, but 
sequence identities were rather low (< 30%; see TABLE 9). Notably, Fallarino et al. 
suggested that WbfT had been falsely annotated.299 Significant similarities to CapN 
were also found with proteins from the dTDP-4-dehydrorhamnose reductase 
family.263  
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To estimate the evolutionary relationships among CapN homologs from different 
protein families, selected amino acid sequences were aligned with MUSCLE 3.7, and 
maximum likelihood trees were calculated from the alignments using PhyML 3.0 (see 
section 2.5). In this phylogenetic reconstruction, the homologs from dTDP-4-
dehydrorhamnose reductase263,264 and C55PP-GlcNAc epimerase
265 protein families 
clustered according to their (proposed) functions (data not shown). The sequences 
likely corresponding to Sugp 4-keto reductases formed a group together with proteins 
annotated as UDP-glucose 4-epimerases. However, there is hardly any experimental 
evidence supporting the assumption that proteins from this group might function as 
epimerases, and sequence similarities to biochemically characterized UDP-glucose 
epimerase proteins are fairly low (data not shown).  
The clustering results were confirmed using the NCBI conserved domain search tool 
as described in the “Materials and methods” section. Based on this analysis, a set of 
119 potential Sugp 4-keto reductase proteins was chosen for phylogenetic tree 
assembly. The majority of these proteins were from Proteobacteria (76 sequences) 
and Firmicutes (24 sequences). Furthermore, the data set included sequences from 
the phyla Bacteroidetes (8), Chlorobi (3), Fusobacteria (3), Actinobacteria (2), 
Cyanobacteria (1), Fibrobacteres (1) and Spirochaetes (1). The N[ST]YK active site 
tetrad was found to be strictly conserved among this set of proteins (a multiple 
sequence alignment is shown in SUPPLEMENTARY FIGURE 1). A phylogenetic tree 
calculated by the maximum likelihood method300 showed five major clades supported 
by bootstrap values ≥ 0.75 (i.e. these clades occured in at least 75 of 100 random 
bootstrap replicates), which were labeled I to V (FIGURE 7A). 
As seen in FIGURE 7, Clade I is composed exclusively of sequences of 
Bacteroidetes. The proteins found in Clade I have a size of 296–339 aa. Notably, 
Clade I comprises two putative 4-keto reductases from Bacteroides fragilis NCTC 
9343. This organism has the capacity to synthesize eight distinct capsular 
polysaccharides, designated polysaccharide A through polysaccharide H.301 The 
proteins identified in the phylogenetic analysis are encoded in the polysaccharide B 
and C biosynthetic loci, by genes named wcgW and wcfK, respectively.302,303 
Polysaccharide B is known to contain D-QuiNAc and, based on sequence 
homologies, polysaccharide C was proposed to contain D-QuiNAc as well.303,304 
However, experimental evidence for the functions of the wcgW and wcfK gene 
products is still lacking. This is also true for all other proteins included in Clade I.  
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FIGURE 7. Maximum likelihood tree of 119 potential Sugp 4-keto reductase proteins (A). Full-length 
amino acid sequences were aligned with MUSCLE 3.7, and phylogenies were calculated from the 
alignment using PhyML 3.0. The tree was rooted using two archaeal homologs of unknown function 
(GenBank ADG90620.1, AGT34472.1) as outgroup (not shown). Bootstrap values (100 replicates) are 
shown for nodes with ≥ 50% support. Accession numbers from GenBank or NCBI are given for all 
sequences. Leaves are colored according to their taxonomic affiliation. Horizontal branch lengths are 
drawn to scale, with the bar indicating 0.3 amino acid substitutions per site. Organisms known to 
produce D-QuiNAc or D-FucNAc are marked by black and red diamonds, respectively. (B) Schematic 
representation of the genomic context of bacterial Sugp 4-keto reductases. Sugp 4-keto reductase 
genes (symbolized by an “R”) co-occur in potential operon structures with genes encoding membrane-
bound UDP-D-GlcNAc 4,6-dehydratases (“D”) and putative D-FucNAc-/D-QuiNAc-1-phosphate 
transferases. The glycosyltransferase genes form two distinct groups, typified by Staphylococcus 
aureus capM (black “T”) and Pseudomonas aeruginosa wbpL (red “T”). Other genes are denoted by 
an “x” and, in the case of multiple genes, by numbers indicating the number of genes. Direction of 
transcription is from left to right, unless indicated otherwise by arrows above gene symbols. Genes 
that are not closely linked (˃ 12 intervening genes) are separated by commas. D-FucNAc, N-acetyl-D-
fucosamine; D-QuiNAc, N-acetyl-D-quinovosamine; UDP-D-GlcNAc, UDP-N-acetyl-D-glucosamine; 
UDP-Sugp, UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose. 
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Clade II consists of rather short sequences (260–295 aa), which are mainly from 
Firmicutes. Most obviously, Clade II is divided into two moderately well-supported 
subclades (FIGURE 7). The smaller one (bootstrap support 0.88) contains several 
putative reductases from staphylococci with canonical nucleotide-binding site,220 
including CapN from S. aureus Newman. Moreover, this subclade contains a protein 
sequence from Listeria grayei with altered TGXXSYIG nucleotide-binding motif. All 
other proteins in the data set comprising the TGXXSYIG motif are found in the 
second subclade of Clade II (boostrap support 0.5); this includes various proteins 
from Firmicutes, as well as three proteins from Gammaproteobacteria, and a single 
protein from each of the phyla Bacteroidetes, Spirochaetes and Fibrobacteres. This 
grouping is not consistent with the established bacterial phylogeny and could be the 
result of horizontal gene transfer or, in the case of the sequences of Spirochaetes 
and Fibrobacteres, of the limited data set used (these sequences were the only 
representatives of the respective phyla).305,306 The vast majority of polysaccharides 
produced by the organisms in Clade II are of unknown structure. As already 
mentioned, D-FucNAc residues are found in several CP types of S. aureus.204,296 
Moreover, D-FucNAc is a component of the Bacillus halodurans C-125 teichuronic 
acid.307 The only protein in Clade II, the function of which has been elucidated so far, 
is the reductase WbtC, which catalyzes the final step in UDP-D-QuiNAc synthesis in 
Francisella tularensis.291 
The protein sequences from Epsilonproteobacteria (285–289 aa in length), as well as 
those from Fusobacteria (290–297 aa), clustered to form monophyletic groups, which 
were named Clade III and Clade IV. Inconsistent with established 16S rRNA 
phylogenies, the sequences of Epsilonproteobacteria seem to be more closely 
related to the sequences of Fusobacteria, than to those of other Proteobacteria.306 
This discrepancy might be the result of horizontal gene transfer. None of the proteins 
in Clade III and Clade IV have been characterized so far. However, one protein 
sequence in Clade III is derived from a gene located in the LPS biosynthetic locus of 
Fusobacterium nucleatum ATCC 25586, which is known to incorporate D-QuiNAc into 
its LPS.308  
Clade V is the largest clade within the UDP-Sugp reductase tree and comprises 
protein sequences of Actinobacteria, Chlorobi, Cyanobacteria, and Proteobacteria, 
amongst those the sequences of the (proposed) 4-keto reductases WbjF, WbpK, 
WbpV, and WreQ (TABLE 3). The proteins in Clade V have a length of 300 to 
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336 aa. The sequence from Cyanobacterium aponium found in Clade V is the only 
representative of the phylum Cyanobacteria included in the analysis. Thus, this 
sequence grouping loosely together with the proteobacterial reductase proteins is 
likely the result of the limited data set used. The same might be true for the two 
sequences of Actinobacteria forming a deep branch within Clade V. Alternatively, this 
grouping might result from lateral gene transfer. Several gene transfer events seem 
to have occurred between members of the phylum Chlorobi and Pseudomononas 
species. However, the deeper branches in Clade V are not well-supported, 
preventing the tracking of the reductase evolutionary history to full extent. 
Nevertheless, an overlay of polysaccharide structural information onto the 
phylogenetic tree revealed a correlation between expression of either D-QuiNAc- or 
D-FucNAc-containing polysaccharides and sequence-based clustering of 
gammaproteobacterial protein sequences (FIGURE 7A).309–320  
STRING275 (www.string-db.org) reported three conserved gene sets widely found 
with Sugp 4-keto reductase genes. As seen in panel B of FIGURE 7, most putative 
reductase genes are associated with genes predicted to encode membrane-bound 
UDP-GlcNAc 4,6-dehydratases. For instance, wbfT from Vibrio cholerae O139 is 
located only 3 kb upstream of the gene wbfY, which encodes a protein (AAC46251.1) 
sharing 40% sequence identity with CapD.295 Furthermore, the majority of reductase 
genes co-occur with either wbpL/wbcO (Clade I, III and V) or capM (Clade II, IV and 
V) homologs (FIGURE 7B), which encode different types of glycosyltransferases 
(FIGURE 8). Similar to MraY and WecA proteins, P. aeruginosa WbpL and its 
homologs, such as WbcO from Yersinia enterocolitica, are large hydrophobic 
proteins belonging to the polyprenol phosphate:N-acetylhexosamine-1-phosphate 
transferase family.321,322 Members of this protein family catalyze glycosyl transfer 
reactions involving a membrane-associated long-chain prenol phosphate acceptor 
(typically C55P) and a soluble UDP-N-acetyl-D-hexosamine sugar nucleotide donor 
substrate.321,322 Though biochemical evidence is lacking so far, WbpL has been 
proposed to catalyze the transfer of D-QuiNAc/D-FucNAc residues onto C55P.
292,323 In 
contrast, S. aureus CapM and homologous proteins (e.g. LpsB1 from R. etli) are 
anchored to the cytoplasmic membrane by a single transmembrane domain that is 
linked to a large C-terminal catalytic domain located in the cytoplasm (FIGURE 8).  
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FIGURE 8. Structural models of the putative initiating N-acetyl-D-fucosamine-1-phosphate 
transferases CapM and WbpL based on TMHMM server 2.0 predictions. (A) The Staphylococcus 
aureus glycosyltransferase CapM (GenBank accession number BAF66379.1) is anchored to the 
membrane by one transmembrane domain (TM). The catalytic domain of CapM is located in the 
cytoplasm; microdomains 1 and 2 (MD1 & MD2) are predicted to interact with the membrane-standing 
substrate C55P, microdomain 3 (MD3) is assumed to interact with the sugar substrate. The depth of 
grey shading indicates the degree of residue conservation across species; a potential tyrosine-
phosphorylation site is highlighted in red. (B) Pseudomonas aeruginosa WbpL (AAF23990.1) is a large 
hydrophobic protein comprising 11 membrane-spanning domains (designated I through XI), which 
define five cytoplasmic loops. The conserved FMGD active site motif (cytoloop 4) and the residues of 
the putative carbohydrate-recognition domain (cytoloop 5) are highlighted in red. 
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In most cases, the gene topology is consistent with reductase, dehydratase and 
glycosyltransferase forming an operon (or being co-transcribed from a bi-directional 
promoter, as in V. cholerae O37). Therefore, it seems likely that the encoded proteins 
have associated functions.324–326 Moreover, the gene context analysis strongly 
supports the assumption that the proteins identified in the phylogenetic analysis are 
UDP-Sugp reductases involved either in the synthesis of UDP-D-FucNac or of UDP-
D-QuiNAc. However, only one protein of the whole group has been characterized at 
the biochemical level, so far.288 Thus, additional experimental data is highly required 
to validate the in silico predictions. 
3.3 Construction of E. coli expression plasmids 
In vitro reconstitution of PglF catalytic activity was performed using a soluble 
derivative of the native C. jejuni membrane protein, lacking transmembrane domains, 
as originally described by Schoenhofen et al.237 For this purpose, a 5′-truncated 
version of the pglF gene from a clinical isolate of C. jejuni was amplified by PCR. The 
respective oligonucleotide primers (see TABLE 5) were designed based on the 
nucleotide sequence of the pglF gene from C. jejuni NCTC 11168 (NCBI GeneID 
905411). The amplicon was cloned into pET28a in E.coli DH5α, using the restriction 
sites NdeI and XhoI. The genetic construct enabling the expression of an N-terminal 
hexahistidine fusion protein was analyzed by DNA sequencing (Sequiserve, 
Vaterstetten, Germany). A GenBank BLASTx search with the deduced amino acid 
sequence revealed 100% sequence identity to residues 130–590 of the PglF enzyme 
from C. jejuni subsp. jejuni 1997-1 (GenBank accession EIB51738.1).  
Creuzenet & Lam described an active truncated variant of the membrane-anchored 
UDP-GlcNAc 4,6-dehydratase WbpM from P. aeruginosa PAO1 (GenBank accession 
number AAC45867.1).281 This enzyme shares substantial sequence similarity with 
CapD from S. aureus Newman (41% identity and 64% similarity over 446 aa). Thus, 
a recombinant plasmid for expression of a soluble CapD variant was generated 
analogously to the genetic construct reported by Creuzenet & Lam.281 
Oligonucleotide primers were designed based on a global alignment of the WbpM 
and CapD amino acid sequences. Purified genomic DNA from S. aureus Newman 
was used as template for PCR amplification of 5′-truncated capD. The purified PCR 
product was digested with NheI and XhoI, and ligated into appropriately restricted 
pET28a. After cloning in E. coli DH5α, the recombinant plasmid pET28a-capDtr was 
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confirmed by sequencing. It enables expression of an N-terminally His6-tagged CapD 
mutant (aa 249–611) lacking the four transmembrane domains and the first 
conserved sequence motif (compare FIGURE 6).  
Recombinant expression of CapD-His6 and CapN-His6 was performed using 
plasmids pET24a-capD and pET24a-capN, which were constructed in the laboratory 
of Professor Jean C. Lee, at Brigham & Women's Hospital/Harvard Medical School, 
Boston, USA. Plasmids pET28a-capA1, pET28a-capB2, and pET24a-capE 
(pKBK50d) used for overexpression of the hexahistidine fusion proteins CapA1-His6, 
CapB2-His6 and CapE-His6, respectively, have been described previously.
207,233 
3.4 Expression and purification of recombinant proteins  
Full-length CapD from S. aureus Newman serotype 5 was overexpressed as 
N-terminal His6-tag fusion protein using E. coli C43.
238 After sonication and 
ultracentrifugation, most of the recombinant protein resided in the membrane fraction. 
CapD-His6 could be purified to about 80–90% purity by nickel chelation 
chromatography after solubilization in DDM. Typically, 5 mg of recombinant protein 
were obtained per litre of culture. E. coli BL21 was employed for overexpression of 
the soluble truncated CapD variant (CapDtr-His6; see previous section). As expected, 
the mutant protein could be isolated at high yield from the cell lysate without use of 
detergent.  
S. aureus CapN was predicted to reside in the cytoplasm, since no putative 
transmembrane helices were identified using TMHMM server version 2.0 (see 
2.5.1).327 However, attempts to isolate the fusion protein CapN-His6 from the 
cytoplasmic content of IPTG-induced E. coli C43 cells, did not succeed. However, 
subjecting the Triton X-100-solubilized membrane fraction to affinity chromatography 
enabled purification of CapN-His6. On the average, 2.5 mg of recombinant protein 
(˃ 90% pure) were isolated from 1 l of culture. The finding that CapN is a membrane-
associated protein, together with the fact that it is supposed to act on UDP-Sugp, 
suggests possible interactions between CapN and other membrane-bound capsule 
biosynthesis proteins, such as CapD and CapM.  
S. aureus CapA1, CapB2 and CapE, and truncated C. jejuni PglF were expressed as 
hexahistidine fusion proteins and purified by affinity chromatography as previously 
described.207,233,237 All recombinant proteins were obtained at high yield and in 
sufficient purity for use in in vitro enzyme assays. The apparent molecular masses of 
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the proteins as determined by SDS-PAGE were in good agreement with the 
calculated molecular masses (i.e. CapA1-His6: 27.0 kDa, CapB2-His6: 27.4 kDa, 
CapD-His6: 70.2 kDa, CapDtr-His6: 42.9 kDa, CapE-His6: 39.9 kDa, CapN-His6: 
34.7 kDa, PglF-His6: 53.1 kDa; FIGURE 9). 
 
FIGURE 9. SDS-PAGE analysis of purified recombinant enzymes. The molecular masses (in kDa) of 
the marker proteins are indicated on the left of each panel (M1, PageRuler Plus prestained protein 
ladder, Thermo Scientific; M2, protein marker broad range, New England BioLabs). Calculated 
molecular masses of N-terminal hexahistidine (His6) fusion proteins are as follows: CapDtr(uncated), 
42.9 kDa; PglF, 53.1 kDa; CapD, 70.2 kDa; CapE, 39.9 kDa; CapN, 34.7 kDa.  
3.5 In vitro reconstitution of S. aureus UDP-D-FucNAc biosynthesis 
Homology searches with CapD and CapN suggested that both proteins are involved 
in the synthesis of the first soluble capsule precursor UDP-D-FucNAc.77 
Corroborating this assignment, Burrows et al. reported that cap8D provided in trans 
can complement the knockout of wbpM in P. aeruginosa, thus restoring O antigen 
biosynthesis.329 However, the pathway proposed for UDP-D-FucNAc biosynthesis in 
S. aureus has yet to be verified biochemically.  
In vitro characterization of capsule biosynthetic enzymes was performed in close 
collaboration with the group of Professor Christa E. Müller of the Department of 
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Pharmacy (Pharmaceutical Chemistry I) at the University of Bonn. To assess the 
catalytic activity of CapD, a capillary electrophoresis (CE)-based method applying 
micellar electrokinetic chromatography330 coupled with UV detection was developed 
for separation and quantification of UDP-D-GlcNAc and dehydrated derivatives 
(Wenjin Li, Pharmaceutical Chemistry I). CE is a simple, economic, and powerful 
method for monitoring enzyme reactions, especially such that generate charged 
products.331–333 Based on predicted net charge differences (MarvinSketch 
software,334 available at www.chemaxon.com/free-software/) between UDP-D-
GlcNAc and the expected product UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose 
(UDP-Sugp), CAPS buffer at pH 12.4 was chosen as the running buffer. Since both 
analytes are negatively charged in alkaline buffer, CE was performed in reversed 
polarity mode, using fused-silica capillaries, and the cationic surfactant polybrene as 
running buffer additive for dynamic coating.333,335 During the running process, 
polybrene micelles are adsorbed onto the inner capillary wall, thus creating a 
positively charged surface and causing a reversal of the electro-osmotic flow.336 With 
this setup, electro-osmotic flow and migration of anionic compounds are both 
directed towards the positive electrode.332  
To confirm its suitability for the investigation of CapD catalytic activity, PglF in vitro 
reactions were analyzed using the new CE method. Truncated, soluble PglF from 
C. jejuni has been demonstrated to catalyze 4,6-dehydratation of UDP-D-GlcNAc, 
leading to the formation of UDP-Sugp, the same product expected to be generated in 
the CapD-catalyzed reaction.237 The reaction involves oxidation at C4 and conversion 
of the hydroxymethyl group at C6 to a methyl group (see FIGURE 5).278,279 The 
resulting 4-keto-6-deoxy intermediate has a reduced charge-to-mass ratio compared 
to UDP-D-GlcNAc and was therefore expected to display enhanced electrophoretic 
mobility in the CE system.  
As revealed by CE analysis of the PglF reaction, the peak corresponding to UDP-D-
GlcNAc disappeared in favor of a new peak (FIGURE 10A); no such conversion was 
observed with a heat-inactivated negative control (data not shown). As predicted, the 
PglF enzymatic product migrated faster in the capillary compared to UDP-GlcNAc, as 
result of a reduced net negative charge. Furthermore, the degradation product UDP 
was detected in samples containing active PglF. Since 4-keto-6-deoxy sugar 
nucleotides are relatively unstable compounds, it seems likely that UDP is formed by 
non-enzymatic hydrolysis of the reaction product.237,279  
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FIGURE 10. Capillary electrophoresis (CE) analysis of in vitro UDP-GlcNAc 4,6-dehydratase activity of 
PglF and CapD. Recombinant purified enzymes were incubated in the presence of substrate UDP-D-
GlcNAc (3 mM). Reaction mixtures were analyzed by CE, with UV detection set at 260 nm (arbitrary 
units, AU). (A) UDP-GlcNAc converted with CapD (3 µg) in the presence of 3 mM NADP
+
 and 0.8% 
(v/v) Triton X-100. (B) UDP-GlcNAc converted with PglF (3.5 µg). Peak identities were confirmed by 
spiking samples with reference compounds. 1, UDP; 2, NADP
+
 impurity; 3, internal standard PAP (3′-
phosphoadenosine 5′-phosphate); 4 and 5, NADP
+
 impurities; 6, product UDP-Sugp (UDP-2-
acetamido-2,6-dideoxy-D-xylo-4-hexulose); 7, substrate UDP-GlcNAc and cofactor NADP
+
.  
To investigate the enzymatic activity of the predicted 4,6-dehydratase,77 purified 
recombinant CapD was incubated with UDP-D-GlcNAc in the presence of detergent 
and cofactors for 2 h. CE analysis of the quenched reaction mixture revealed a peak 
with identical UV spectrum and retention time as observed for the PglF enzymatic 
product (FIGURE 10B). The identity of each peak was confirmed by spiking with 
reference compounds. In contrast to PglF, which displayed full in vitro activity without 
externally added cofactors, CapD activity was dependent on the presence of 
detergent and NADP+; addition of NAD+ or the absence of any cofactor resulted in 
less than 5% substrate conversion (see section 3.6, FIGURE 16). Since NADP+ co-
migrated with UDP-GlcNAc in CE analysis, the percentage of substrate conversion 
could only be assessed indirectly by quantifying the amount of UDP-Sugp and UDP 
in the samples. According to these calculations, CapD is, like PglF, capable to 
catalyze almost complete conversion of the substrate UDP-GlcNAc.  
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MALDI-TOF mass spectrometry was used to further characterize the product of the 
CapD in vitro reaction. To this end, sugar nucleotides were purified from the CapD 
reaction mixture by ion-pair reversed-phase HPLC as described in the “Materials and 
Methods” section (2.4.9). Fractions containing sugar nucleotides were lyophilized and 
subjected to MS analysis; enzymatic product generated with PglF-His6 was 
processed in identical manner and served as standard for MALDI-TOF MS. MS 
spectra were kindly recorded by Michaele Josten (Institute of Medical Microbiology, 
Immunology and Parasitology, University of Bonn). 
 
FIGURE 11. Mass spectrometric analysis of in vitro UDP-GlcNAc 4,6-dehydratase activity of CapD. 
Purified recombinant CapD (30 µg) was incubated with substrate UDP-D-GlcNAc (0.9 mg) in the 
presence of 3 mM NADP
+
 and 0.8% (v/v) Triton X-100. HPLC-purified sugar nucleotides were 
analyzed by negative-mode MALDI-TOF mass spectrometry. (A) Mass spectrum obtained from a 
control reaction without recombinant enzyme. (B) UDP-GlcNAc converted with CapD. The peak at m/z 
588.4 corresponds to the deprotonated molecular ion of UDP-Sugp (CapD product). Peaks at m/z 
606.5 arise either from UDP-GlcNAc or from the hydrated (diol) form of UDP-Sugp. AU, arbitrary units; 
UDP-Sugp, UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose. 
A molecular ion at m/z 588.4 (negative mode; [M−H]−), consistent with the expected 
mass of 589.3 for UDP-Sugp, was visible in both MS spectra (FIGURE 11). Although 
complete substrate conversion was expected under the conditions applied, a second 
peak at m/z 606.5 was observed with both samples, which could arise from residual 
substrate UDP-D-GlcNAc (neutral mass 607.4). In aqueous environment, the 4-keto 
group of UDP-Sugp undergoes hydration, resulting in the formation of a 4-dihydroxy 
(diol) derivative, that has the same molecular mass as UDP-D-GlcNAc.279 Thus, the 
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peak at m/z 606.5 might also correspond to the hydrated form of the PglF/CapD 
reaction product.  
Taken together, these results demonstrate that CapD functions as dehydratase 
initiating the synthesis of the soluble capsule precursor UDP-D-FucNAc by 
conversion of the substrate UDP-D-GlcNAc. As demonstrated by in vitro assays 
performed with a soluble CapD variant (see section 3.3), the C-terminal domain is 
sufficient for catalytic activity (Marvin Rausch, personal communication). It should be 
noted that accurate mass determination alone does not allow for the differentiation 
between isomers, and is thus not sufficient to unequivocally confirm the identity of a 
compound. Taking into account the genetic evidence, and the knowledge gained 
from biochemical studies on homologous 4,6-dehydratases, it seems highly likely that 
the CapD reaction product is indeed UDP-Sugp.237,281,283,284,287,329 However, further 
experiments should be performed for structure elucidation.  
 
FIGURE 12. Capillary electrophoresis (CE) analysis of in vitro UDP-Sugp 4-keto reductase activity of 
CapN. In a combined assay, purified recombinant CapN (12 µg) and PglF (3.5 µg) were incubated 
simultaneously with substrate UDP-D-GlcNAc (3 mM), in the presence of 1.9 mM NADPH and 0.8% 
(v/v) Triton X-100. Reaction mixtures were analyzed by CE, with UV detection set at 260 nm (arbitrary 
units, AU). (A) UDP-D-GlcNAc converted by sequential action of PglF and CapN. (B) 
Electropherogram of a control reaction containing heat-inactivated CapN. Peak identities were 
confirmed by spiking samples with reference compounds. 1, UDP-D-GlcNAc; 2, UDP-D-FucNAc (CapN 
product); 3, UDP-Sugp (UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose; PglF product); 4, NADP
+
. 
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CapN is proposed to further convert the CapD reaction product to UDP-D-FucNAc by 
stereospecific reduction of the C4 keto group.77 To assess the catalytic activity of the 
putative reductase, purified CapN-His6 was incubated in the presence of the 
intermediate UDP-Sugp. PglF-His6 was utilized to produce the substrate for CapN 
functional reconstitution, as it enabled 100% conversion of UDP-D-GlcNAc and was 
not dependent on externally added cofactors or detergent for activity. PglF assays 
were quenched by heating and directly used for CapN in vitro reactions, or, 
alternatively, synthesis of UDP-D-FucNAc was performed in a combined assay.  
For analysis of the CapN reaction, a CE method described by Kneidinger et al. was 
applied.207 Purified CapN-His6 was able to convert UDP-Sugp into a new 
carbohydrate species displaying altered CE migration behavior (FIGURE 12A); no 
such peak was observed with the heat-inactivated negative controls (FIGURE 12B).  
FIGURE 13. Mass spectrometric analysis of CapN in vitro activity. In a combined assay, purified 
recombinant CapN (120 µg) and PglF (35 µg) were incubated simultaneously with substrate UDP-D-
GlcNAc (1.1 mg), in the presence of 1.9 mM NADPH and 0.8% (v/v) Triton X-100. HPLC-purified 
sugar nucleotides were analyzed by negative-mode MALDI-TOF mass spectrometry. (A) Mass 
spectrum of a control reaction containing heat-inactivated CapN. (B) UDP-GlcNAc converted with PglF 
and CapN. The peak at m/z 590.5 corresponds to the deprotonated molecular ion of UDP-D-FucNAc 
(CapN product). Peaks at m/z 588.5 correspond to the singly charged UDP-Sugp molecule (PglF 
product); peaks at m/z 606.5 arise either from UDP-GlcNAc or from the hydrated (diol) form of UDP-
Sugp. AU, arbitrary units; UDP-Sugp, UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose. 
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In good agreement with the studies of Kneidinger et al. on UDP-L-FucNAc 
biosynthesis, the CapN enzymatic product migrated faster in the capillary than the 
PglF enzymatic product, but slower than UDP-D-GlcNAc (FIGURE 12).207 Analogous 
results were obtained using the CapD enzymatic product as a substrate for CapN 
reactions (data not shown). 
MALDI-TOF MS analysis of HPLC-purified sugar nucleotides from the CapN reaction 
mixture revealed an ion ([M−H]−) at m/z 590.4 (FIGURE 13), consistent with the 
formation of UDP-D-FucNAc (neutral mass 591.4). These results confirm that CapN 
functions as a reductase and, using NADPH as a cofactor, is able to convert the 
substrate UDP-Sugp to form the first soluble capsule precursor UDP-D-FucNAc. 
3.6 Kinetic characterization of CapD- and CapE-catalyzed reactions 
The newly established CE method was applied for in vitro characterization of the 
UDP-GlcNAc 5-inverting 4,6-dehydratase CapE (see FIGURE 5). In the CapE 
enzyme–substrate reaction, the peak corresponding to UDP-D-GlcNAc disappeared, 
and a faster-migrating peak appeared instead in the CE chromatogram (FIGURE 14). 
 
FIGURE 14. Capillary electropherogram of CapE in vitro reaction run to apparent completion. Peaks: 
1, UDP; 2, Internal Standard PAP; 3, CapE product UDP-2-acetamido-2,6-dideoxy-L-arabino-4-
hexulose (likely together with epimeric by-product UDP-Sugp). AU, arbitrary units; PAP, 3′-
phosphoadenosine 5′-phosphate; UDP-Sugp, UDP-2-acetamido-2,6-dideoxy-D-xylo-4-hexulose. 
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FIGURE 15. Mass spectrum obtained from a CapE reaction. MALDI-TOF MS analysis (negative 
mode) of HPLC-purified sugar nucleotides gave the expected molecular ion peak for UDP-Sugp 
([M−H]
−
, m/z 588.5). The peak at m/z 606.5 may correspond to the hydrated (diol) forms of these 
compounds, or to residual substrate UDP-D-GlcNAc. AU, arbitrary units; UDP-Sugp, UDP-2-
acetamido-2,6-dideoxy-D-xylo-4-hexulose. 
The 4,6-dehydratase/5-epimerase activity of CapE, which converts UDP-GlcNAc to 
UDP-2-acetamido-2,6-dideoxy-L-arabino-4-hexulose, has already been demonstrated 
in vitro.207,234 CapE was also found to catalyze slow “back-epimerization” of the initital 
reaction product with L-arabino-configuration, leading to formation of the by-product 
UDP-Sugp.234 Thus, the CapE product peak on CE analysis probably represents a 
mixture of the two isomeric UDP-amino sugars. As expected, a molecular mass of 
588.5 ([M−H]−) was determined for the HPLC-purified CapE reaction product(s) 
(FIGURE 15).  
 
FIGURE 16. Cofactor dependency of CapD and CapE in vitro enzymatic activity. Recombinant purified 
enzymes were incubated with substrate UDP-GlcNAc (3 mM), in the presence or absence of cofactors 
(3 mM NAD
+
/NADP
+
) and substrate conversion was quantified by capillary electrophoresis (triplicate 
samples with duplicate measurements). (A) CapD catalytic activity is strictly NADP
+
-dependent. (B) 
CapE catalytic activity is maximal without exogenous cofactors. Addition of NAD
+
 has no effect on 
CapE-mediated substrate conversion, whereas addition of NADP
+
 inhibits CapE in vitro activity 
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CapE-His6 was able to catalyze complete conversion of the substrate UDP-D-
GlcNAc, and was not dependent on externally added cofactors for full enzymatic 
activity. Astonishingly, CapE enzymatic activity was inhibited when the assay was 
supplemented with high concentrations of NADP+ (FIGURE 16). 
The CE-based detection method for monitoring UDP-GlcNAc 4,6-dehydratase activity 
was validated according to the guidelines published by the International Conference 
on Harmonisation (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, and by the US Food and Drug Administration 
(FDA), demonstrating its suitability for the analysis of enzyme kinetics and for 
inhibitor testing.247,248 A summary of the parameters of method validation is provided 
in TABLE 8.  
 
FIGURE 17. Enzyme kinetics of CapD and CapE. Time-dependent enzymatic reaction of CapD (A) 
and CapE (B). (C) Michaelis–Menten plot for CapD, Km 3650 ± 270 µM, Vmax 0.127 ± 0.011 
µmol/min/mg; (D) Michaels–Menten plot for CapE, Km 457 ± 76 µM, Vmax 0.071 ± 0.004 µmol/min/mg.  
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Enzyme kinetics (Michaelis-Menten constant, Km, and maximum velocity, Vmax) were 
determined for both CapD and CapE (FIGURE 17). CapD displayed a Km value of 
3650 ± 270 µM and a Vmax value of 0.127 ± 0.011 µmol/min/mg. For CapE, a Km 
value of 457 ± 76 µM and a Vmax value of 0.071 ± 0.004 µmol/min/mg were 
determined. The CapD in vitro reaction was in the linear range (steady-state phase) 
for up to 120 min, whereas CapE measurements were in the linear range for 60 min 
under the conditions applied. 
3.7 Screening for inhibitors of CapD and CapE enzymatic activity 
The validated CE method (see TABLE 8) was used for compound screening, in order 
to identify CapD and/or CapE inhibitors. A series of selected small molecules was 
tested, including uracil nucleotide derivatives, compounds known to bind nucleotide-
binding sites, and clinically applied antibiotics.331,337,338  
 
FIGURE 18. Concentration-dependent inhibition of CapD and CapE. (A) CapE inhibition by suramin, 
IC50 1.82 ± 0.40 µM; (B) CapD inhibition by ampicillin, IC50 40.1 ± 14.9 µM; (C) CapD inhibition by the 
pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala, IC50 73.9 ± 12.8 µM. Substrate (UDP-D-GlcNAc) 
concentration was 1 mM.  
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Altogether, 73 compounds were investigated for CapD inhibition, and 46 compounds 
were screened for inhibition of CapE (SUPPLEMENTARY TABLE 1). Inhibitory 
effects on CapD or CapE were observed with several compounds, and 
concentration–inhibition curves were determined for the most potent inhibitors 
(FIGURE 18). 
Suramin339 was found to be a potent and CapE inhibitor with an IC50 value of 
1.82 ± 0.40 µM (FIGURE 18A), whereas CapD was not inhibited at a test 
concentration of 10 µM (SUPPLEMENTARY TABLE 1). Intriguingly, the β-lactam 
antibiotic ampicillin efficiently inhibited CapD enzymatic activity (IC50 40.1 ± 14.9 µM; 
FIGURE 18B). The related compound amoxicillin and the ampicillin prodrug 
pivampicillin were inactive at a test concentration of 10 µM, while dicloxacillin was 
similarly potent as ampicillin in the screening assay (see SUPPLEMENTARY TABLE 
1). All other investigated β-lactams (cefitixime, cefotaxime, cefuroxime, ceftaroline 
fosamil, oxacillin, phenoxymethylpenicillinic acid, benzathine benzylpenicillin, 
flucloxacillin, piperacillin , sultamicillin, ticarcillin, bacampicillin, cloxacillin, penicillin G, 
mecillinam, ertapenem, meropenem, aztreonam, and potassium clavulanate) did not 
show any significant inhibition at a test concentration of 10 µM.  
Beta-lactam antibiotics interfere with bacterial peptidoglycan biosynthesis by 
inhibiting penicillin-binding proteins, and thus the transpeptidation of cell wall building 
blocks.340 The β-lactam ring structurally mimics the D-Ala-D-Ala terminus of the 
pentapeptide side chain, which is attached to the MurNAc moiety of the central 
peptidoglycan precursor lipid II. Because of this structural analogy, we investigated 
the effects of different cell wall precursor molecules on CapD enzymatic activity. The 
pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala was found to inhibit CapD enzymatic 
activity with an IC50 value of 73.9 ± 12.8 µM (FIGURE 18C). Moreover, the 
peptidoglycan building block lipid II showed significant inhibition (67%) of CapD 
activity at a test concentration of 100 µM (SUPPLEMENTARY TABLE 1). Suramin 
and ampicillin were found to be selective inhibitors of CapE and CapD, respectively. 
Concentration–inhibition curves for suramin at CapE, and the pentapeptide L-Ala-D-
Glu-L-Lys-D-Ala-D-Ala and ampicillin at CapD are shown in FIGURE 18. 
Furthermore, the inhibition mechanisms for suramin, ampicillin, and the pentapeptide 
L-Ala-D-Glu-L-Lys-D-Ala-D-Ala were investigated (FIGURE 19). Suramin was found to 
act as a non-competitive inhibitor of CapE. Ampicillin appeared to be a non-
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competitive inhibitor of CapD, while the peptidoglycan pentapeptide showed a 
competitive inhibition mechanism at CapD.  
 
FIGURE 19. Determination of enzyme inhibition mechanism. (A) CapE inhibition by suramin is non-
competitive; (B) CapD inhibition by ampicillin is non-competitive; (C) CapD inhibition by the 
pentapeptide L-Ala-D-Glu-L-Lys-D-Ala-D-Ala is competitive.  
 
 
Results 
 
71 
3.8 CapAB-mediated modulation of S. aureus capsule biosynthesis  
The reversible phosphorylation of proteins is a fundamental mechanism for regulation 
of various cellular processes.341 In S. aureus, the bacterial tyrosine (BY-)kinase 
complex CapAB has been proposed to regulate capsule biosynthesis on the protein 
level.160,161,216 So far, one endogenous protein substrate of the CapAB complex has 
been identified: the dehydrogenase CapO is activated by CapAB phosphorylation, as 
judged by measuring its capacity to catalyze conversion of NAD+ to NADH.216,218  
To identify endogenous protein substrates of the CapAB kinase complex, selected 
proteins involved in the syntheses of soluble capsule precursors were examined for 
phosphotransfer (Marvin Rausch, unpublished results and reference 233). The full 
length integral membrane protein CapA1 and the cytoplasmic kinase CapB2 were 
overexpressed as His6-tagged fusion proteins, purified by Ni-NTA chromatography, 
and utilized to reconstitute CapAB tyrosine kinase activity in vitro in the presence of 
γ-labeled [33P]-ATP (FIGURE 20A).  
 
FIGURE 20. CapE is phosphorylated by the CapAB tyrosine kinase complex. (A) Autophosphorylation 
of CapB2 in the presence of CapA1. (B) CapE is intensely phosphorylated in the presence of 
CapA1B2. Recombinant purified proteins CapE (3 µg), CapA1, and CapB2 were incubated in the 
presence of γ-labeled [
33
P]-ATP, and phosphotransfer was analyzed by SDS-PAGE and 
phosphoimaging. The apparent molecular masses of the radiolabeled protein bands were in good 
agreement with the calculated masses of the respective hexahistidine (His6) fusion proteins, i.e. CapB-
His6, 27.4 kDa; CapE-His6, 39.9 kDa. 
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Investigation of CapA1B2-mediated phosphotransfer onto putative target proteins 
revealed tyrosine phosphorylation of the dehydratase CapE (FIGURE 20B). In 
contrast, only marginal phosphotransfer to CapD, and no phosphorylation of 
recombinant CapN, CapF, or CapG could be detected (data not shown). 
 
FIGURE 21. CapE enzymatic activity is modulated by tyrosine phosphorylation. (A) Mapping of CapE 
phosphorylation sites by NanoLC-MS/MS. Confirmed tyrosine phosphorylation sites are marked by 
arrows. Cofactor-binding domain, substrate-binding domain and the mobile latch are marked blue, 
yellow and red, respectively. The active site motif MXXXK (stars) and the cofactor-binding motif 
TGXXGXXG (circles) are highlighted. (B) Impact of CapAB kinase activity on CapE-mediated 
substrate conversion. CapE was incubated in the presence of either active CapAB (white) or heat-
inactivated CapAB (black) with UDP-D-GlcNAc for 30 min. Substrate conversion was quantified by 
capillary electrophoresis (triplicate samples with duplicate measurements). Statistical significance was 
analyzed by an unpaired t-test (p = 0.0029). 
Using the NetPhos 2.0 prediction software (www.cbs.dtu.dk/services/NetPhos/),259 
eight potential tyrosine phosphorylation sites were identified within the CapE amino 
acid sequence, with Tyr76 having the highest probability score (FIGURE 21). Tryptic 
fragments of in vitro phosphorylated CapE-His6 were analyzed by nanoscale liquid 
chromatography-tandem mass spectrometry (nanoLC-MS/MS) to experimentally 
validate the in silico results. LC-MS/MS analysis was performed at the MS service lab 
of Bonn University, by Dr Marc Sylvester. In good agreement with the computational 
predictions, Tyr76 of the CapE protein was found to be phosphorylated. As revealed 
by sequence analysis, this residue is located in proximity to the conserved 
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TGXXGXXG cofactor-binding motif and the MXXXK catalytic site (FIGURE 21A).220 
Three other phosphotyrosine residues (Tyr290, Tyr293 and Tyr329), which had also 
been predicted by NetPhos 2.0, were mapped to a C-terminal loop of CapE (FIGURE 
21A; red). 
More recently, crystal structure analysis of CapE revealed that the protein assembles 
into a hexamer (trimer of dimers), and that the C-terminal mobile loop connects two 
contiguous subunits of CapE, involving contacts to Tyr290 and Tyr293 (see 
Discussion, FIGURE 27).228 Moreover, the mobile loop appears to occupy a strategic 
position in close proximity to the entrance of the substrate-binding pocket, and its 
phosphorylation might enhance the access of UDP-D-GlcNAc to the active site.228 No 
phosphotyrosine residues could be identified when CapE-His6 was subjected to MS 
analysis without prior in vitro phosphorylation, demonstrating that the recombinant 
enzyme is not modified by protein kinases of the E. coli expression host. 
To study the impact of CapAB-mediated phosphorylation on CapE enzymatic activity, 
CapE assays were performed in the presence of either active or of heat-inactivated 
CapAB kinase complex, and product yields were quantified by CE. As shown in panel 
B of FIGURE 21, the product yield was increased by 60% in the presence of CapAB, 
compared to the control reaction, indicating that the CapE-catalyzed reaction is 
positively modulated through phosphorylation.  
Taken together these results support the hypothesis, that the CapE reaction 
represents a regulatory checkpoint within the CP biosynthesis pathway, with CapE 
Tyr290 (NetPhos probability score: 0.547) and Tyr293 (NetPhos probability score: 
0.837) being the most promising candidates for regulatory tyrosine phosphorylation 
sites. Moreover, the experimental data presented here identify UDP-GlcNAc 
4,6-dehydratases belonging to the extended SDR protein family as a further enzyme 
class that is regulated by BY-kinases.219,220 
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4 Discussion 
4.1 Inhibitors of capsule biosynthesis as potential anti-virulence 
agents 
The number of new antibiotics developed and approved has steadily decreased in 
the past three decades, leaving fewer options to treat infections caused by resistant 
bacteria.342 As a consequence thereof, doctors now routinely encounter patients with 
infections that do not respond to available treatment.343 Since the output of the drug 
pipelines is not well-positioned to control the growing number of resistant pathogens, 
there is an urgent need to develop new treatment strategies. Capsule biosynthesis is 
not essential for bacterial cell viability; however, inhibitors targeting this process may 
have the potential for use as anti-virulence drugs. Development of anti-virulence 
drugs represents an emerging strategy to combat multi drug-resistant bacteria.344 
This strategy is especially attractive since anti-infective drugs, that act by inhibiting 
virulence rather than bacterial growth, might apply a milder evolutionary pressure for 
the development of resistance.344  
Inhibition of capsule formation may unmask patterns on the bacterial cell surface, 
which are important for pathogen recognition and clearance by the innate immune 
system (see Introduction, section 1.2). Encapsulated S. aureus strains are more 
virulent than isogenic acapsular mutants in rodent models of staphylococcal 
bacteremia,4,345 surgical wound infection,346 septic arthritis,37 and subcutaneous and 
renal abscess formation.38,346 In vitro assays revealed that capsule-deficient mutants 
are more efficiently phagocytosed and killed by human neutrophils4,345 and mouse 
macrophages,37 than the parental strains. Recently, the marine sponge metabolite 
fascioquinol E, impairing S. pneumoniae capsule formation, has been put forward as 
a novel anti-virulence agent. It could be demonstrated that bacterial cells produced 
less CP and were more readily captured by murine macrophages upon fascioquinol 
treatment.347 Inhibition of capsule formation leading to enhanced complement 
opsonization and phagocytosis211,348 could as well have beneficial effects on already 
established infections.  
Inhibitors of capsule formation might also be used in combination with established 
antibiotics, to extend the life-span of these drugs. The combination of CP inhibitors 
and cell wall antibiotics appears especially promising for drug development since 
these compounds may have synergistic effects. CP precursors are assembled onto 
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the lipid carrier bactoprenol (C55P),
122 which is also crucial for biosynthesis of the cell 
wall polymers peptidoglycan (PG) and wall teichoic acid (WTA). Unlike PG, WTA is 
not required for the viability of S. aureus cells.121,349 Nevertheless, inhibition of the 
late-stage WTA biosynthesis reactions leads to cell death, probably due to 
accumulation of toxic intermediates, or due to depletion of the universal lipid carrier 
C55P, resulting in impaired PG synthesis.
121 WTA inhibitors have therefore been 
proposed as potential anti-MRSA β-lactam combination agents.350,351 In analogy to 
the WTA biosynthesis in S. aureus, loss-of-function mutations in enzymes involved in 
S. pneumoniae CP polymerization and transport are lethal unless the function of the 
initiating glycosyltransferase Cps2E is disrupted by suppressor mutations abolishing 
flux of C55P into capsule biosynthesis.
123 
To explore constituents of the capsule biosynthetic pathway as drug targets, we need 
a profound understanding of the underlying molecular processes. The present study 
contributes to the elucidation of capsule biosynthesis in the important opportunistic 
pathogen S. aureus. The enzymatic reactions involved in the syntheses of the 
soluble capsule precursors UDP-L-FucNAc and UDP-D-ManNAcA have already been 
studied in vitro.38,207,208 However, in vitro characterization of the biosynthesis of the 
first soluble capsule precursor UDP-D-FucNAc has long been hampered by the fact 
that CapD, the enzyme catalyzing the initiating step, is a protein with multiple 
transmembrane domains (FIGURE 6). This thesis describes the successful 
reconstitution and thorough characterization of CapD enzymatic activity in vitro using 
recombinant, full-length CapD. The established in vitro system provided the basis for 
subsequent reconstitution of the complete biosynthetic pathway, and for inhibitor 
screening. Furthermore, the present study reports new insights into the post-
translational regulation of CP biosynthesis in S. aureus.  
4.2 Characterization of S. aureus UDP-GlcNAc 4,6-dehydratases 
In the course of evolution, proteins deriving from a common ancestral protein can 
accumulate sequence divergence, giving rise to families of homologous proteins. 
Amino acid residues which are important for protein function, stability, or folding are 
in general less susceptible to mutational alteration, and this is directly reflected in 
characteristic patterns of conserved residues (for reviews, see references 352–354). 
There are many aspects of protein function that contribute to the evolution of protein 
(sub)families. These may include the global conservation of catalytic mechanisms (in 
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the case of enzymes), specific binding to substrates and cofactors, as well as the 
interaction with other proteins in processes such as cell signaling, the regulation of 
reactions, and the formation of macromolecular complexes.354 It is commonly 
accepted that fully conserved amino acid residues are related to functional features 
common to all family members, whereas positions that are differentially conserved 
within subfamilies reflect on functional specificity.354 
The family of UDP-GlcNAc 4,6-dehydratases can be further divided into two 
subfamilies, one consisting of short soluble enzymes, and the other of large 
membrane proteins.280 Besides size and cellular localization, the two protein 
subfamilies seem to differ in function (see section 3.1). Based on in silico predictions 
and genetic experiments, S. aureus CapD was grouped into the subfamily of large, 
membrane-bound proteins and predicted to function as 5-retaining 
4,6-dehydratase.77,329,355 The results obtained in this thesis provide biochemical 
evidence for this prediction. Reconstituted CapD converted UDP-GlcNAc to a 
carbohydrate species with a molecular mass of 589.4, consistent with the formation 
of UDP-Sugp (FIGURE 10 + FIGURE 11). Taking into account the genetic evidence, 
and the knowledge gained from biochemical studies on homologous 
4,6-dehydratases, it seems highly likely that the CapD reaction product is indeed 
UDP-Sugp.237,281,283,284,287,329 However, further experiments should be performed for 
structure elucidation.  
Antisense-mediated depletion of CapD was shown to abolish capsule production in 
S. aureus.355 Similarly, a naturally occurring mutation in the capE gene of S. aureus 
HG001, leading to an M to R substitution in the active site, renders the strain CP-
negative.207,356 capE provided in trans restored CP expression in HG001.355 Since 
S. aureus strains defective in CapD or CapE expression are viable, these enzymes 
are not expected to represent suitable targets for monotherapeutic antibiotic 
intervention. However, inhibition of CapD or CapE resulting in full repression of 
capsule biosynthesis might support immune clearance. Thus, compounds targeting 
these enzymatic steps may have the potential for use as anti-virulence drugs (e.g. for 
surgical prophylaxis357).  
The enzyme CapD consists of 4 transmembrane domains (aa 1–130), a linker region 
(aa 131–281), and a C-terminal catalytic domain (aa 282–611) (FIGURE 6). The 
biological relevance of the membrane domains is still elusive. It has been 
demonstrated with soluble variants (i.e. variants lacking transmembrane domains) of 
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C. jejuni PglF and P. aeruginosa WbpM, that the cytoplasmic C-terminal domain is 
sufficient for catalytic activity in vitro.237,281 Expression of the WbpM catalytic domain 
from a recombinant plasmid restored LPS production in a wbpM knock-out mutant. 
However, the complemented strain failed to produce high-molecular-weight B-band 
LPS, suggesting that the WbpM membrane domains are crucial for high-level 
O antigen polymerization in vivo.281 The membrane localization of CapD is especially 
intriguing since substrate and product of this enzyme are water-soluble and reside in 
the cytoplasm. In contrast to CapD and homologs from other pathogens, the vast 
majority of enzymes synthesizing nucleotide-activated sugar precursors (for diverse 
biosynthetic pathways) are located in the cytoplasm. For instance, all other enzymes 
involved in the synthesis of soluble CP precursors in S. aureus are devoid of 
membrane-spanning domains (as predicted with TMHMM 2.0, see 2.5.1). Assembly 
of capsule building blocks involves the transfer of activated sugar monomers to the 
membrane lipid C55P.
122 As revealed by in vitro assays using a truncated mutant 
protein, the transmembrane domains of CapD are not required for catalytic activity 
per se (see section 3.5). Thus, it seems possible that CapD acts as a docking station, 
recruiting proteins of the CP biosynthetic machinery to the cytoplasmic membrane, 
bringing them in close vicinity to the membrane-bound acceptor C55P. Moreover, the 
membrane-spanning domains may be required for the modulation of CapD enzymatic 
activity (see also 4.6). Changes in the membrane lipid composition during cell 
growth, such as an increase of cardiolipin,358 might influence CapD activity. For 
several membrane proteins, it has been shown that protein–lipid interactions are 
crucial for in vitro or in vivo enzymatic activity, as they may affect correct insertion, 
folding, and topology.359–361  
The large membrane-bound dehydratases predominantly harbor an altered catalytic 
tetrad, in which the conserved tyrosine is replaced by a methionine, while the short 
soluble proteins contain NTMK and NTYK tetrads in roughly equal portions.362 
Furthermore, a few enzymes seem to contain a NTLK tetrad (FIGURE 22). The 
reason for the emergence of the unusual methionine-based active site, found in 
CapD as well as in CapE, is still unclear. It has been suggested that its catalytic 
inertness at physiological pH (in comparison to tyrosine-based active sites) may 
represent a way to regulate the conversion of the essential cell wall precursor UDP-
GlcNAc.362,363 
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FIGURE 22. Three variations of the extended SDR family catalytic tetrad are found within UDP-
GlcNAc 4,6-dehydratases. The soluble enzymes (A) contain NTYK (canonical) and NTMK tetrads in 
roughly equal portions, while most membrane-bound dehydratases (B) contain a NTMK active site. A 
NTLK tetrad is found in a few proteins. Protein sequences were aligned using COBALT; active site 
residues are highlighted in yellow. GenBank accession numbers are as follows: Staphylococcus 
aureus CapD, BAF66370.1, CapE, BAF66371.1; Helicobacter pylori FlaA1, O25511.1; Pseudomonas 
aeruginosa WbjB, AAD45265.1, WbpM, AAD45269.1; Vibrio cholerae WbvB, AAM22595.1; 
Campylobacter jejuni PglF, AAD51388.1, PseB, ADT73107.1; Francisella tularensis WbtA, 
AAS60264.1; Rhizobium etli LpsB2, ABC93046.1; Xylella fastidiosa CapDXyl, EWG15203.1. SDR, 
short-chain dehydrogenase/reductase. 
The kinetic data presented here clearly support this hypothesis (FIGURE 17). CapE 
was found to exhibit similar kinetic characteristics as a FlaA1 mutant protein 
containing an altered methionine-based active site (Km FlaA1 Y141M: 565 ± 6 µM; Km 
CapE: 457 ± 76 µM).363 The enzyme kinetics of full-length CapD (Km at pH 7: 
3.65 ± 0.27 mM) resemble those reported for a truncated WbpM mutant protein (Km 
at pH 10: 2.77 ± 0.007 mM).281 As revealed by crystallographic studies, FlaA1 and 
CapE protomers self-assemble to form “doughnut-shaped” hexamers in 
solution.228,282 This oligomerization is thought to be crucial for “fine-tuning” of the 
active site conformation and for cofactor-binding.234,363 Consistent with this 
hypothesis, a FlaA1 mutant defective in oligomer formation was found to be devoid of 
catalytic activity.363 To date, there is no crystal structure of a membrane-bound UDP-
GlcNAc 4,6-dehydratase. However, it is well conceivable that oligomerization of 
CapD and other large homologs may proceed in a different manner, and via different 
residues.362 Furthermore, it could be speculated that different modes of oligomer 
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formation may account for the differences in enzyme kinetics observed between 
soluble and membrane-bound enzymes. 
The observations made in this thesis regarding cofactor requirements for CapD and 
CapE catalytic activity (FIGURE 16), as well as the published results of others, 
suggest that different modes of cofactor-binding exist among UDP-GlcNAc 
4,6-dehydratases. Some recombinantly expressed enzymes (e.g. CapE) are purified 
with tightly bound nicotinamide cofactor, and thus do not depend on the addition of 
exogenous cofactor for activity,228,237,280 while other proteins (e.g. CapD) require 
exogenous NAD(P)+ for catalytic activity.207,281 These different modes of cofactor 
binding have been attributed to differentially conserved residues within the cofactor-
binding site.282,362 Within a given constellation of side chains, a single residue can 
have a significant impact on the selectivity and avidity of an enzyme for a given 
cofactor.364–366 For instance, wild-type glucose–fructose oxidoreductase from 
Zymomonas mobilis contains tightly bound NADP+ as non-dissociable redox cofactor 
reacting in a “ping-pong type” mechanism; a single amino acid exchange is sufficient 
to generate an active mutant protein utilizing dissociable NAD(P)+ as cosubstrate and 
displaying a sequential reaction type.364 Ishiyama et al. reported that the soluble 
UDP-GlcNAc dehydratase FlaA1 contains several positively charged amino acid 
residues that associate with the 2ʹ-phosphate group of NADP(H), while these 
interactions seem to be absent in the case of the large homolog WbpM.362 As 
revealed by multiple sequence alignments, the respective residues are present in 
CapE, but absent in CapD (FIGURE 23).  
 
FIGURE 23. Alignment of UDP-GlcNAc 4,6-dehydratase protein sequences showing the region 
around the TGXXGXXG nucleotide-binding site (red). The cationic residues R44, D45 and K48 of 
Helicobacter pylori FlaA1 (yellow highlights) have been implied in tight binding of the nucleotide 
cofactor. Sequences were aligned using COBALT; their GenBank accession numbers are as follows: 
Staphylococcus aureus CapD, BAF66370.1, CapE, BAF66371.1; H. pylori FlaA1, O25511.1; 
Pseudomonas aeruginosa WbjB, AAD45265.1, WbpM, AAD45269.1. 
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However, the activity of recombinant WbjB has been found to depend on the addition 
of NADP+,207 though this protein contains the residues identified by Ishiyama et al. 
(FIGURE 23). Thus, in the WbjB protein background, other amino acid residues 
might play a decisive role in determining cofactor specificity. In contrast to WbjB, 
CapE was inhibited in the presence of 1 mM NADP+ (FIGURE 16). One possible 
explanation for this finding is that NADP+ acts as competitor of NADPH-binding, and 
that the concluding reduction step within CapE catalysis is inhibited when the 
oxidized form of the nicotinamide cofactor is present in excess (compare references 
282,285,367). Similarly, CapE enzymatic activity in vivo might be modulated by the 
cellular NADP+/NADPH ratio.367 Since the coenzyme moiety is not observed in the 
structure of CapE in complex with substrate analog,228 it is also conceivable that the 
inhibition in the presence of NADP+ is due to interference with substrate binding.  
4.3 Sugp 4-keto reductases—a novel protein family 
Phylogenomic inference of protein molecular function is a multistep process involving 
selection of homologs, multiple sequence alignment, and phylogenetic tree 
construction, overlaying annotations on the tree topology, discriminating between 
orthologs and paralogs, and, finally, inferring the function of a protein based on the 
orthologs identified by this process and the annotations retrieved (for reviews, see 
references 368,369). Phylogenomic analysis is thought to be more accurate than 
function prediction based on mere sequence homology.369,370 This is especially true 
for SDR enzymes, for which pairwise-sequence identities are generally low, 
rendering homology-based function predictions difficult.219,222 Here, phylogenetic 
trees were used to assess orthology among homologs of S. aureus CapN, leading to 
the identification of the novel protein family of “Sugp 4-keto reductases” (FIGURE 7).  
The members of the newly defined protein family likely catalyze stereospecific 
reduction of UDP-Sugp, to form either UDP-D-QuiNAc or UDP-D-FucNAc 
(alternatively, they might catalyze the reduction of lipid-bound Sugp; see FIGURE 
24). Notably, a similar cluster of proteins with “unknown function” was identified in a 
phylogenetic analysis of gammaproteobacterial UDP-hexose 4-epimerase protein 
families conducted by Cunneen et al.265 The results of Cunneen et al., along with the 
data presented in section 3.2, suggest a close relationship between Sugp 4-keto 
reductases and UDP-hexose 4-epimerases. UDP-hexose 4-epimerases, such as 
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E. coli GalE, utilize NAD+ to alter the configuration of the chiral C4 atom of the 
saccharide moiety by transient oxidation–reduction, which involves the formation of a 
transient 4-keto intermediate equivalent to UDP-Sugp.371 Sugp 4-keto reductases 
may have evolved from UDP-hexose 4-epimerase proteins by sequence changes 
stabilizing the conformational shape adopted during the transition state.  
The assumption that the proteins identified in the phylogenetic analysis function as 
Sugp reductases is strengthened by the genomic context analysis, which revealed 
co-occurrence (in all cases exept one) and genomic association of membrane-bound 
UDP-GlcNAc 4,6-dehydratases, alleged Sugp 4-keto reductases, and two different 
types of glycosyltransferases (CapM- or WbpL-like; FIGURE 8), suggesting 
functional, as well as physical interactions between these proteins.324–326 The 
arrangement of these genes (i.e. relative order and orientation) in potential operon 
structures was relatively well preserved within bacterial phyla. Gene order 
conservation could be due to any of the three following reasons: first, the species 
have diverged only recently and gene order has not yet been destroyed; second, 
there has been lateral gene transfer of a block of genes; and third, the integrity of the 
cluster is important to the fitness of the cell, and thus selectable.372 Gene pairing was 
most obvious in the case of reductases and glycosyltransferases, which were 
encoded by directly adjacent genes in ~90% of analyzed genomes. The exclusive 
coding patterns of the capM and wbpL homologs provide an example of non-
orthologous gene displacement;373 the encoded glycosyltransferases, though they 
are non-orthologous, are supposed to perform analogous functions as priming 
N-acetyl-D-hexosamine-1-phosphate transferases. 
Having said that, the question arises: why have bacteria evolved two types of 
glycosyltransferases that are, at first glance, functionally redundant? A full description 
of a protein's function ideally requires knowledge of all partner proteins with which it 
specifically associates, in a direct way, by physical interactions, as well as in an 
indirect way, e.g. through participation in the same metabolic pathway.374 Intriguingly, 
the BY-kinase proteins CapB1 (high confidence, score: 0.84) and CapB2 (medium 
confidence, score: 0.572) were identified as functional partner of CapM based on 
co-occurrence and gene neighborhood in different genomes (www.string-db.org).275 
No such association was reported using the P. aeruginosa WbpL protein sequence 
as input for STRING, suggesting that the presence of different glycosyltransferase 
types reflects differences in the regulation of polysaccharide production. 
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4.4 In vitro enzymatic synthesis of UDP-D-FucNAc 
The epimeric dideoxy sugars D-QuiNac and D-FucNAc (for structures, see FIGURE 
5) are present in various polysaccharides important for bacterial virulence (see 
Results, section 3.2), but are absent from human glycans. Thus, their biosynthetic 
pathways might serve as targets for antibacterial drug action. Furthermore, 
oligosaccharide antigens containing these amino sugars may be interesting 
candidates for vaccine development.375 Only recently, the synthesis of UDP-D-
QuiNAc has been reconstituted in vitro using a purified recombinant version of the 
enzyme WreQ of R. etli for reduction of the key intermediate UDP-Sugp.288 In the 
present study, in vitro enzymatic synthesis of UDP-D-FucNAc was achieved for the 
first time, by functional reconstitution of the Sugp 4-keto reductase CapN from 
S. aureus serotype 5. 
Recombinantly expressed CapN resided in the membrane fraction and could be 
purified by nickel chelation chromatography after extraction with Triton X-100 
(FIGURE 9). Subsequent removal of the detergent by dialysis resulted in precipitation 
of the protein. Similar observations have been reported for recombinant WreQ.288 
One possible explanation is that CapN and homologous proteins are membrane-
associated, and that the interactions with the lipid bilayer are crucial for the 
conformational stability of these proteins.288 Moreover, heterocomplex formation with 
partner proteins (e.g. glycosyltransferases) may be required for protein stability.376 
Corroborating the in silico predictions, purified serotype 5 CapN protein catalyzed 
NADPH-dependent reduction of UDP-Sugp, producing a nucleotide sugar species 
with a molecular mass of 591.5 (FIGURE 12 + FIGURE 13), consistent with the 
formation of UDP-D-FucNAc. Since the composition of S. aureus CP5 is known,204,205 
and because previous biochemical studies have elucidated the biosynthetic routes 
leading to the synthesis of the other soluble capsule precursors, UDP-L-FucNAc and 
UDP-D-ManNAc,38,207,208,286 it can be concluded that the reaction product is UDP-D-
FucNAc.  
The pathways for the biosynthesis of D-FucNAc and D-QuiNAc have been subject of 
a debate, lately. P. aeruginosa O5 strains have D-FucNAc at the reducing terminus of 
their O antigen,310 while serotype O6 strains have D-QuiNAc at the same position.309 
Nevertheless, wbpLO5 is able to complement the loss of wbpL in serotype O6.
292 This 
has been attributed to donor substrate promiscuity of WbpL.292 Similarly, a lack of 
selectivity in CapM-like glycosyltransferases might represent an explanation for the 
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incorporation of Sugp instead of D-QuiNAc seen in the R. etli mutant strain CE166.377 
However, it is also possible that WbpL and CapM are specific for the donor substrate 
UDP-Sugp, and that the reduction step in D-QuiNAc/D-FucNAc biosynthesis occurs 
after transfer of Sugp to C55P (FIGURE 24B).
287 This would allow the 
glycosyltransferases to be selective, yet still provide a mechanism by which different 
amino sugars may be incorporated at the first position of the repeating unit. 
Furthermore, this would represent a very economical way for enlarging the diversity 
of O antigen structures and for phase variation. Notably, a close resemblance 
between Sugp 4-keto reductases and C55PP-GlcNAc epimerases was noted in this 
study, as well as by others.265,290 C55PP-Sugp being the natural substrate forSugp 4-
keto reductases might also explain the low catalytic efficiency for reduction of UDP-
Sugp observed with WreQ,288 as well as with CapN. 
 
FIGURE 24. Alternative pathways for the biosynthesis of UDP-D-FucNAc in S. aureus. The integral 
membrane protein CapD is a 4,6-dehydratase, that generates the intermediate UDP-Sugp (UDP-2-
acetamido-2,6-dideoxy-D-xylo-4-hexulose) by eliminating a water molecule from UDP-D-GlcNAc. In the 
first scenario (A), this intermediate is further converted to UDP-D-FucNAc by the action of the 4-keto 
reductase CapN. Subsequently, the glycosyltransferase CapM transfers the N-acetyl-D-fucosamine 
moiety of UDP-D-FucNAc to the membrane-anchored lipid carrier bactoprenol (C55P), yielding lipid Icap. 
In the second scenario (B), the reduction step occurs after transfer of Sugp to C55P. 
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4.5 The approved pharmaceutical suramin is a potent inhibitor of 
CapE 
Establishment of a robust, validated test system allowed for inhibitor screening of 
UDP-GlcNAc 4,6-dehydratases. The developed CE method (see “Materials and 
methods”) enabled quantitation of the enzymatic reaction products with a low 
detection limit such that substrate concentrations around the Km value of the 
enzymes (see FIGURE 16) could be employed for inhibitor testing.378 Suramin, a 
pharmaceutical used for the treatment of onchocerciasis and trypanosome infections 
(for reviews, see references 339,379,380), showed selective inhibition of CapE with an 
IC50 value of 1.82 µM tested at a substrate concentration of 1 mM (FIGURE 18A). It 
acted as a non-competitive inhibitor with respect to the substrate UDP-D-GlcNAc 
(FIGURE 19A). 
Suramin (Germanin™; manufactured by Bayer) was introduced in the early 1920s, 
and to this day remains the drug of choice for treatment of the early phase of 
Trypanosoma brucei rhodesiense infections.381,382 Notably, no significant clinical 
resistance to suramin has emerged despite almost 100 years of use as trypanocidal 
agent.380 Suramin is a symmetrical naphthylamine derivative of urea carrying six 
sulfonate groups, which are negatively charged at physiological pH (FIGURE 18). By 
virtue of its polyanionic nature, suramin can form tight complexes with various protein 
targets, resulting in a broad range of biological activities (e.g. immunomodulatory, 
antiproliferative, antiangiogenic, antineoplastic, contraceptive, anthelmintic, 
antiprotozoal, antibacterial, and antiviral activities339,379,380,383–385). It is thus 
considered a “dirty drug”.386 Several enzymes from microbial pathogens are inhibited 
by suramin in vitro, for instance the Mycobacterium tuberculosis DNA repair protein 
RecA,387 HIV-1 reverse transcriptase,388 and various glycolytic enzymes from 
T. brucei.389 
Although suramin binds to a variety of proteins, it can also discriminate between 
closely related members of the same protein family, suggesting the existence of 
rather specific docking sites.390 For instance, suramin is a potent inhibitor of human 
elastase, neutrophil protease 3, and cathepsin G, but has only little or no inhibitory 
activity towards pancreatic trypsin and chymotrypsin.391 Differential inhibition of 
proteins from different UDP-GlcNAc 4,6-dehydratase subfamilies was observed in 
this thesis. Due to its relatively high potency and selectivity for CapE compared to 
CapD, suramin may be a useful tool for studying capsule biosynthetic enzymes. 
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Suramin is a non-aggregator (i.e. it does not inhibit its targets in an unspecific 
manner by formation of self-aggregates), and its inhibitory activity was, at least in one 
case, shown to be insensitive to the presence of Triton X-100 and bovine serum 
albumin.392,393 Thus, it seems unlikely that differences in inhibitor binding are caused 
by the detergents used for purification and reconstitution of full-length CapD. 
However, further UDP-GlcNAc dehydratases should be assayed for inhibition to 
evaluate the discriminatory capacity of suramin. The evaluation of suramin 
derivatives may yield even more potent inhibitors. 
 
FIGURE 25: Space-filling representation of the three-dimensional structure of the hexameric CapE 
holoenzyme in top view (left) and side view (right). The structural model was created using NCBI's 
interactive 3D structure viewer Cn3D, and is based on the crystal structure published by Miyafusa et 
al.
228
 The holoenzyme is shown with bound cofactor NADP
+
; the cofactor molecules are depicted as 
Corey-Pauling-Koltun (CPK) models. The six CapE protomers are colored differently, and labeled E1 
through E6. Within the cofactor-binding domain of E1 (pink protomer), the region comprising amino 
acids 22–55 is highlighted in yellow. This sequence stretch is rich in basic residues (K, R) and 
contains a heparin-binding motif, which might represent a docking site for the CapE inhibitor suramin. 
The respective amino acid sequence is given at the bottom of the left panel; the heparin-binding motif 
is denoted by stars.  
Suramin is structurally similar to heparin and acts as a competitor of 
glycosaminoglycan binding.394 The ability of suramin to bind to heparin-binding 
growth factors was shown to depend on the correct spatial alignment between 
sulfonate groups on the terminal naphthalene rings and basic amino acid residues 
(especially K and R) on the surface of the target protein, in a manner similar to that 
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found for heparin–antithrombin III interactions.395–397 The cofactor-binding domain of 
CapE harbors a region rich in basic amino acids (residues 22–55; FIGURE 25), 
which contains a motif consistent with a heparin-binding site398 (K40KXXXXRKK). 
This motif might represent a docking site for the heparin analog suramin. According 
to the crystal structure published by Miyafusa et al.,228 the respective residues are 
located on the outer surface of the CapE hexamer, in a cleft formed between two 
contiguous CapE monomers (FIGURE 25). Since K41 is part of the NADP+-binding 
pocket,228 binding of suramin to this residue might result in displacement of the 
cofactor. In good agreement with this hypothesis, a different mode of cofactor binding 
was observed for CapD and CapE (FIGURE 16). As revealed by aligning the amino 
acid sequences of CapE and CapD, the latter protein lacks an equivalent motif (data 
not shown).  
Suramin has been shown to penetrate into eukaryotic cells by an active transport  
mechanism and can even cross the blood-brain barrier.399,400 It is thought to adsorp 
to cell membranes by the sulfonate groups interacting with positively charged 
membrane moieties (e.g. phosphatidylcholine), and by the internaphthalene bridge 
hydrophobically interacting with the acyl chains.399 Suramin is likely internalized by a 
combination of pinocytosis and adsorptive endocytosis, with the 
endosomal/lysosomal compartment as endpoint.399 However, its large molecular size 
(Mr 1429) and high negative net charge impair gastrointestinal absorption, and thus 
peroral bioavailability.401 Two close analogs of suramin, trypan blue (Mr 961) and 
trypan red (Mr 1003), are routinely used as so-called vital stains, because they 
cannot cross the intact cytoplasmic membrane of viable cells.402,403 Similarly, suramin 
is likely not able to passively diffuse across the highly polarized (interior negative), 
highly anionic (i.e. high content of anionic phospholipids in the outer leaflet) 
cytoplasmic membrane of S. aureus.404,405 Nevertheless, whole-cell effects have 
been reported for Firmicutes species: inhibition of β-lactam-mediated cell lysis by 
suramin was shown in S. aureus,406 and impairment of cell division, combined with 
altered “rough” cell surface properties, was observed in E. faecalis upon exposure to 
the compound.407 The mode of action that underlies these effects remains elusive. It 
has been suggested, that suramin interferes with the function of bacterial autolysins, 
though there are no indications of a direct inhibitory effect on such cell wall-degrading 
enzymes.408 The observed phenotypical changes may be related to binding of 
suramin to transmembrane protein kinases, such as PknB,409 or WalK.410  
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Although suramin has been extensively used to treat parasitic infectious diseases, it 
is not an ideal drug. Therapy requires intravenous administration in a clinical setting 
(www.who.int). Serum level monitoring is mandatory, since the drug has a narrow 
therapeutic window and can cause serious toxicities, including coagulopathy, adrenal 
necrosis, and motor neuropathy (Guillain-Barré-like syndrome).411,412 Clinical 
pharmacokinetic studies have demonstrated that suramin is highly (> 99.7%) bound 
to plasma proteins and stays in the body for a considerable period of time (terminal 
half-life of ~50 days).413 Due to its high toxicity and unfavourable pharmacokinetics, 
suramin has only limited potential for use in antibacterial chemotherapy. Moreover, 
the immunosuppressant activities of suramin may impair bacterial clearance by the 
human immune system.385,414,415  
4.6 A novel mechanism for regulation of capsule biosynthesis  
In CapD inhibition studies, we identified the β-lactam antibiotic ampicillin as an 
inhibitor of CapD (IC50 40.1 µM) showing a non-competitive mechanism of enzyme 
inhibition (FIGURE 18B + FIGURE 19B). Dicloxacillin was similarly potent as 
ampicillin in the screening assay (see SUPPLEMENTARY TABLE 1), while all other 
investigated β-lactams did not show any significant inhibition at a test concentration 
of 10 µM. Ampicillin is a perorally bioavailable drug, able to penetrate eukaryotic lipid 
bilayers. Ampicillin also appears to cross the staphylococcal cell membrane (see 
below). The inhibitory concentration of ampicillin at CapD is not much higher than 
typically observed therapeutic drug levels.416  
The fact that the C55P carrier is only present in limited amounts within the bacterial 
cell,119 and is required for the biosynthesis of diverse cell envelope components, 
such as CP, WTA and PG,120,122,124 makes a well-orchestrated spatial and temporal 
regulation of these processes crucial for viability. In S. aureus, CP biosynthesis 
occurs predominantly in the late-exponential and post-exponential growth phase.211 
Post-translational control of S. aureus capsule expression is exerted by the bacterial 
tyrosine (BY-)kinase complex CapAB.161 It has been reported that the synthesis of 
UDP-D-ManNAcA is regulated by CapAB-mediated tyrosine phosphorylation of the 
dehydrogenase CapO.216 Moreover, the present thesis identifies the dehydratase 
CapE, involved in the synthesis of UDP-L-FucNAc, as regulatory target of the CapAB 
complex. In contrast, no CapAB protein target could be identified among the 
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enzymes of the UDP-D-FucNAc biosynthesis pathway; neither CapD, nor CapN was 
phosphorylated by CapAB in vitro (see section 3.8). 
As revealed by in vitro inhibition studies, CapD catalytic activity is inhibited in the 
presence of the PG pentapeptide side chain (FIGURE 18C) and of the PG precursor 
lipid II (SUPPLEMENTARY TABLE 1). The findings that ampicillin (FIGURE 18B) and 
the structurally analogous D-Ala-D-Ala dipeptide (SUPPLEMENTARY TABLE 1) 
inhibit CapD activity suggest that the C-terminal end of the pentapeptide side chain 
may represent the minimal structure required for inhibition.  
 
FIGURE 26. ELISA inhibition experiment showing that capsular polysaccharide production by the 
serotype 5 strain Staphylococcus aureus Reynolds is inhibited when the culture is incubated in the 
presence of ampicillin (Amp). The binding ratio was calculated by comparing the OD405 nm of the serum 
samples incubated with different bacterial concentrations to that of the serum sample containing no 
bacteria. For quantitation, the 50% inhibitory bacterial concentration was compared between cultures 
grown in the presence or absence of ampicillin. CFU, colony-forming units; OD405 nm, optical density at 
a wavelength of 405 nm. 
 
Corroborating the in vitro findings, staphylococcal cells grown in the presence of 
subinhibitory concentrations of ampicillin displayed drastically reduced CP 
production, suggesting an integrated mechanism of regulation for cell envelope 
biosynthesis pathways in S. aureus that controls the coordinated assembly of vital 
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cell wall polymers in time and space (results from the laboratory of Prof Jean C. Lee, 
Brigham & Women's Hospital/Harvard Medical School, Boston, USA; FIGURE 26). 
Effects of β-lactam antibiotics on capsule expression have been described in other 
studies. For instance, De Hennezel et al. reported that non-capsular antibodies were 
protective in a mouse-model of pneumococcal pneumonia when combined with 
subcurative doses of ampicillin.418 Since non-capsular antibodies are not promoting 
phagocytic clearance in the presence of a capsule,44 this points to ampicillin-induced 
reduction of CP production. It should be noted that the alleged capacity of ampicillin 
to penetrate into staphylococcal cells has not been experimentally proven, and that 
other mechanisms than inhibition of CapD are conceivable for the observed 
phenomenon, for instance direct or indirect modulatory effects of ampicillin on the 
activity of bacterial “receptor kinases”, such as CapAB and PknB.161,409  
Taken together, the results of the present study strongly indicate that synchronization 
of CP and PG biosynthesis in S. aureus is, besides its regulation by transcription 
factors143,213,214 and tyrosine kinases,161,216 facilitated through kinetic modulation of 
CapD activity by peptidoglycan precursors. Moreover, the inhibitory effect of 
ampicillin on capsule production observed in whole cells might be of clinical 
relevance, and raises the possibility of additional target sites for β-lactam antibiotics. 
4.7 Enzymatic checkpoints within capsule biosynthesis are 
controlled by the tyrosine kinase complex CapAB 
Protein phosphorylation is one of the most common modes of regulation of protein 
function in both prokaryotes and eukaryotes.341 Several biosynthetic enzymes 
involved in polysaccharide production have been identified as endogenous 
substrates of bacterial tyrosine kinases (see section 1.6), for example the 
UDP-glucose 6-dehydrogenases TuaA and YwqF of Bacillus subtilis,149 the 
homologous E. coli dehydrogenase Ugd,175 and the UDP-ManNAc dehydrogenase 
CapO involved in S. aureus capsule biosynthesis.216 
The fact that CapO (FIGURE 4), is a regulatory target of the CapAB kinase 
complex216,218 led us to assume that earlier checkpoints within the biosynthetic 
pathway are also controlled by CapAB. As deduced from kinase assays, the 
dehydratase CapE is an endogenous protein substrate of CapAB (FIGURE 20), and 
phosphorylation of CapE results in enhanced conversion of the precursor 
UDP-D-GlcNAc in vitro (FIGURE 21B).  
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The identification of phosphorylation sites revealed phosphotransfer to four tyrosine 
residues, with Tyr76, Tyr290, and Tyr293 being widely conserved among 
homologous proteins from different pathogens (FIGURE 21A). Interestingly, these 
residues are located in strategic functional regions of CapE, i.e. next to the cofactor 
binding site, in close proximity to the active site, and within a recently described 
mobile loop (FIGURE 27A). Crystal structure analysis identified this mobile “latch” to 
connect two CapE protomers within the hexameric complex, and showed that the 
latch of one dimerization partner is associated with the substrate-binding domain of 
the contiguous CapE monomer (FIGURE 27B), suggesting that this mobile loop is 
involved in regulating the access of the substrate UDP-GlcNAc to the active site.228 
Since contacts to Tyr290 and Tyr293 appear to be involved in the interaction, 
phosphorylation might induce conformational changes that facilitate access of 
UDP-GlcNAc, increasing CapE enzymatic activity.  
 
FIGURE 27. Structure of CapE monomer bound to substrate analog UDP-6N3-GlcNAc (A; adapted 
from Miyafusa et al.
228
). The coenzyme-binding domain, substrate-binding domain, and a mobile loop 
(“latch”) are colored in blue, yellow, and orange, respectively. The potential regulatory phosphorylation 
sites Tyr290 and Tyr293 are indicated by stars. (B) Worm representation of two contiguous subunits 
within the hexameric CapE complex, created using NCBI's 3D structure viewer Cn3D. The two 
protomers are connected via their mobile latches (highlighted in yellow in each subunit) making 
contacts with the substrate-binding domain of the dimerization partner. 
Two couples of adjacent genes encoding for a transmembrane adaptor and a 
cytoplasmic BY-kinase were identified in the genome of S. aureus serotype 5: the 
capA1/capB1 couple located at the 5ʹ-end of the cap operon, and the highly similar 
capA2/capB2 triplet, which is located elsewhere on the bacterial chromosome, and 
probably arose from gene duplication.161,206 The in vitro assays presented here were 
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performed with the tyrosine kinase CapB2, since attempts to reconstitute CapB1 
autokinase activity have failed so far.161,233 However, a recent biochemical study 
indicates that BY-kinases have evolved rather relaxed substrate specificities; despite 
originating from phylogenetically distant bacteria, six out of seven tested BY-kinases 
(S. aureus CapB2, S. pneumoniae CpsD, B. subtilis PtkA, as well as BY-kinases of 
Klebsiella pneumoniae, Acinetobacter baumanii, and Bifidobacterium animalis) were 
able to catalyze in vitro phosphorylation of protein substrates from B. subtilis (YwqF, 
YvyG, and YjoA).419 The authors suggested that BY-kinases maintain the capability 
to phosphorylate the same set of substrates across very distant bacterial phyla, since 
they recognize the overall structure of a target protein, and not a particular short 
sequence or phosphorylation site.419 With regard to these findings, it seems likely 
that CapB1 and CapB2 recognize largely overlapping spectra of substrates. 
Moreover, since potential phosphorylation sites are determined by the sequence 
properties of the target protein,420,421 CapB1 and CapB2 are expected to 
phosphorylate the same tyrosine residues in a given protein. Nevertheless, efforts to 
reconstitute CapB1 kinase activity are ongoing in our group. 
A recent study identified an exopolysaccharide of B. subtilis as quorum-sensing 
molecule modulating BY-kinase signaling by binding to the extracellular sensor 
domain of EpsA.422 In addition, it was demonstrated that the S. aureus 
exopolysaccharide PIA (polysaccharide intercellular adhesin) binds to CapA in 
vitro.422 The signal detected by CapA in vivo has not yet been identified, but it is 
tempting to speculate that the activator protein senses the presence or absence of 
membrane-bound cell envelope precursors, such as lipid IIIcap, resulting in regulation 
of enzymatic checkpoints that ensures the sufficient supply of precursors for CP 
polymerization. Moreover, CapAB might be required for correct localization and 
assembly of the capsule biosynthetic machinery.  
4.8 Future directions 
In the present study, in vitro enzymatic synthesis of the nucleotide-activated dideoxy 
sugar precursor UDP-N-acetyl-D-fucosamine was achieved for the first time. As 
revealed by CE and MS analysis, the purified recombinant enzymes CapD and CapN 
from Staphylococcus aureus serotype 5 converted the substrate UDP-D-GlcNAc into 
a sugar nucleotide species having a molecular mass of 591.5, consistent with the 
formation of UDP-D-FucNAc. Taking into account the genetic evidence and the 
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knowledge gained in studies on homologous enzymes,237,281,283,284,287,288,329 it seems 
highly likely that the enzymatic product generated by sequential action of the 
4,6-dehydratase CapD and the 4-keto reductase CapN is indeed UDP-D-FucNAc—
the first soluble precursor required for CP repeat unit assembly in S. aureus. 
However, NMR spectroscopy should be performed for structure elucidation, to 
unequivocally confirm the identity of the reaction product. 
Moreover, substrate specificity and preferences of the reductase CapN should be 
determined. In vitro, CapN is obviously capable of catalyzing reduction of the 
substrate UDP-Sugp, though with low catalytic efficiency. However, it is conceivable 
that in vivo the reduction step could occur after transfer of Sugp to C55P (see 
FIGURE 24). Preliminary results from our laboratory indicate that CapM may indeed 
accept UDP-Sugp as donor substrate, which provides the opportunity to test 
C55PP-Sugp as alternative substrate for CapN, in order to elucidate the exact 
biosynthetic route leading to the formation of D-FucNAc.  
If both D-FucNAc and Sugp may occupy the first position in the repeating unit, 
inactivation of Sugp 4-keto reductases such as CapN might represent a simple and 
economic mechanism for serotype switching or phase variation. Sugp is an extremely 
rare sugar, and has so far only been detected in a few bacterial 
polysaccharides.287,377,423–426 Sugp is present in the CP produced by S. pneumoniae 
type 5 strains,426 and the expression of a type 5 capsule has been linked with high 
virulence and invasiveness.427,428 Sugp is also found in the LPS outer core of the 
enteric pathogen Yersinia enterocolitica serotype O:3.287 The outer core 
hexasaccharide is required for full virulence, and plays a role in outer membrane 
integrity relevant in the resistance to polycations and hydrophobic agents.429 
Y. enterocolitica O:3 mutants lacking the LPS outer core, but expressing the 
O antigen, were more susceptible than the wild-type bacteria to polymyxin B, melittin, 
poly-L-lysine, and poly-L-ornithine.429 Interestingly, substitution of the outer core Sugp 
residue by D-QuiNAc or D-FucNAc (by providing wbpV or wbpK in trans) was 
reported to enhance resistance against the phage tail-like bacteriocin 
enterocoliticin.287 In this context, it would be interesting to analyze capsule production 
in a capN knockout mutant of S. aureus and, in case formation of CP occurs, to 
analyze the virulence properties of the mutant strain, as well as its susceptibility to 
antimicrobial peptides.  
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The finding that selected β-lactam antibiotics as well as structurally similar 
peptidoglycan precursors inhibit CapD enzymatic activity in vitro suggests an 
integrated mechanism of regulation for cell envelope biosynthesis pathways. 
Construction of non-binding mutants of CapD by site-directed mutagenesis and 
expression of these mutant proteins in a capD negative background may allow for 
conclusions about the in vivo relevance of the observed inhibitory effect of PG 
precursors on CapD catalytic activity. First of all, this requires mapping of the 
inhibitor-binding sites on CapD, ideally by crystallographic studies.  
The present study provides evidence that the dehydratase CapE, which initiates the 
synthesis of the second soluble capsule precursor UDP-L-FucNAc, is a regulatory 
target of the CapAB tyrosine kinase complex. As assessed by CE quantification of 
the CapE enzymatic product, CapE catalytic activity in vitro was markedly enhanced 
in the presence of the reconsituted CapAB complex. In depth biochemical 
characterization revealed phosphotransfer onto four tyrosine residues, suggesting 
that CapE is positively modulated by CapAB-mediated phosphorylation. Site-directed 
mutagenesis studies are currently performed in our laboratory, to confirm the role of 
the four tyrosine residues as regulatory phosphorylation sites of CapE.  
Two couples of adjacent genes encoding for a transmembrane adaptor and a 
cytoplasmic BY-kinase were identified in the genome of S. aureus serotype 5: the 
capA1/capB1 gene couple located at the 5ʹ-end of the cap operon, and the highly 
similar capA2/capB2 couple, which is located elsewhere on the bacterial 
chromosome, and probably arose from gene duplication.161,206Since attempts to 
reconstitute CapB1 autokinase activity have failed so far, biochemical assays were 
performed with the homologous tyrosine kinase CapB2. There is, as yet, no in vivo 
experimental evidence supporting a regulatory role for the CapA2B2 complex in 
S. aureus capsule biosynthesis. No differences in the amount of cell wall-attached 
CP were observed with capA2 and capB2 knock-out mutant strains (Prof Jean C. 
Lee, unpublished results). However, at least in vitro, CapB1 and CapB2 are expected 
to recognize largely overlapping spectra of substrates (compare Shi et al.419). 
Moreover, since potential phosphorylation sites are determined by the sequence 
properties of the target protein,420,421 CapB1 and CapB2 are expected to 
phosphorylate the same tyrosine residues in a given protein. Nevertheless, efforts to 
reconstitute CapB1 kinase activity are ongoing in our group. 
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6 Supporting information 
SUPPLEMENTARY TABLE 1 
Screening results 
Compound 
code/name 
(test concentration) 
Structure % Inhibition 
 
CapD CapE 
UDP/UTP derivatives and analogs 
Ali 179
a 
(100 µM) 
 
1% 
 
33% 
 
Ali 412C
a 
(100 µM) 
 
6% 
 
27% 
 
Ali 404B
a
 
(100 µM) 
 
7% 
 
33% 
 
Ali 411A
a 
(100 µM) 
 
15% 
 
35% 
 
Ali 409A
a 
(100 µM) 
 
4% 
 
22% 
 
Ali 149
a 
(100 µM) 
 
−18% 
 
18% 
 
Ali 452
a 
(100 µM) 
 
−4% 
 
25% 
 
UDP-glucose 
(100 µM)
a
 
 
13% 
 
17% 
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SUPPLEMENTARY TABLE 1 (continued) 
UDP
a 
(100 µM) 
 
15% 
 
22% 
 
UTP
a 
(100 µM) 
 
−4% 
 
20% 
 
anthraquinone derivatives 
YB001
a 
(10 µM) 
 
10% 
 
17% 
 
YB003
a 
(10 µM) 
 
2% 
 
18% 
 
YB005
a 
(10 µM) 
 
0% 
 
21% 
 
YB009
a 
(10 µM) 
 
25% 
 
15% 
 
YB010
b 
(10 µM) 
 
17% 
 
21% 
 
YB011
a 
(10 µM) 
 
25% 
 
7% 
 
YB012
a 
(10 µM) 
 
26% 
 
12% 
 
 
Supporting information 
 
123 
SUPPLEMENTARY TABLE 1 (continued) 
YB013
a 
(10 µM) 
 
24% 
 
9% 
 
YB014
a 
(10 µM) 
 
21% 
 
5% 
 
YB015
a 
(10 µM) 
 
10% 
 
7% 
 
YB016
b 
(10 µM) 
 
−1% 
 
7% 
 
YB017
b 
(10 µM) 
 
14% 
 
−1% 
 
YB019
a 
(10 µM) 
 
11% 
 
9% 
 
YB020
b 
(10 µM) 
 
34% 
 
15% 
 
YB024
a 
(10 µM) 
 
13% 
 
9% 
 
YB028
b 
(10 µM) 
 
29% 
 
19% 
 
YB029
a 
(10 µM) 
 
13% 
 
13% 
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SUPPLEMENTARY TABLE 1 (continued)   
YB031
a 
(10 µM) 
 
−4% 
 
5% 
 
YB032
b 
(10 µM) 
 
25% 
 
18% 
 
YB035
b 
(10 µM) 
 
32% 
 
18% 
 
YB038
a 
(10 µM) 
 
23% 
 
15% 
 
YB042
b 
(10 µM) 
 
0% 
 
12% 
 
YB047
a 
(10 µM) 
 
20% 
 
8% 
 
YB053
b 
(10 µM) 
 
33% 
 
7% 
 
YB055
a 
(10 µM) 
 
−10% 
 
−1% 
 
YB056
b 
(10 µM) 
 
27% 
 
4% 
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SUPPLEMENTARY TABLE 1 (continued)   
YB057
b 
(10 µM) 
 
 
32% 
 
13% 
 
YB058
b 
(10 µM) 
 
25% 
 
0% 
 
YB068
b 
(10 µM) 
 
17% 
 
12% 
 
YB083
b 
(10 µM) 
 
35% 
 
6% 
 
YB086
b 
(10 µM) 
 
25% 
 
9% 
 
YB087
b 
(10 µM) 
 
32% 
 
17% 
 
RB2
a 
(10 µM) 
 
17% 
 
15% 
 
β-lactam drugs 
ampicillin
b 
(10 µM) 
 
41% 
 
5% 
 
dicloxacillin
b 
(10 µM) 
 
44% 
 
6% 
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SUPPLEMENTARY TABLE 1 (continued)   
      amoxicillin
b 
        (10 µM) 
 
 
−3% 
 
n.d. 
cefixime
b 
(10 µM) 
 
3% 
 
n.d. 
cefotaxime sodium
b 
(10 µM) 
 
5% 
 
n.d. 
phenoxymethyl-
penicillinic acid
b 
(10 µM) 
 
−8% 
 
n.d. 
benzathine 
benzylpenicillin
b 
(10 µM) 
 
−3% 
 
n.d. 
flucloxacillin 
sodium
b 
(10 µM) 
 
−5% 
 
n.d. 
piperacillin
b 
(10 µM) 
 
−4% 
 
n.d. 
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SUPPLEMENTARY TABLE 1 (continued)   
pivampicillin
b
 
prodrug 
(10 µM) 
 
−1% 
 
n.d. 
sultamicillin
b
 
prodrug 
(10 µM) 
 
−6% 
 
n.d. 
sultamicillin 
tosylate
b
  
prodrug 
(10 µM) 
 
 
1% 
 
n.d. 
ticarcillin 
monosodium
b 
(10 µM) 
 
−8% 
 
n.d. 
bacampicillin 
hydrochloride
b
 
prodrug 
(10 µM) 
 
4% 
 
n.d. 
cloxacillin 
sodium
b 
(10 µM) 
 
0% 
 
n.d. 
penicillin G sodium 
salt
b 
(10 µM) 
 
−33% 
 
n.d. 
mecillinam
b 
(10 µM) 
 
−6% 
 
n.d. 
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aztreonam
b 
(10 µM) 
 
−11% 
 
n.d. 
cefuroxime sodium 
salt
b 
(10 µM) 
 
−12% 
 
n.d. 
ceftaroline fosamil
b 
(10 µM) 
 
9% 
 
n.d. 
oxacillin sodium
b 
(10 µM) 
 
16% 
 
n.d. 
ertapenem sodium 
salt
b 
(10 µM) 
 
1% 
 
n.d. 
meropenem 
trihydrate
b 
(10 µM) 
 
−26% 
 
n.d. 
potassium 
clavulanate
b 
(100 µM) 
 
−23% 
 
n.d. 
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bacterial metabolites 
peptidoglycan 
pentapetide
a
  
L-Ala-γ-D-Glu-L-
Lys-D-Ala-D-Ala 
(100 µM) 
 
51% 
 
n.d. 
lipid II
a 
(100 µM) 
 
67% 
 
n.d. 
UDP-D-MurNAc-
pentapeptide
a 
(100 µM) 
 
14% 
 
 
n.d. 
D-Ala-D-Ala
a 
(100 µM) 
 
26% 
 
n.d. 
N
α
,N
ε
-diacetyl-L-
Lys-D-Ala-D-Ala
a
 
(100 µM) 
 
28% 
 
n.d. 
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other compounds 
suramin
b 
(10 µM) 
 
−14% 
 
75% 
 
Note. Compounds were screened either at 10 µM or at 100 µM, depending on their water-solubility. 
Substrate (UDP-D-GlcNAc) concentration was 1 mM in all screening tests. Percent inhibition of 
CapD/CapE enzymatic activity at the screening concentration is provided; negative values indicate 
activation of enzymatic activity; n.d. = not determined. For potent inhibitors, full concentration–
inhibition curves were recorded, and IC50 values were determined (see main manuscript).  
a
compound screened in buffer without DMSO  
b
compound screened in buffer with 1% DMSO 
 
  
 
SUPPLEMENTARY TABLE 2 
Sequence set for phylogenetic analysis of the Sugp 4-keto reductase family 
Accession number Organism Source 
YP_001516388.1 Acaryochloris marina MBIC11017 OrtholugeDB 
AFA48881.1 Acetobacterium woodii DSM 1030 BLASTp search CapN 
YP_001235365.1
b
 Acidiphilium cryptum JF-5 OrtholugeDB 
EXS24708.1 Acinetobacter baumanii 573719 BLASTp search WbpK 
EGJ67248.1 A. baumanii 6014059 BLASTp search WbpK 
AGK44886.1 A. baumannii AB0057 OrtholugeDB 
AEA00564.1 Aerococcus urinae ACS-120-V-Col10a OrtholugeDB 
AEB50812.1 Aeromonas veronii B565 OrtholugeDB 
CAQ80715.1 Aliivibrio salmonicida LFI1238 OrtholugeDB 
YP_003239525.1
a
 Ammonifex degensii KC4 OrtholugeDB 
ACL67752.1 Anaeromyxobacter dehalogenans 2CP-1 OrtholugeDB 
ADG94190.1 Arcobacter nitrofigilis DSM 7299 OrtholugeDB 
YP_157917.1 Aromatoleum aromaticum EbN1 OrtholugeDB 
YP_003180026.1
a
 Atopobium parvulum DSM 20469 OrtholugeDB 
CAL96199.1 Azoarcus species BH72 OrtholugeDB 
CBS87488.1  Azospirillum species B510 OrtholugeDB 
YP_004096659.1
a
 Bacillus cellulosilyticus DSM 2522 OrtholugeDB 
NP_977659.1
a
 Bacillus cereus ATCC 10987 OrtholugeDB 
EEK97603.1 Bacillus cereus AH187 OrtholugeDB 
YP_177182.1
a
 Bacillus clausii KSM-K16 OrtholugeDB 
AEH52402.1 Bacillus coagulans 2-6 OrtholugeDB 
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SUPPLEMENTARY TABLE 2 (continued)  
BAB07434.1 Bacillus halodurans C-125 OrtholugeDB 
ADI00528.1 Bacillus selenitireducens MLS10 OrtholugeDB 
YP_003868079.1
a
 Bacillus subtilis subspecies spizizenii strain W23 OrtholugeDB 
NP_391661.3
a
 Bacillus subtilis subspecies subtilis strain 168 OrtholugeDB 
YP_003667391.1
a
 Bacillus thuringiensis BMB171 OrtholugeDB 
ABY46214.1 Bacillus weihenstephanensis KBAB4 OrtholugeDB 
EDM19840.1 Bacteroides caccae ATCC 43185 BLASTp search CapN 
CAH06763.1 Bacteroides fragilis NCTC 9343 OrtholugeDB 
CAH07611.1 B. fragilis NCTC 9343 OrtholugeDB 
YP_212215.1
a
 B. fragilis NCTC 9343 OrtholugeDB 
YP_211209.1
a
 B. fragilis NCTC 9343 OrtholugeDB 
YP_213273.1
a
 B. fragilis NCTC 9343 OrtholugeDB 
YP_100924.1
a
 B. fragilis YCH46 OrtholugeDB 
YP_098834.1
a
 B. fragilis YCH46 OrtholugeDB 
YP_099850.1
a
 B. fragilis YCH46 OrtholugeDB 
ADV44138.1 Bacteroides helcogenes P 36-108 OrtholugeDB 
YP_004161543.1
a
 B. helcogenes P 36-108 OrtholugeDB 
YP_004161803.1
a
 B. helcogenes P 36-108 OrtholugeDB 
YP_004258251.1
a
 Bacteroides salanitronis DSM 18170 OrtholugeDB 
NP_811799.1
a
 Bacteroides thetaiotaomicron VPI-5482 OrtholugeDB 
YP_001300216.1
a
 Bacteroides vulgatus ATCC 8482 OrtholugeDB 
YP_001301242.1
a
 B. vulgatus ATCC 8482 OrtholugeDB 
YP_001633455.1 Bordetella petrii DSM 12804 OrtholugeDB 
NP_772563.1 Bradyrhizobium diazoefficiens USDA 110 OrtholugeDB 
YP_002732468.1
b
 Brucella melitensis ATCC 23457 OrtholugeDB 
YP_001627391.1
b
 Brucella suis ATCC 23445 OrtholugeDB 
AAU49962.1 Burkholderia mallei ATCC 23344 OrtholugeDB 
ACQ98521.1 Burkholderia pseudomallei MSHR346 OrtholugeDB 
YP_001681771.1
a
 Caulobacter species K31 OrtholugeDB 
YP_001983909.1 Cellvibrio japonicus Ueda107 OrtholugeDB 
ABG64558.1
b
 Chelativorans species BNC1 OrtholugeDB 
YP_003124384.1
a
 Chitinophaga pinensis DSM 2588 OrtholugeDB 
YP_001943893.1
a
 Chlorobium limicola DSM 245 OrtholugeDB 
ABB24695.1 Chlorobium luteolum DSM 273 OrtholugeDB 
ABL66603.1 Chlorobium phaeobacteroides DSM 266 OrtholugeDB 
ABX43855.1 Clostridium phytofermentans ISDg OrtholugeDB 
EMS70345.1 Clostridium termitidis CT1112 BLASTp search CapN 
AAZ28046.1 Colwellia psychrerythraea 34H OrtholugeDB 
YP_003549169.1
a
 Coraliomargarita akajimensis DSM 45221 OrtholugeDB 
BAC17172.1 Corynebacterium efficiens YS-314 OrtholugeDB 
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SUPPLEMENTARY TABLE 2 (continued) 
AFZ53196.1 Cyanobacterium aponinum PCC 10605 BLASTp search WbpK 
AFT68008.1 Cycloclasticus species P1 BLASTp search WbpK 
YP_003808718.1 Desulfarculus baarsii DSM 2075 OrtholugeDB 
YP_002431668.1
a
 Desulfatibacillum alkenivorans AK-01 OrtholugeDB 
YP_002460906.1
a
 Desulfitobacterium hafniense DCB-2 OrtholugeDB 
ADW19313.1 Desulfobulbus propionicus DSM 2032 OrtholugeDB 
ABW67105.1 Desulfococcus oleovorans Hxd3 OrtholugeDB 
YP_003159756.1 Desulfomicrobium baculatum DSM 4028 OrtholugeDB 
YP_004498346.1
a
 Desulfotomaculum carboxydivorans CO-1-SRB OrtholugeDB 
ADH86493.1 Desulfurivibrio alkaliphilus AHT2 OrtholugeDB 
ACT08204.1 Dickeya zeae Ech1591 OrtholugeDB 
YP_002250211.1
a
 Dictyoglomus thermophilum H-6-12 OrtholugeDB 
YP_002932741.1
a
 Edwardsiella ictaluri 93-146 OrtholugeDB 
EZR14264.1 Enterobacter species BWH 27 BLASTp search WbpK 
NP_815853.1
a
 Enterococcus faecalis V583 OrtholugeDB 
AGE29663.1 Enterococcus faecium NRRL B-2354 BLASTp search CapN 
AFC91450.1 Escherichia coli O45:H10 strain H61 BLASTp search WbpK 
YP_002271284.1
a
 E. coli O157:H7 strain EC4115 OrtholugeDB 
ADO36951.1 Eubacterium limosum KIST612 OrtholugeDB 
ACB62080.1 Exiguobacterium sibiricum 255-15 OrtholugeDB 
ADL24802.1 Fibrobacter succinogenes S85 OrtholugeDB 
ACU08375.1 Flavobacteriaceae bacterium 3519-10 OrtholugeDB 
ABQ03373.1  Flavobacterium johnsoniae UW101 OrtholugeDB 
ABZ87470.1 Francisella philomiragia subspecies philomiragia 
ATCC 25017 
OrtholugeDB 
CAG46095.1 Francisella tularensis subspecies tularensis SCHU 
S4 
reference sequence 
WbcT 
EYD70022.1 Fusobacterium necrophorum subspecies 
funduliforme B35 
BLASTp search WbcT 
AAL93809.1 Fusobacterium nucleatum ATCC 25586 OrtholugeDB 
EHO82815.1 Fusobacterium ulcerans 12-1B BLASTp search WbcT 
ADL56823.1 Gallionella capsiferriformans ES-2 OrtholugeDB 
ACH38643.2 Geobacter bemidjiensis Bem OrtholugeDB 
ACT18628.1 Geobacter species M21 OrtholugeDB 
AGM38884.1 Haemophilus parasuis 84-15995 BLASTp search CapN 
ADJ62001.1 Herbaspirillum seropedicae SmR1 OrtholugeDB 
CAL61328.1 Herminiimonas arsenicoxydans OrtholugeDB 
YP_003756842.1
b
 Hyphomicrobium denitrificans ATCC 51888 OrtholugeDB 
AAV81403.1 Idiomarina loihiensis L2TR OrtholugeDB 
CDG81600.1 Janthinobacterium species Marseille OrtholugeDB 
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SUPPLEMENTARY TABLE 2 (continued) 
EJN56509.1  Lactobacillus coryniformis CECT 5711 BLASTp search CapN 
YP_001271650.1
a
 Lactobacillus reuteri DSM 20016 OrtholugeDB 
YP_003352668.1
a
 Lactococcus lactis KF147 OrtholugeDB 
YP_003455544.1 Legionella longbeachae NSW150 OrtholugeDB 
YP_094797.1 Legionella pneumophila strain Philadelphia 1 OrtholugeDB 
EUJ27787.1 Listeria grayi FSL F6-1183 BLASTp search CapN 
BAE48842.1 Magnetospirillum magneticum AMB-1 OrtholugeDB 
ABM19688.1 Marinobacter aquaeolei VT8 OrtholugeDB 
ABR69745.1 Marinomonas species MWYL1 OrtholugeDB 
BAK21004.1 Melissococcus plutonius ATCC 35311 OrtholugeDB 
ABE49544.1 Methylobacillus flagellatus KT OrtholugeDB 
YP_001639501.1
b
 Methylobacterium extorquens PA1 OrtholugeDB 
AAU93112.1 Methylococcus capsulatus strain Bath OrtholugeDB 
AEF99624.1 Methylomonas methanica MC09 OrtholugeDB 
EEF78408.1  Methylophaga thiooxydans DMS010 BLASTp search WbpK 
ACT47946.1 Methylotenera mobilis JLW8 OrtholugeDB 
ADI29637.1 Methylotenera versatilis 301 OrtholugeDB 
YP_318993.1 Nitrobacter winogradskyi Nb-255 OrtholugeDB 
YP_344157.1 Nitrosococcus oceani ATCC 19707 OrtholugeDB 
CAD84411.1 Nitrosomonas europaea ATCC 19718 OrtholugeDB 
EAR60515.1 Oceanospirillum species MED92 BLASTp search WbpV 
YP_001371115.1
b
 Ochrobactrum anthropi ATCC 49188 OrtholugeDB 
YP_004254159.1
a
 Odoribacter splanchnicus DSM 220712 OrtholugeDB 
YP_810971.1
a
 Oenococcus oeni PSU-1 OrtholugeDB 
YP_003949006.1
a
 Paenibacillus polymyxa SC2 OrtholugeDB 
YP_004275600.1
a
 Pedobacter saltans DSM 12145 OrtholugeDB 
ACF42880.1 Pelodictyon phaeoclathratiforme BU-1 OrtholugeDB 
CAG21077.1 Photobacterium profundum SS9 OrtholugeDB 
CAQ86427.1 Photorhabdus asymbiotica ATCC43949 OrtholugeDB 
ABM38779.1 Polaromonas naphthalenivorans CJ2 OrtholugeDB 
AEA21732.1 Prevotella denticola F0289 OrtholugeDB 
YP_003575047.1
a
 Prevotella ruminicola 23 OrtholugeDB 
YP_002016412.1
a
 Prosthecochloris aestuarii DSM 271 OrtholugeDB 
AAC45865.1 Pseudomonas aeruginosa O5 PAO1 reference sequence 
WbpK 
AAB39483.1 P. aeruginosa O11 PA103 reference sequence WbjF 
AAF23991.1 P. aeruginosa IATS O6 reference sequence 
WbpV 
EOT14879.1 P. aeruginosa O10 PA14 OrtholugeDB 
ABR86892.1 P. aeruginosa O12 PA7 OrtholugeDB 
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SUPPLEMENTARY TABLE 2 (continued) 
ABA75791.1 Pseudomonas fluorescens Pf0-1 OrtholugeDB 
AAY96279.1 Pseudomonas protegens Pf-5 OrtholugeDB 
ABQ80062.1 Pseudomonas putida F1 OrtholugeDB 
EIK67266.1 Pseudomonas synxantha BG33R BLASTp search WbpK 
AAY38670.1 Pseudomonas syringae pathovar syringae B728a OrtholugeDB 
ABY23173.1 Renibacterium salmoninarum ATCC 33209 OrtholugeDB 
AAQ93037.1 Rhizobium etli CFN 42 reference sequence 
WreQ 
ACS57111.1 Rhizobium leguminosarum biovar trifolii WSM1325 OrtholugeDB 
YP_003578087.1
a
 Rhodobacter capsulatus SB 1003 OrtholugeDB 
EXM38188.1 Ruminococcus albus SY3 BLASTp search CapN 
AHG21859.1 Serratia fonticola RB-25 BLASTp search WbpK 
YP_004501405.1
a
 Serratia species AS12 OrtholugeDB 
ACK45991.1 Shewanella baltica OS223 OrtholugeDB 
AAN56173.1 Shewanella oneidensis MR-1 OrtholugeDB 
ABP76250.1 Shewanella putrefaciens CN-32 OrtholugeDB 
YP_001879836.1
a
 Shigella boydii CDC 3083-94 OrtholugeDB 
ADE13107.1 Sideroxydans lithotrophicus ES-1 OrtholugeDB 
ADY12094.1 Sphaerochaeta globosa strain Buddy OrtholugeDB 
ADZ78392.1 Sphingobacterium species 21 OrtholugeDB 
YP_616633.1
b
 Sphingopyxis alaskensis RB2256 OrtholugeDB 
BAB94002.1 Staphylococcus aureus serotype 8 MW2  OrtholugeDB 
BAF66380.1 S. aureus serotype 5 Newman reference sequence CapN  
AAL26668.1 S. aureus strain M BLASTp search CapN 
ADC86484.1 Staphylococcus lugudensis HKU09-01 OrtholugeDB 
YP_330067.1
a
 Streptococcus agalactiae A909 OrtholugeDB 
AGM98615.1 Streptococcus iniae SF1 BLASTp search CapN 
YP_003485108.1
a
 Streptococcus mutans NN2025 OrtholugeDB 
ABN45584.1 Streptococcus sanguinis SK36 OrtholugeDB 
YP_004401334.1
a
 Streptococcus suis ST3 OrtholugeDB 
AGS58366.1 Streptococcus suis 14A BLASTp search CapN 
ADN09535.1 Sulfurimonas autotrophica DSM 16294 OrtholugeDB 
ACZ12787.1 Sulfurospirillum deleyianum DSM 6946 OrtholugeDB 
NP_896554.1
b
 Synechococcus species WH 8102 OrtholugeDB 
BAK93722.1  Tetragenococcus halophilus NBRC 12172 BLASTp search CapN 
ADC72044.1 Thioalkalivibrio species K90mix OrtholugeDB 
AAZ97826.1 Thiobacillus denitrificans ATCC 25259 OrtholugeDB 
EKF08323.1  Thalassospira profundimaris WP0211 BLASTp search WbpV 
AGT34472.1 Thermofilum species 1910b outgroup 
ADG90620.1 Thermosphaera aggregans DSM 11486 outgroup 
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NP_972045.1
a
 Treponema denticola ATCC 35405 OrtholugeDB 
ADU38842.1 Variovorax paradoxus EPS OrtholugeDB 
AEH32018.1 Vibrio anguillarum 775 OrtholugeDB 
AGA82312.1 Vibrio cholerae O1 biovar El Tor strain N16961 OrtholugeDB 
AAM22609.1 V. cholerae O37 1322-69 BLASTp search WbpV 
AAC46247.1 V. cholerae O139 AI1837 BLASTp search WbpV 
ACH64821.1 Vibrio fischeri MJ11 OrtholugeDB 
CCO59607.1 Vibrio nigripulchritudo SFn1 BLASTp search WbpK 
EGF42689.1 Vibrio parahaemolyticus 10329 BLASTp search WbpK 
WP_017074481.1 Vibrio splendidus ZS-139 BLASTp search WbpK 
AAO09281.1 Vibrio vulnificus CMCP6 OrtholugeDB 
ABD38630.1 V. vulnificus MO6-24/O OrtholugeDB 
YP_001418446.1
a
 Xanthobacter autotrophicus Py2 OrtholugeDB 
YP_001721901.1
a
 Yersinia pseudotuberculosis YPIII OrtholugeDB 
EHM45344.1  Yokenella regensburgei ATCC 43003 BLASTp search WbpK 
Note. Accession numbers are from GenBank, or from the NCBI non-redundant protein database. A 
grey background indicates protein sequences used for assembly of the final phylogenetic tree of the 
Sugp 4-keto reductase family (see main text).  
a
putative dTDP-4-dehydrorhamnose reductase or C55PP-GlcNAc epimerase 
b
sequence producing low alignment score with domain models cd05232 and COG0451 
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SUPPLEMENTARY FIGURE 1. Multiple alignment of Sugp 4-keto reductase sequences of Proteobacteria and Firmicutes (computed by Clustal Omega version 
1.2.1). The residues of the active site tetrad (N[ST]YK) are marked by yellow stars. Potential cofactor-binding sites are shaded grey. An * (asterisk) indicates 
positions which have a single, fully conserved residue. A : (colon) indicates conservation between groups of strongly similar properties (scoring > 0.5 in the 
Gonnet PAM 250 matrix). A . (period) indicates conservation between groups of weakly similar properties (scoring ≤ 0.5). 
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